Citation Report

List of articles citing

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

DOI: 10.1016/j.eururo.2016.08.003
European Urology, 2017, 71, 618-629.

Source: https://exaly.com/paper-pdf/67708083/citation-report.pdf
Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2258	Metabolic Imaging in Prostate Cancer: Where We Are. **2016**, 6, 225		16
2257	Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening. **2016**, 34, 2684-6		5
2256	Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. **2016**, 2, 499-505		42
2255	Active Surveillance for Small Renal Masses: When Less is More. **2016**, 2, 660-668		23
2254	Intravoxel Incoherent Motion (IVIM) Diffusion Weighted Imaging (DWI) in the Periferic Prostate Cancer Detection and Stratification. **2017**, 34, 35		38
2253	Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. **2017**, 44, 941-949		156
2252	Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. *European Urology*, **2017**, 72, 521-531	10.2	106
2251	Multiparametric Magnetic Resonance/Ultrasound Fusion Prostate Biopsy: Number and Spatial Distribution of Cores for Better Index Tumor Detection and Characterization. **2017**, 198, 58-64		37
2250	Reply to Thomas Zilli, Gilles Cr* hange and Olivier Chapet's Letter to the Editor re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol 2017;71:267-73. *European Urology*, **2017**, 72, e15-e16	10.2	1
2249	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. *European Urology*, **2017**, 72, 84-109	10.2	203
2248	Clinical Outcome Following Low Suspicion Multiparametric Prostate Magnetic Resonance Imaging or Benign Magnetic Resonance Imaging Guided Biopsy to Detect Prostate Cancer. **2017**, 198, 310-315		8
2247	Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. **2017**, 20, 125-133		27
2246	UICC drops the ball in the 8th edition TNM staging of urological cancers. **2017**, 71, 5-11		25
2245	Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. *European Urology*, **2017**, 72, 689-709	10.2	57
2244	Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity. **2017**, 98, 318-337		9
2243	Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force. **2017**, 77, 127-139		10
2242	Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. **2017**, 77, 951-965		12

2241	Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?. **2017**, 119, 652-653		
2240	Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years. **2017**, 5, 425-428		2
2239	Prostate Cancer Management in an Ageing Population. *European Urology*, **2017**, 72, 532-533	10.2	2
2238	The role of whole-lesion apparent diffusion coefficient analysis for predicting outcomes of prostate cancer patients on active surveillance. **2017**, 42, 2340-2345		12
2237	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. *European Urology*, **2017**, 72, 632-640	10.2	93
2236	Darolutamide (ODM-201) for the treatment of prostate cancer. **2017**, 18, 945-952		40
2235	Intraindividual Comparison of F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. **2017**, 58, 1805-1810		59
2234	The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. **2017**, 20, 407-412		14
2233	Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. **2017**, 116, 1520-1525		94
2232	Editorial comment on: Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml. **2017**, 51, 258-259		
2231	Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. *European Urology*, **2017**, 72, 910-917	10.2	17
2230	Toxicity after post-prostatectomy image-guided intensity-modulated radiotherapy using Australian guidelines. **2017**, 61, 804-811		
2229	Postoperative upgrading of prostate cancer in men â75 years: a propensity score-matched analysis. **2017**, 35, 1517-1524		12
2228	Utilization of Pelvic Lymph Node Dissection for Patients With Low-Risk Prostate Cancer Treated With Robot-Assisted Radical Prostatectomy. **2017**, 15, e1001-e1006		6
2227	MRI pathway and TRUS-guided biopsy for detecting clinically significant prostate cancer. **2017**,		1
2226	Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. **2017**, 44, 1647-1655		32
2225	Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary. **2017**, 18, 53		6
2224	Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. **2017**, 18, 48		1

2223	Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. **2017**, 58, 1-13	146
2222	Effect of Prior Focal Therapy on Perioperative, Oncologic and Functional Outcomes of Salvage Robotic Assisted Radical Prostatectomy. **2017**, 198, 1069-1076	29
2221	Therapy assessment in prostate cancer using choline and PSMA PET/CT. **2017**, 44, 78-83	25
2220	The role of the multiparametric MRI in the diagnosis of prostate cancer in biopsy-naïve men. **2017**, 27, 488-494	14
2219	Re: Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial. *European Urology*, **2017**, 71, 833	10.2
2218	Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. **2017**, 5, 125-129	24
2217	GATA3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall. **2017**, 71, 150-155	8
2216	Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers. **2017**, 3, 265-272	33
2215	[Prostate Cancer - Update 2017]. **2017**, 159, 58-65	
2214	Low-risk Prostate Cancer: Identification, Management, and Outcomes. *European Urology*, **2017**, 72, 238-249	42
2213	[Significance of PSMA imaging in prostate cancer]. **2017**, 56, 3-12	2
2212	Early dynamic imaging in Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. **2017**, 44, 765-775	49
2211	CT-guided transgluteal biopsy for systematic sampling of the prostate in patients without rectal access: a 13-year single-center experience. **2017**, 27, 3326-3332	4
2210	How to Biopsy: Transperineal Versus Transrectal, Saturation Versus Targeted, What's the Evidence?. **2017**, 44, 525-534	15
2209	Whom to Treat: Postdiagnostic Risk Assessment with Gleason Score, Risk Models, and Genomic Classifier. **2017**, 44, 547-555	4
2208	Gallium-Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary and Secondary Staging in Prostate Cancer. **2017**, 44, 557-563	5
2207	The Efficiency and Safety of Intrarectal Topical Anesthesia for Transrectal Ultrasound-Guided Prostate Biopsy: A Systematic Review and Meta-Analysis. **2017**, 99, 373-383	11
2206	[Indications and limits of ablative therapies in prostate cancer]. **2017**, 27, 865-886	

2205	[Ablative therapy in urology: Good practice and perspective]. **2017**, 27, 994-1014	
2204	[Radiation therapy of locally advanced prostate cancer]. **2017**, 56, 1402-1409	0
2203	Current evidence on the effect of dietary polyphenols intake on chronic diseases. **2017**, 110, 286-299	139
2202	Diffusion Kurtosis Imaging Helps to Predict Upgrading in Biopsy-Proven Prostate Cancer With a Gleason Score of 6. **2017**, 209, 1081-1087	6
2201	African-American Prostate Cancer Disparities. **2017**, 18, 81	44
2200	Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway. **2017**, 110, 140-147	4
2199	The Effects of Population-based Prostate-specific Antigen Screening Beginning at Age 40. **2017**, 110, 127-133	3
2198	Validation and head-to-head comparison of three nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended and/or sentinel lymph node dissection. **2017**, 44, 2213-2226	17
2197	Elevated hardness of peripheral gland on real-time elastography is an independent marker for high-risk prostate cancers. **2017**, 122, 944-951	1
2196	Where Do Transrectal Ultrasound- and Magnetic Resonance Imaging-guided Biopsies Miss Significant Prostate Cancer?. **2017**, 110, 154-160	12
2195	Current status of robotic surgery in urology. **2017**, 10, 372-381	14
2194	The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer. **2017**, 38, 956-963	20
2193	Therapeutic outcomes of the LHRH antagonists. **2017**, 17, 481-488	6
2192	WNT signalling in prostate cancer. **2017**, 14, 683-696	148
2191	Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator. **2017**, 24, 826-832	5
2190	Retzius-Sparing Robotic-Assisted Laparoscopic Radical Prostatectomy: A Safe Surgical Technique with Superior Continence Outcomes. **2017**, 31, 1244-1250	50
2189	Assessing the Impact of Surgeon Experience on Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons. **2017**, 31, 872-877	30
2188	Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium. **2017**, 123, 4139-4146	7

2187	Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan. **2017**, 108, 1673-1680	3
2186	Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer. **2017**, 141, 1643-1653	12
2185	Nanomaterial-based biosensors for detection of prostate specific antigen. **2017**, 184, 3049-3067	67
2184	Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection. **2017**, 77, 1325-1334	8
2183	Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer. **2017**, 51, 498-501	2
2182	Knowledge, attitudes, and practices towards prostate cancer screening amongst men living in the southern Italian peninsula: the Prevention and Research in Oncology (PRO) non-profit Foundation experience. **2017**, 35, 1857-1862	1
2181	Salvage surgery for nodal recurrent prostate cancer. **2017**, 27, 604-611	8
2180	Epid‘ miologie, diagnostic et pronostic du cancer de la prostate. **2017**, 41, 329-334	
2179	The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory. **2017**, 13, 1801-1807	1
2178	Concomitant bladder cancer and prostate cancer: challenges and controversies. **2017**, 14, 620-629	10
2177	Diagnostic characteristics of lethal prostate cancer. **2017**, 84, 18-26	19
2176	MRI Fusion-Targeted Transrectal Prostate Biopsy and the Role of Prostate-Specific Antigen Density and Prostate Health Index for the Detection of Clinically Significant Prostate Cancer in Southeast Asian Men. **2017**, 31, 1111-1116	9
2175	Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer. **2017**, 51, 457-463	4
2174	Biomarkers in prostate cancer - Current clinical utility and future perspectives. **2017**, 120, 180-193	81
2173	Prostate cancer biomarkers: new scenarios in the multi-parametric magnetic resonance imaging era. **2017**, 120, 745-746	2
2172	[Management of ablative therapies in prostate cancer]. **2017**, 27, 909-925	
2171	Urodynamic changes in patients with prostate cancer undergoing robotic-assisted radical prostatectomy: A comparison with laparoscopic radical prostatectomy. **2017**, 28, 174-179	1
2170	Obesity and its implications on oncological urological surgery. **2017**, 27, 446-455	8

2169	Estradiol for the mitigation of adverse effects of androgen deprivation therapy. **2017**, 24, R297-R313		9
2168	Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older. *European Urology*, **2017**, 71, 710-713	10.2	9
2167	Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression. **2017**, 97, 347-354		10
2166	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. *European Urology*, **2017**, 71, 630-642	10.2	924
2165	Magnetic Resonance Imaging for Membranous Urethral Length Assessment Prior to Radical Prostatectomy: Can it Really Improve Prostate Cancer Management?. *European Urology*, **2017**, 71, 379-380	10.2	2
2164	Comprehensive Geriatric Assessment in the Older Adult with Cancer: A Review. **2017**, 3, 330-339		35
2163	AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin. **2017**, 8, e3060		23
2162	Watchful Waiting â□□eine Zukunftsstrategie beim Prostatakarzinom. **2017**, 21, 54-59		
2161	Three-dimensional estimation of ultrasound-contrast-agent dispersion and convection in the prostate. **2017**,		
2160	. **2017**, 24, 117-122		
2159	Dose-escalated radiotherapy for clinically localised and locally advanced prostate cancer. **2017**,		2
2158	Does T1- and diffusion-weighted magnetic resonance imaging give value-added than bone scintigraphy in the follow-up of vertebral metastasis of prostate cancer?. **2017**, 58, 324-330		3
2157	Differences in Recurrence Rate and Incontinence after Endoscopic Treatment of Vesicourethral Stenosis and Bladder Neck Stenosis. **2017**, 4, 44		12
2156	Recommandations de l'Association des urologues du Canada sur le d‸ pistage et le diagnostic pr‸ coce du cancer de la prostate. **2017**, 11, 298-309		36
2155	Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. **2017**, 18,		17
2154	Magnetic Marking and Intraoperative Detection of Primary Draining Lymph Nodes in High-Risk Prostate Cancer Using Superparamagnetic Iron Oxide Nanoparticles: Additional Diagnostic Value. **2017**, 22,		8
2153	Dietary Consumption of Phenolic Acids and Prostate Cancer: A Case-Control Study in Sicily, Southern Italy. **2017**, 22,		25
2152	Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer. **2017**, 7, 280		6

2151	Evaluation of MRI/Ultrasound Fusion-Guided Prostate Biopsy Using Transrectal and Transperineal Approaches. **2017**, 2017, 2176471	18
2150	Index-Based Dietary Patterns and the Risk of Prostate Cancer. **2017**, 6, 229-246	11
2149	Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies. **2017**, 12, e0175070	1
2148	A population-based study of the clinical utility of 18Fâholine PET/CT for primary metastasis staging of high-risk prostate cancer. **2017**, 1,	2
2147	Watchful Waiting âeine Zukunftsstrategie beim Prostatakarzinom. **2017**, 12, 40-45	
2146	. **2017**, 19, 115-119	
2145	Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer. **2017**, 14, 1301-1306	5
2144	Orgasmic Dysfunction after Radical Prostatectomy. **2017**, 35, 1-13	22
2143	Diagnostic performance of Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with FEC PET/CT. **2017**, 8, 111073-111083	26
2142	Impact of bladder dysfunction in the management of post radical prostatectomy stress urinary incontinence-a review. **2017**, 6, S103-S111	7
2141	Using support vector machine analysis to assess PartinMR: A new prediction model for organ-confined prostate cancer. **2018**, 48, 499-506	6
2140	Diffusion-Weighted Imaging in Magnetic Resonance Imaging of the Prostate. **2018**, 167-178	
2139	Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection. **2018**, 24, 2342-2349	8
2138	An In-Depth Glycosylation Assay for Urinary Prostate-Specific Antigen. **2018**, 90, 4414-4421	34
2137	Evaluation of pharmacokinetics/pharmacodynamics and efficacy of one-month depots of TAK-448 and TAK-683, investigational kisspeptin analogs, in male rats and an androgen-dependent prostate cancer model. **2018**, 822, 138-146	4
2136	Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies. **2018**, 12, 545-560	32
2135	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. **2018**, 78, 469-475	29
2134	A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification. **2018**, 4, 678-685	92

2133	Multicenter evaluation of guideline adherence for pelvic lymph node dissection in patients undergoing open retropubic vs. laparoscopic or robot assisted radical prostatectomy according to the recent German S3 guideline on prostate cancer. **2018**, 36, 855-861		5
2132	Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA. **2018**, 36, 687-691		14
2131	Tiny Obturator Node Metastasis from Prostate Cancer Not Shown by FDG-PET/CT, CT, or MRI Detected by C-Choline PET/CT. **2018**, 11, 33-37		1
2130	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. **2018**, 21, 386-393		8
2129	Prospective comparative study of F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. **2018**, 57, 1063-1069		6
2128	Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI. **2018**, 36, 705-712		4
2127	Predictors for the detection of prostate cancer and clinically significant prostate cancer using TRUS-guided biopsy in patients with negative initial biopsy results. **2018**, 36, 1047-1053		
2126	Comparison of choline influx from dynamic F-Choline PET/CT and clinicopathological parameters in prostate cancer initial assessment. **2018**, 32, 281-287		8
2125	Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study. **2018**, 200, 95-103		53
2124	Development and internal validation of a side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer. **2018**, 122, 1025-1033		54
2123	Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater. **2018**, 48, 485-490		1
2122	Impact of Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. *European Urology*, **2018**, 74, 179-190	10.2	170
2121	Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis. **2018**, 122, 946-958		47
2120	Long-term oncological results of treatment for high-risk prostate cancer using radical prostatectomy in a cancer hospital. **2018**, 42, 507-515		1
2119	Local staging with multiparametric MRI in daily clinical practice: diagnostic accuracy and evaluation of a radiologic learning curve. **2018**, 36, 1409-1415		10
2118	Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4-10 ng/mL. **2018**, 34, 461-466		8
2117	Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer: The first real-life experience in Asia. **2018**, 14, 347-352		11
2116	Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse. **2018**, 122, 610-617		5

2115	Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. **2018**, 36, 1383-1389		15
2114	Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate. **2018**, 122, 211-218		28
2113	Calcifications in prostate cancer: An active phenomenon mediated by epithelial cells with osteoblast-phenotype. **2018**, 81, 745-748		14
2112	Repeat prostate-specific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancer. **2018**, 122, 83-88		1
2111	Cognitive versus Software-Assisted Registration: Development of a New Nomogram Predicting Prostate Cancer at MRI-Targeted Biopsies. **2018**, 16, e953-e960		7
2110	Androgen receptor moonlighting in the prostate cancer microenvironment. **2018**, 25, R331-R349		12
2109	Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer. **2018**, 122, 535-548		7
2108	Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?. **2018**, 122, 794-800		19
2107	Metabolic syndrome is not associated with greater evidences of proliferative inflammatory atrophy and inflammation in patients with suspected prostate cancer. **2018**, 36, 240.e21-240.e26		1
2106	The cumulative incidence and risk factors of postoperative inguinal hernia in patients undergoing radical prostatectomy. **2018**, 23, 742-748		5
2105	Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. *European Urology*, **2018**, 74, 84-91	10.2	92
2104	Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma. **2018**, 200, 104-113		22
2103	Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review. **2018**, 122, 371-383		11
2102	Accuracy of standardized 12-core template biopsies versus non-standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen. **2018**, 78, 365-369		3
2101	A clinician-centred programme for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer. **2018**, 121 Suppl 3, 22-27		9
2100	Precision Matters in MR Imaging-targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies. **2018**, 287, 534-542		39
2099	Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer. **2018**, 78, 419-425		8
2098	Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy. **2018**, 36, 761-768		27

2097	F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer. **2018**, 210, 635-640		10
2096	Whole Body MRI and oncology: recent major advances. **2018**, 91, 20170664		20
2095	Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. **2018**, 36, 158.e13-158.e20		17
2094	Concordance of Gleason grading with three-dimensional ultrasound systematic biopsy and biopsy core pre-embedding. **2018**, 36, 863-869		2
2093	Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients. **2018**, 188, 795-804		8
2092	Cancer Treatment and Bone Health. **2018**, 102, 251-264		36
2091	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. **2018**, 11, 425-438		8
2090	Association of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis. **2018**, 114, 155-162		12
2089	Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice. **2018**, 36, 383-391		10
2088	Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. **2018**, 45, 904-912		22
2087	Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection. **2018**, 28, 1969-1976		33
2086	Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: A systematic review and meta-analysis. **2018**, 477, 94-104		37
2085	Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases. *European Urology*, **2018**, 73, 664-671	10.2	38
2084	The new Epstein gleason score classification significantly reduces upgrading in prostate cancer patients. **2018**, 44, 835-839		15
2083	Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?. **2018**, 28, 18-24		7
2082	Long-term penile morphometric alterations in patients treated with robot-assisted versus open radical prostatectomy. **2018**, 6, 136-141		5
2081	Current status of theranostics in prostate cancer. **2018**, 45, 471-495		80
2080	Internal Fusion: exact correlation of transrectal ultrasound images of the prostate by detailed landmarks over time for targeted biopsies or follow-up. **2018**, 36, 693-698		2

2079	Irreversible Electroporation of Prostate Tumors. **2018**, 215-222	
2078	Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. **2018**, 21, 57-63	73
2077	Outcome of Robotic Radical Prostatectomy in Men Over 74. **2018**, 32, 106-110	8
2076	Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer. **2018**, 16, e619-e627	2
2075	Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN and Antagonist RM26. **2018**, 29, 410-419	18
2074	Prostate cancer rates in patients with initially negative elastography-targeted biopsy vs. systematic biopsy. **2018**, 36, 623-628	4
2073	Molecular Biomarkers in the Clinical Management of Prostate Cancer. **2018**, 8,	10
2072	Treatment effects in prostate cancer. **2018**, 31, S110-121	51
2071	Review of optimal techniques for robotic-assisted radical prostatectomy. **2018**, 28, 102-107	2
2070	Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer. **2018**, 121, 863-870	8
2069	Study of diagnostic accuracy of Fagan's two-step nomogram in increasing the value of predictive tools for prostate cancer: application of specific spatial distribution of positive/negative bioptic cores to predict extracapsular extension. **2018**, 30, 1497-1504	1
2068	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. **2018**, 18, 354	10
2067	The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. **2018**, 16, 31	19
2066	Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a Cochrane Review and network meta-analysis. **2018**,	1
2065	Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes. **2018**, 11, 3-4	
2064	Update on techniques to prevent infections associated with prostate needle biopsy. **2018**, 28, 392-397	4
2063	Bone Metastases in Prostate Cancer. **2018**, 323-343	
2062	Comparative quality-adjusted survival analysis between radiation therapy alone and radiation with androgen deprivation therapy in patients with locally advanced prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 85-31 with novel decision analysis methods. **2018**, 6, 140-144	5

2061	A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy. **2018**, 200, 302-308		8
2060	Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single institution experience. **2018**, 10, 29-35		4
2059	Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?. **2018**, 23, 757-764		7
2058	Defining the optimal method for reporting prostate cancer grade and tumor extent on magnetic resonance/ultrasound fusion-targeted biopsies. **2018**, 76, 68-75		15
2057	Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial. **2018**, 178, 565-576		8
2056	Measurement uncertainty in laboratory reports: A tool for improving the interpretation of test results. **2018**, 57, 41-47		18
2055	Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?. *European Urology*, **2018**, 74, 48-54	10.2	96
2054	Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. *European Urology*, **2018**, 73, 81-91	10.2	47
2053	Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer. **2018**, 121, 209-216		2
2052	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. **2018**, 4, 369-375		8
2051	Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?. *European Urology*, **2018**, 73, 343-350	10.2	15
2050	Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. *European Urology*, **2018**, 73, 11-20	10.2	48
2049	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *European Urology*, **2018**, 73, 178-211	10.2	313
2048	Prostate cancer: in-bore magnetic resonance guided biopsies at active surveillance inclusion improve selection of patients for active treatment. **2018**, 59, 619-626		11
2047	The Impact of Adding Sentinel Node Biopsy to Extended Pelvic Lymph Node Dissection on Biochemical Recurrence in Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy. **2018**, 59, 204-209		15
2046	The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland. **2018**, 142, 891-898		5
2045	A novel model to predict positive prostate biopsy based on serum androgen level. **2018**, 25, 59-67		5
2044	Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy. **2018**, 16, e451-e467		11

2043	Prognostic parameter for high risk prostate cancer patients at initial presentation. **2018**, 78, 11-16	17
2042	Laparoscopic and robot-assisted vs open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review. **2018**, 121, 845-853	54
2041	Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer. **2018**, 121, 421-427	17
2040	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. **2018**, 36, 7-13	17
2039	Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making. **2018**, 45, 235-242	73
2038	Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancer. **2018**, 28, 172-177	9
2037	The accuracy of patients' perceptions of the risks associated with localised prostate cancer treatments. **2018**, 121, 405-414	10
2036	Are prostate biopsies necessary for all patients 75years and older?. **2018**, 9, 124-129	2
2035	Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis. **2018**, 73, 158-167	10
2034	Clinical performance of Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. **2018**, 45, 20-30	56
2033	Drug development for noncastrate prostate cancer in a changed therapeutic landscape. **2018**, 15, 168-182	5
2032	Optimising preoperative risk stratification tools for prostate cancer using mpMRI. **2018**, 28, 1016-1026	14
2031	Combined F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer. **2018**, 59, 762-768	19
2030	A novel biopsy-related parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy: a useful parameter for predicting tumor volume compared to number of positive cores. **2018**, 144, 135-143	1
2029	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. **2017**,	9
2028	Local Salvage Treatment of Post-brachytherapy Recurrent Prostate Cancer via Theranostic Application of PSMA-labeled Lutetium-177. **2018**, 16, 99-102	1
2027	Prevalence analysis of urinary incontinence after radical prostatectomy and influential preoperative factors in a single institution. **2018**, 21, 24-30	23
2026	Survival outcomes in elderly men undergoing radical prostatectomy in Australia. **2018**, 88, E189-E193	0

2025	Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patients. **2018**, 121, 53-60		35
2024	Lymphadenectomy in Gleason 7 prostate cancer: Adherence to guidelines and effect on clinical outcomes. **2018**, 36, 13.e11-13.e18		3
2023	Depressive Symptoms and Low Sexual Desire after Radical Prostatectomy: Early and Long-Term Outcomes in a Real-Life Setting. **2018**, 199, 474-480		15
2022	Role of robot-assisted radical prostatectomy in locally advanced prostate cancer. **2018**, 25, 30-35		23
2021	Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy. **2018**, 199, 969-975		5
2020	Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. **2018**, 199, 961-968		4
2019	Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7?. **2018**, 199, 706-712		15
2018	Tc-HDP bone scintigraphy and F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer. **2018**, 36, 27-34		23
2017	Focused ultrasound: tumour ablation and its potential to enhance immunological therapy to cancer. **2018**, 91, 20170641		42
2016	Removing the urinary catheter on post-operative day 2 after robot-assisted laparoscopic radical prostatectomy: a feasibility study from a single high-volume referral centre. **2018**, 12, 467-473		2
2015	Retzius space reconstruction following transperitoneal laparoscopic robot-assisted radical prostatectomy: does it have any added value?. **2018**, 12, 475-479		6
2014	The use of PET/CT in prostate cancer. **2018**, 21, 4-21		49
2013	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. *European Urology*, **2018**, 73, 512-518	10.2	27
2012	Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis. **2018**, 45, 751-758		6
2011	Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy. **2018**, 121, 791-798		18
2010	Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors. **2018**, 59, 494-501		11
2009	[Inhibitors of the androgen receptor N-terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer]. **2018**, 57, 148-154		4
2008	SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). **2018**, 20, 57-68		10

2007	Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. **2018**, 36, 15-20		12
2006	The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset. **2018**, 26, 1297-1304		12
2005	Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer. **2018**, 78, 25-31		15
2004	Patterns of relapse as determined by Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment. **2018**, 194, 303-310		19
2003	Re: Rita Faria, Marta O. Soares, Eldon Spackman, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol 2018;73:23-30. *European Urology*, **2018**, 73, e108-e109	10.2	5
2002	Prostate Specific Membrane Antigen Targeted F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. **2018**, 199, 126-132		69
2001	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. *European Urology*, **2018**, 73, 436-444	10.2	41
2000	The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. *European Urology*, **2018**, 73, 94-108	10.2	27
1999	Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. **2018**, 57, 362-367		19
1998	Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG. **2018**, 20, 392-401		1
1997	Gallium 68-PSMA PET/CT for lesion characterization in suspected cases of prostate carcinoma. **2018** , 39, 1013-1021		6
1996	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. **2018**, 2018,		17
1995	Rastreamento populacional para o c□ncer de pr□tata: mais riscos que benef□cios. **2018**, 28,		2
1994	The impact of surgery in oligometastatic prostate cancer. **2018**, 11, 305-308		
1993	Intrafascial nerve-sparing radical prostatectomy improves patients' postoperative continence recovery and erectile function: A pooled analysis based on available literatures. **2018**, 97, e11297		9
1992	Being on active surveillance: the patient perspective. **2018**, 7, 182-187		2
1991	Oncological Outcomes of Open Radical Retropubic Prostatectomy in Ireland: A Single Surgeon's 5-Year Experience. **2018**, 4, e226-e234		1
1990	Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome. **2018**, 7, 18-26		20

1989	Machine Learning for the Prediction of Prostate Cancer Biopsy Based on 3D Dynamic Contrast-Enhanced Ultrasound Quantification. **2018**,	
1988	The prostate cancer focal therapy. **2018**, 7, 89-102	12
1987	Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes. **2018**, 7, 243-255	23
1986	Prostate cancer screening-when to start and how to screen?. **2018**, 7, 34-45	6
1985	Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy. **2018**, 10, 365-376	2
1984	Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer. **2018**, 7, S484-S489	7
1983	Short interval of biopsy to robotic-assisted laparoscopic radical prostatectomy does not render any adverse effects on the perioperative outcomes. **2018**, 97, e11686	2
1982	New and Emerging Applications of Magnetic Resonance Elastography of Other Abdominal Organs. **2018**, 27, 335-352	3
1981	Radical prostatectomy performed via robotic, transperitoneal and extraperitoneoscopic approaches: functional and early oncological outcomes. **2018**, 71, 378-385	1
1980	Liquid Biopsy Potential Biomarkers in Prostate Cancer. **2018**, 8,	7
1979	Rate of misclassification in patients undergoing radical prostatectomy but fulfilling active surveillance criteria according to the European Association of Urology guidelines on prostate cancer: a high-volume center experience. **2018**, 70, 588-593	5
1978	18F-DCFPyL PET/CT in primary staging of prostate cancer. **2018**, 2,	4
1977	Personalized prostate cancer diagnosis and treatmentâre we ready?. **2018**, 11, 255-256	
1976	Correlation Between 3D ARFI and Quantitative Imaging Metrics from SWEI and Multi-Parametric MRI in Vivo in Normal and Cancerous Prostate Tissue. **2018**,	
1975	Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy. **2018**, 1, 109-117	17
1974	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. **2018**, 1, 91-100	34
1973	The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. **2018**, 1, 215-222	10
1972	68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study. **2018**, 43, 579-585	16

1971	Three-dimensional localization and targeting of prostate cancer foci with imaging and histopathologic correlation: establishing a multidisciplinary team for quality improvement. **2018**, 28, 506-511	1
1970	The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features: An updated PRISMA-compliant systematic review and meta-analysis. **2018**, 97, e13537	7
1969	Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer. **2018**, 97, e13344	8
1968	Initial experience of magnetic resonance imaging/ultrasonography fusion transperineal biopsy: Biopsy techniques and results for 75 patients. **2018**, 59, 363-370	3
1967	Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). **2018**, 35, 2186-2200	4
1966	Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. **2018**, 52, 277-284	3
1965	Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts. **2018**, 119, 1445-1450	
1964	Consensus on molecular imaging and theranostics in prostate cancer. **2018**, 19, e696-e708	59
1963	Integrative epigenetic taxonomy of primary prostate cancer. **2018**, 9, 4900	61
1962	Free-hand transperineal prostate biopsy provides acceptable cancer detection and minimizes risk of infection: evolving experience with a 10-sector template. **2018**, 36, 528.e15-528.e20	21
1961	Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy. **2018**, 17, 899-905	4
1960	A prospective study on dual time F-FDG-PET/CT in high-risk prostate cancer patients. **2018**, 11, 871	2
1959	Cryotherapy of the Prostate. **2018**, 1580-1588	
1958	Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. **2018**, 8, 623	52
1957	New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. **2018**, 8, 653	39
1956	Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. **2018**, 8, 8-16	5
1955	A Definitive IMRT-SIB with Concomitant Chemotherapy for Synchronous Locally Advanced Anal Canal Cancer and Prostate Cancer. **2018**, 2018, 6101759	2
1954	Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients. **2018**, 2018, 9840962	12

1953	Current Imaging Techniques for Lymph Node Staging in Prostate Cancer: A Review. **2018**, 5, 74	18
1952	Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. **2018**, 13, e0208063	14
1951	Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching. **2018**, 2018, 4307207	7
1950	Multiparametric ultrasound: evaluation of greyscale, shear wave elastography and contrast-enhanced ultrasound for prostate cancer detection and localization in correlation to radical prostatectomy specimens. **2018**, 18, 98	19
1949	Comparison of hock- and footpad-injection as a prostate adenocarcinoma model in rats. **2018**, 14, 327	1
1948	Management of non-metastatic castrate-resistant prostate cancer: A systematic review. **2018**, 70, 223-231	11
1947	miR-17-3p Downregulates Mitochondrial Antioxidant Enzymes and Enhances the Radiosensitivity of Prostate Cancer Cells. **2018**, 13, 64-77	39
1946	Head-to-Head Comparison Between Biparametric and Multiparametric MRI for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. **2018**, 211, W226-W241	78
1945	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. **2018**, 19, e534-e545	65
1944	Difference in Frequency and Distribution of Nodal Metastases Between Intermediate and High Risk Prostate Cancer Patients: Results of a Superextended Pelvic Lymph Node Dissection. **2018**, 5, 52	6
1943	MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy. **2018**, 2018, 6368309	9
1942	68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients. **2018**, 39, 871-880	3
1941	Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. **2018**, 124, 4010-4022	28
1940	Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists. **2018**, 36, 501.e15-501.e21	7
1939	Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease. **2018**, 10, 297-305	5
1938	Whole-Body Magnetic Resonance Imaging in Oncology: Uses and Indications. **2018**, 26, 495-507	19
1937	Metastasis Reporting and Data System for Prostate Cancer in Practice. **2018**, 26, 527-542	6
1936	Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. **2018**, 36, 529.e11-529.e22	12

1935	Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK. **2018**, 8, e024941	8
1934	Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy. **2018**, 8, 438	25
1933	The effects of shared decision-making compared to usual care for prostate cancer screening decisions: a systematic review and meta-analysis. **2018**, 18, 1015	6
1932	Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer. **2018**, 122, 721-722	1
1931	Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. **2018**, 7, 83-97	58
1930	Prostate Cancer Screening among High-Risk Black Men. **2018**, 14, 677-682.e2	4
1929	Monitoring of platelet function parameters and microRNA expression levels in patients with prostate cancer treated with volumetric modulated arc radiotherapy. **2018**, 16, 4745-4753	4
1928	Multiparametric MRI and MRI/TRUS Fusion Guided Biopsy for the Diagnosis of Prostate Cancer. **2018**, 1096, 87-98	3
1927	Reporting and Handling of Indeterminate Bone Scan Results in the Staging of Prostate Cancer: A Systematic Review. **2018**, 8,	5
1926	Imaging of distant metastases of prostate cancer. **2018**, 35, 148	12
1925	MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?. **2018**, 7, 70-82	66
1924	Long-term oncological results of treatment for high-risk prostate cancer using radical prostatectomy in a cancer hospital. **2018**, 42, 507-515	
1923	A Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men. **2018**, 103, 3239-3249	3
1922	Expression, localisation and potential significance of aquaporins in benign and malignant human prostate tissue. **2018**, 18, 75	13
1921	[Urinary incontinence after radical prostatectomy : Possibilities of conservative management]. **2018**, 57, 1251-1254	1
1920	Multi-disciplinary and shared decision-making approach in the management of organ-confined prostate cancer. **2018**, 16, 367-377	4
1919	Therapeutic Effect of Controlled Release of Dual Growth Factor Using Heparin-Pluronic Hydrogel/Gelatin-Poly (Ethylene Glycol)-Tyramine Hydrogel System in a Rat Model of Cavernous Nerve Injury. **2018**, 24, 1705-1714	5
1918	Risk Assessment Based on Molecular and Genetic Markers in Prostate Cancer. **2018**, 1-16	

1917	Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. *European Urology*, **2018**, 74, 796-804	10.2	239
1916	Are localized prostate cancer biomarkers useful in the clinical practice?. **2018**, 40, 1010428318799255		11
1915	Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. **2018**, 12, 1807-1823		196
1914	Patient Selection for Active Surveillance in the Multi-parametric Magnetic Resonance Imaging Era: A Step Forward in a Rapidly Evolving Field. **2018**, 25, 3423-3424		1
1913	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer-From Cell Line Models to Liquid Biopsies. **2018**, 8,		12
1912	Bidirectional Barbed Only vs Poliglecaprone Suture with Rhabdosphincter Reconstruction for Urethrovesical Anastomosis During Robotic Radical Prostatectomy: Does It Make Any Difference?. **2018**, 32, 944-949		4
1911	Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer. **2018**, 7, 5411-5419		2
1910	Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation. **2018**, 10, 1189-1199		14
1909	ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. **2018**, 13, 166		17
1908	Genome-Based Classification and Therapy of Prostate Cancer. **2018**, 8,		10
1907	Promise and Implementation of Proteomic Prostate Cancer Biomarkers. **2018**, 8,		4
1906	A Novel Scoring System for Prediction of Prostate Cancer Based on Shear Wave Elastography and Clinical Parameters. **2018**, 121, 112-117		2
1905	Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease. **2018**, 7, 132-144		29
1904	Role of 11C-choline PET/CT in radiation therapy planning of patients with prostate cancer. **2018**, 39, 951-956		7
1903	Focal therapy for prostate cancer: concepts and future directions. **2018**, 28, 536-543		5
1902	Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges. **2018**, 19, 819-831		16
1901	Anterior Localization of Prostate Cancer Suspicious Lesions in 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies. **2018**, 200, 1035-1040		14
1900	Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. **2018**, 25, 929-936		1

1899	Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study. **2018**, 3, e000397	23
1898	Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. **2018**, 43, e226-e231	15
1897	Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. **2018**, 91, 20180308	36
1896	How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. **2018**, 122, 823-830	13
1895	The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide. **2018**, 46, 176-183	17
1894	Focal Treatment for Unilateral Prostate Cancer Using High-Intensity Focal Ultrasound: A Comprehensive Study of Pooled Data. **2018**, 32, 797-804	11
1893	Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy-Are 2 Biopsy Cores per Magnetic Resonance Imaging Lesion Required?. **2018**, 200, 1030-1034	18
1892	Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer. **2018**, 200, 767-773	40
1891	microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer. **2018**, 40, 1010428318775864	26
1890	Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence. **2018**, 25, 615-620	8
1889	Prostate cancer diagnostics: A review of practice across the northwest of England. **2018**, 11, 220-225	
1888	The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy. **2018**, 36, 2021-2025	12
1887	Primary hyperparathyroidism in prostate cancer: guilty or not guilty?. **2018**, 62, 271-273	
1886	Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer. **2018**, 27, 553-559	12
1885	Editorial Comment: Advances in MRI and PET of the prostate: concurrence or complementarity?. **2018**, 28, 3138-3140	
1884	[Prostate brachytherapy: New techniques, new indications]. **2018**, 22, 352-358	1
1883	PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naïve patient population. **2018**, 104, 64-70	22
1882	Comparison of [Ga]Ga-PSMA-11 PET/CT with [F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. **2018**, 45, 1873-1883	28

1881 Avances en radio oncologí de tumores urologicos. **2018**, 29, 163-168

1880 Systemic treatments for high-risk localized prostate cancer. **2018**, 15, 498-510 24

1879 Optimizing radiotherapy for intermediate-risk localized disease. **2018**, 15, 470-471 1

1878 One-Stop-Shop Whole-Body Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer. **2018**, 59, 1850-1856 37

1877 Four-point Peritoneal Flap Fixation in Preventing Lymphocele Formation Following Radical Prostatectomy. **2018**, 1, 443-448 18

1876 Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer. **2018**, 1, 208-214 17

1875 Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective, Multi-institutional, Nationwide series. **2018**, 1, 338-345 6

1874 Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?. **2018**, 3, 64-74 23

1873 Risk of secondary rectal cancer and colon cancer after radiotherapy for prostate cancer: a meta-analysis. **2018**, 33, 1149-1158 8

1872 Comparison of 3D printed prostate models with standard radiological information to aid understanding of the precise location of prostate cancer: A construct validation study. **2018**, 13, e0199477 16

1871 Sentinel lymph node dissection in prostate cancer using superparamagnetic particles of iron oxide: early clinical experience. **2018**, 50, 1427-1433 2

1870 Management of Localised Prostate Cancer in Kidney Transplant Patients: A Systematic Review from the EAU Guidelines on Renal Transplantation Panel. **2018**, 4, 153-162 13

1869 Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. *European Urology*, **2018**, 74, 525-526 10.2 2

1868 Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression. **2018**, 36, 366.e1-366.e9 8

1867 [Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence?]. **2018**, 28, 475-481 7

1866 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. **2018**, 45, 2035-2044 50

1865 Landmarks in prostate cancer. **2018**, 15, 627-642 39

1864 Performance of In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy. **2018**, 45, 2062-2070 10

1863	Accurate validation of ultrasound imaging of prostate cancer: a review of challenges in registration of imaging and histopathology. **2018**, 21, 197-207		13
1862	Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. *European Urology*, **2018**, 74, 680-681	10.2	
1861	Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?. **2018**, 16, 392-401		52
1860	Mind the gap: Physicians' assessment of patients' importance weights in localized prostate cancer. **2018**, 13, e0200780		3
1859	The impact of moderate wine consumption on the risk of developing prostate cancer. **2018**, 10, 431-444		13
1858	Marital status independently predicts prostate cancer survival in men who underwent radical prostatectomy: An analysis of 95,846 individuals. **2018**, 15, 4737-4744		14
1857	[Limits of surgery in uro-oncology]. **2018**, 57, 1058-1068		
1856	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. **2018**, 200, 1056-1061		1
1855	Trends in Treatment for Prostate Cancer in China: Preliminary Patterns of Care Study in a Single Institution. **2018**, 9, 1797-1803		8
1854	Leveraging the clinical collaborative model to drive value improvement. **2018**, 28, 348-353		2
1853	Prostate Imaging-Reporting and Data System Version 2: Beyond Prostate Cancer Detection. **2018**, 19, 193-200		8
1852	A Supervised Learning Tool for Prostate Cancer Foci Detection and Aggressiveness Identification using Multiparametric magnetic resonance imaging/magnetic resonance spectroscopy imaging. **2018**, 17, 1176935118786260		1
1851	Combined Analysis of Biparametric MRI and Prostate-Specific Antigen Density: Role in the Prebiopsy Diagnosis of Gleason Score 7 or Greater Prostate Cancer. **2018**, 211, W166-W172		12
1850	Survival outcomes of locally advanced prostate cancer in patients aged . **2018**, 50, 1435-1444		5
1849	Diffusion weighted MRI as an early predictor of tumor response to hypofractionated stereotactic boost for prostate cancer. **2018**, 8, 10407		11
1848	Predictors of participation in risk-based prostate cancer screening. **2018**, 13, e0200409		6
1847	Identifying the Best Candidate for Radical Prostatectomy in High-Risk Prostate Cancer. **2018**, 11-19		
1846	Pelvic Lymphadenectomy for High-Risk Prostate Cancer. **2018**, 41-49		

1845	External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients. **2018**, 1, 411-417	17
1844	Construction of a Preoperative Radiologic-Risk Signature for Predicting the Pathologic Status of Prostate Cancer at Radical Prostatectomy. **2018**, 211, 805-811	0
1843	Downregulation of NDR1 contributes to metastasis of prostate cancer cells via activating epithelial-mesenchymal transition. **2018**, 7, 3200	5
1842	Multiparametric magnetic resonance imaging versus Partin tables and the Memorial Sloan-Kettering cancer center nomogram in risk stratification of patients with prostate cancer referred to external beam radiation therapy. **2018**, 123, 778-787	3
1841	Evaluation and Treatment for Older Men with Elevated PSA. **2018**, 21-41	
1840	Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management. **2018**, 25, 293-303	8
1839	An initial melanoma diagnosis may increase the subsequent risk of prostate cancer: Results from the New South Wales Cancer Registry. **2018**, 8, 7167	8
1838	Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. **2018**, 122, 744-753	41
1837	Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer. **2018**, 123, 952-965	9
1836	Clinical evaluation of the iXip index to reduce prostate re-biopsies. **2018**, 16, 59-63	6
1835	Proteoform Analysis to Fulfill Unmet Clinical Needs and Reach Global Standardization of Protein Measurands in Clinical Chemistry Proteomics. **2018**, 38, 487-497	11
1834	Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review. **2018**, 70, 370-379	6
1833	Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review. **2018**, 70, 347-360	16
1832	Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. **2018**, 122, 152-157	17
1831	Is oxidative stress measured by thiol/disulphide homeostasis status associated with prostate adenocarcinoma?. **2018**, 43, 174-179	10
1830	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. **2018**, 24, 6300-6307	67
1829	Positron-emission tomography imaging in urological oncology: Current aspects and developments. **2018**, 25, 912-921	9
1828	MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years. **2018**, 21, 473-487	31

1827	Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?. **2018**, 59, 83-90		7
1826	Nuclear Medicine Imaging of Prostate Cancer in the Elderly. **2018**, 48, 541-547		3
1825	Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 'real-life' studies. **2018**, 10, 305-315		11
1824	Effect of the number of removed lymph nodes on prostate cancer recurrence and survival: evidence from an observational study. **2018**, 19, 200		2
1823	Clinical and pathologic factors predicting reclassification in active surveillance cohorts. **2018**, 44, 440-451		8
1822	Preoperative Staging With C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. **2018**, 16, 305-312.e1		11
1821	Convective-Dispersion Modeling in 3D Contrast-Ultrasound Imaging for the Localization of Prostate Cancer. **2018**, 37, 2593-2602		10
1820	The association of lymph node dissection with 30-day perioperative morbidity among men undergoing minimally invasive radical prostatectomy: analysis of the National Surgical Quality Improvement Program (NSQIP). **2018**, 21, 245-251		6
1819	Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study. **2018**, 21, 438-445		6
1818	□Viniferin activates autophagic apoptosis and cell death by reducing glucocorticoid receptor expression in castration-resistant prostate cancer cells. **2018**, 35, 105		8
1817	Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging. **2018**, 45, 503-524		19
1816	Association between dietary flavonoids intake and prostate cancer risk: A case-control study in Sicily. **2018**, 39, 14-18		20
1815	External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study. **2018**, 36, 364.e1-364.e7		9
1814	Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. **2018**, 1, e180219		93
1813	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. *European Urology*, **2018**, 74, 357-368	10.2	72
1812	Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. **2018**, 1, 29-36		26
1811	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. *European Urology*, **2019**, 75, 385-396	10.2	121
1810	Imaging modalities in synchronous oligometastatic prostate cancer. **2019**, 37, 2573-2583		11

1809	Improvement of prostate cancer detection combining a computer-aided diagnostic system with TRUS-MRI targeted biopsy. **2019**, 44, 264-271		5
1808	Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy. **2019**, 39, 40-69		64
1807	Comparison of the accuracy of multiparametric magnetic resonance imaging (mpMRI) results with the final pathology findings for radical prostatectomy specimens in the detection of prostate cancer. **2019**, 15, e20-e27		5
1806	Elderly patients aged â□¥75´years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis. **2019**, 37, 317-325		4
1805	Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. **2019**, 22, 24-38		108
1804	Ga-PSMA-PET/CT in comparison with F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. **2019**, 29, 1221-1230		44
1803	Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. **2019**, 22, 101-109		41
1802	A risk-based approach to identifying oligometastatic disease on imaging. **2019**, 144, 422-430		8
1801	Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. *European Urology*, **2019**, 75, 310-318	10.2	66
1800	Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer. **2019**, 37, 2565-2571		7
1799	Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies. **2019**, 37, 269-275		9
1798	Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. **2019**, 124, 98-106		7
1797	Extra-target low-risk prostate cancer: implications for focal high-intensity focused ultrasound of clinically significant prostate cancer. **2019**, 37, 261-268		5
1796	Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. **2019**, 123, 22-34		20
1795	Current Management of pT3b Prostate Cancer After Robot-assisted Laparoscopic Prostatectomy. **2019**, 2, 110-117		7
1794	The role of protein tyrosine phosphatases in prostate cancer biology. **2019**, 1866, 102-113		7
1793	Prostate volume index and prostatic chronic inflammation have an effect on tumor load at baseline random biopsies in patients with normal DRE and PSA values less than 10 ng/ml: results of 564 consecutive cases. **2019**, 11, 1756287219868604		4
1792	A machine learning-assisted decision-support model to better identify patients with prostate cancer requiring an extended pelvic lymph node dissection. **2019**, 124, 972-983		9

1791	Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation. **2019**, 10,		7
1790	Preliminary results of a Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making. **2019**, 79, 1514-1522		12
1789	Risk Assessment Based on Molecular and Genetic Markers in Prostate Cancer. **2019**, 109-124		
1788	Diagnostic Performance of Prostate Multiparametric Magnetic Resonance Imaging in African-American Men. **2019**, 134, 181-185		2
1787	Grade groups at diagnosis in African Caribbean men with prostate cancer: Results of a comparative study. **2019**, 79, 1640-1646		1
1786	Bone Target Therapy in Urologic Malignancies. **2019**, 77-93		
1785	A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer. **2019**, 18, 759-767		1
1784	Anatomical localization of radiocolloid tracer deposition affects outcome of sentinel node procedures in prostate cancer. **2019**, 46, 2558-2568		6
1783	Cost-utility analysis of focal high-intensity focussed ultrasound vs active surveillance for low- to intermediate-risk prostate cancer using a Markov multi-state model. **2019**, 124, 962-971		1
1782	3-D Multi-parametric Contrast-Enhanced Ultrasound for the Prediction of Prostate Cancer. **2019**, 45, 2713-2724		8
1781	MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study. **2019**, 104, 1045-1053		15
1780	Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy. **2019**, 17, e1036-e1047		3
1779	I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer. **2019**, 18, 72-80		3
1778	Salvage lymph node dissection in patients with prostate cancer treated with radical prostatectomy or radiotherapy and positive choline positron emission tomography (PET/CT) scan. **2019**, 43, 331-335		
1777	Advances in whole body MRI for musculoskeletal imaging: Diffusion-weighted imaging. **2019**, 10, 680-686		7
1776	Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis. **2019**, 497, 76-80		18
1775	Diagnostic performance of multiparametric MRI parameters for Gleason score and cellularity metrics of prostate cancer in different zones: a quantitative comparison. **2019**, 74, 895.e17-895.e26		4
1774	Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. *European Urology*, **2019**, 76, 732-739	10.2	55

1773	The EORTC quality of life questionnaire predicts early and long-term incontinence in patients treated with robotic assisted radical prostatectomy: Analysis of a large single center cohort. **2019**, 37, 1006-1013	4
1772	Anti-PSMA I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle. **2019**, 38, 326	9
1771	Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. **2019**, 46, 2289-2297	10
1770	Functional outcomes of artificial urinary sphincter implantation with distal bulbar double cuff in men with and without a history of external beam radiotherapy: an analysis of a prospective database. **2019**, 124, 1040-1046	4
1769	Shared decision making for men facing prostate cancer treatment: a systematic review of randomized controlled trials. **2019**, 13, 1153-1174	8
1768	Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer. **2019**, 11,	4
1767	Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16. **2019**, 11, 195-200	7
1766	Comparison of analgesic techniques in MRI-guided in-bore prostate biopsy. **2019**, 29, 6965-6970	1
1765	Phytochemicals in Prostate Cancer: From Bioactive Molecules to Upcoming Therapeutic Agents. **2019**, 11,	25
1764	Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus. **2019**, 140, 131-142	19
1763	Electrochemical aptamer-based bioplatform for ultrasensitive detection of prostate specific antigen. **2019**, 297, 126762	30
1762	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. **2019**, 292, 273-286	24
1761	Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?. **2019**, 45, 459-467	8
1760	Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients. **2019**, 10, 2237-2242	9
1759	Active Surveillance beim Prostatakarzinom. **2019**, 14, 442-451	
1758	Health-related quality of life by human immunodeficiency virus status in a cross-sectional survey of gay and bisexual prostate cancer survivors. **2019**, 28, 2351-2357	5
1757	Yield of prostate cancer screening at a community based clinic in Saudi Arabia. **2019**, 40, 681-686	2
1756	Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. **2019**, 14, 177	8

1755	MRI-Fusion Targeted vs. Systematic Prostate Biopsy-How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?. **2019**, 6, 55	9
1754	Integrity of the Urethral Sphincter Complex, Nerve-sparing, and Long-term Continence Status after Robotic-assisted Radical Prostatectomy. **2019**, 5, 823-830	16
1753	Automated grading of prostate cancer using convolutional neural network and ordinal class classifier. **2019**, 17, 100256	16
1752	Imaging for radiation treatment planning and monitoring in prostate Cancer: Precision, personalization, individualization of therapy. **2019**, 11, 61-62	1
1751	Oncological Outcome After Radical Prostatectomy without Pelvic Lymph Node Dissection for Localized Prostate Cancer: Follow-up Results in a Single Institution. **2019**, 37, 524-530	1
1750	Herbal formula (Danggui Beimu Kushen Wan) for prostate disorders: a systematic review of classical literature. **2019**, 8, 240-246	6
1749	A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer. **2019**, 124 Suppl 1, 31-36	14
1748	Knockdown of COPS3 inhibits the progress of prostate cancer through reducing phosphorylated p38 MAPK expression and impairs the epithelial-mesenchymal transition process. **2019**, 79, 1823-1831	3
1747	Hereditary prostate cancer - Primetime for genetic testing?. **2019**, 81, 101927	10
1746	In Search for risk predictors at the microscopic scenario of a negative biopsy. A systematic review. **2019**, 43, 337-347	
1745	PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery. **2019**, 9, 6824-6839	34
1744	Proportion of cores with the highest Gleason grade group among positive cores on prostate biopsy: does this affect the probability of upgrading or downgrading?. **2019**, 53, 372-377	2
1743	DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer. **2019**, 11, 152	3
1742	[Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review]. **2019**, 29, 393-401	5
1741	The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research. **2019**, 11,	31
1740	Surface-projection-based transperineal cognitive fusion targeted biopsy of the prostate: an original technique with a good cancer detection rate. **2019**, 19, 107	2
1739	Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy. **2019**, 14, 198	4
1738	Diagnostic Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy After Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Intermediate- and High-Risk Prostate Cancer Using the Magnetic Activity of Sentinel Nodes. **2019**, 10, 1123	0

1737	Retzius-sparing robot-assisted laparoscopic radical prostatectomy: functional and early oncologic results in aggressive and locally advanced prostate cancer. **2019**, 19, 113		20
1736	Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?. **2019**, 2, 664-669		13
1735	PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years. **2019**, 141, 188-191		5
1734	FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer. **2019**, 5, 272-286		12
1733	Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer. **2019**, 39, 962-974		5
1732	Novel Diagnostic Biomarkers of Prostate Cancer: An Update. **2019**, 26, 1045-1058		14
1731	Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer-A Comprehensive Review. **2019**, 9,		8
1730	Machine learning applications in prostate cancer magnetic resonance imaging. **2019**, 3, 35		59
1729	Does therapy of the primary tumor matter in oligometastatic prostate cancer? A prospective 10-year follow-up study. **2019**, 11, 215-221		1
1728	Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy. **2019**, 51, 2169-2180		5
1727	Glycosylation products in prostate diseases. **2019**, 498, 52-61		5
1726	Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. *European Urology*, **2019**, 76, 823-830	10.2	10
1725	Quality of Life Changes >10 Years After Postoperative Radiation Therapy After Radical Prostatectomy for Prostate Cancer. **2019**, 105, 382-388		5
1724	Artificial intelligence-based versus manual assessment of prostate cancer in the prostate gland: a method comparison study. **2019**, 39, 399-406		21
1723	Multimodality Imaging of Prostate Cancer. **2019**, 60, 1350-1358		23
1722	Emerging therapeutic agents for genitourinary cancers. **2019**, 12, 89		22
1721	Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy. **2019**, 14, 487-498		1
1720	[Prophylactic nodal radiotherapy in prostate cancer]. **2019**, 23, 688-695		0

1719	Tumor infiltrating M2 macrophages could predict biochemical recurrence of localized prostate cancer after radical prostatectomy. **2019**, 384, 111588	8
1718	Management Strategies and Patient Selection After a Hospital Funding Reform for Prostate Cancer Surgery in Canada. **2019**, 2, e1910505	
1717	Diagnostic Accuracy of Multiparametric MRI versus Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer. **2019**, 293, 350-358	41
1716	MRI-Derived Radiomics to Guide Post-operative Management for High-Risk Prostate Cancer. **2019**, 9, 807	21
1715	Salvage Local Treatments After Focal Therapy for Prostate Cancer. **2019**, 2, 526-538	18
1714	Discrepancy between Expectations and Experiences after Prostate Cancer Treatment: A Dutch Multicenter Study. **2019**, 134, 135-142	2
1713	Is There an Optimal Curative Option in HIV-Positive Men with Localized Prostate Cancer? A Systematic Review. **2019**, 12, 169-176	2
1712	F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis. **2019**, 11,	15
1711	Op metastasen gerichte behandeling van prostaatcarcinoom. **2019**, 9, 108-116	1
1710	Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. **2019**, 20, 1531-1543	172
1709	[Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer. **2019**, 141, 214-219	50
1708	Psychological nursing approach on anxiety and depression of patients with severe urinary incontinence after radical prostatectomy - a pilot study. **2019**, 47, 5689-5701	4
1707	Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study. **2019**, 11,	35
1706	Patterns of recurrence after prostate bed radiotherapy. **2019**, 141, 174-180	10
1705	High surgeon volume and positive surgical margins can predict the risk of biochemical recurrence after robot-assisted radical prostatectomy. **2019**, 11, 1756287219878283	3
1704	Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients. **2019**, 11,	13
1703	Dosimetric variations for high-risk prostate cancer by VMAT plans due to patientâ weight changes. **2019**, 18, 336-342	
1702	Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology. **2019**, 124, 221-241	1

1701	Optical Coherence Tomography in Urologic Oncology: a Comprehensive Review. **2019**, 1, 67-84		7
1700	Perioperative and oncological outcomes of radical prostatectomy for high-risk prostate cancer in the UK: an analysis of surgeon-reported data. **2019**, 124, 441-448		6
1699	Detection Rate of F-Choline PET/CT and Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes. **2019**, 60, 971-977		22
1698	Stereotactic Re-irradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: Preliminary Results. **2019**, 9, 71		16
1697	Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy. **2019**, 17, e494-e504		2
1696	Open and robotic radical prostatectomy. **2019**, 6, 125-128		5
1695	The Learning Curve for Magnetic Resonance Imaging/Ultrasound Fusion-guided Prostate Biopsy. **2019**, 2, 135-140		30
1694	Safety and Image Quality of 1.5-T Endorectal Coil Multiparametric MRI of the Prostate or Prostatectomy Fossa for Patients With Pacemaker or Implantable Cardioverter-Defibrillator. **2019**, 212, 815-822		3
1693	Prostate-specific antigen screening for prostate cancer in males older than 75 years. **2019**, 152, 237-240		2
1692	ERG expression can predict the outcome of docetaxel combinedwith androgen deprivation therapy in metastatic hormone-sensitiveprostate cancer. **2019**, 37, 289.e1-289.e9		2
1691	Establishing a prediction model for prostate cancer bone metastasis. **2019**, 15, 208-220		9
1690	A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. **2019**, 37, 2099-2108		2
1689	Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience. **2019**, 11, 1756287218820804		2
1688	Re: Abdenour Nabid, Nathalie Carrier, Andr‰ -Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31. *European Urology*, **2019**, 75, e61-e62	10.2	1
1687	Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. **2019**, 37, 2147-2153		15
1686	A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?. **2019**, 37, 2343-2353		25
1685	Complications, oncological and functional outcomes of salvage treatment options following focal therapy for localized prostate cancer: a systematic review and a comprehensive narrative review. **2019**, 37, 1517-1534		10
1684	Combined-modality J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects. **2019**, 37, 2355-2363		1

1683	Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists. **2019**, 11, 3079-3097		6
1682	Prostate cancer screening: guidelines review and laboratory issues. **2019**, 57, 1474-1487		19
1681	Vasectomy and Prostate Cancer Risk: A 38-Year Nationwide Cohort Study. **2020**, 112, 71-77		6
1680	Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. *European Urology*, **2019**, 76, 284-303	10.2	90
1679	The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival. **2019**, 33, 681-688		11
1678	Prostate cancer - Advantages and disadvantages of MR-guided RT. **2019**, 18, 68-73		31
1677	Deformable registration of x ray and MRI for postimplant dosimetry in low dose rate prostate brachytherapy. **2019**, 46, 3961-3973		
1676	Prostate Radiotherapy in India: Evolution, Practice and Challenges in the 21st Century. **2019**, 31, 492-501		6
1675	Periprostatic nerve block alone versus combined with perineal pudendal nerve block or intrarectal local anesthesia during transrectal ultrasound-guided prostate biopsy: A prospective randomized controlled trial. **2019**, 26, 833-838		5
1674	Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: a retrospective radiomics study. **2019**, 92, 20190286		22
1673	Evolution of prostate MRI: from multiparametric standard to less-is-better and different-is better strategies. **2019**, 3, 5		11
1672	[Screening for prostate cancer using prostate-specific antigen (PSA) : A commentary on a systematic review and meta-analysis]. **2019**, 58, 925-928		1
1671	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. **2019**, 140, 68-75		11
1670	Fluorescence Detection of Prostate Cancer by an Activatable Fluorescence Probe for PSMA Carboxypeptidase Activity. **2019**, 141, 10409-10416		42
1669	Epidemiology of Prostate Cancer. **2019**, 10, 63-89		689
1668	Robot-assisted radical prostatectomy versus volumetric modulated arc therapy: Comparison of front-line therapies for localized prostate cancer. **2019**, 140, 62-67		2
1667	Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population-based propensity score matching study. **2019**, 8, 4475-4483		4
1666	TRIM24 as an independent prognostic biomarker for prostate cancer. **2019**, 37, 576.e1-576.e10		9

1665	A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy. **2019**, 145, 3445-3452	9
1664	Supervised risk predictor of central gland lesions in prostate cancer using H MR spectroscopic imaging with gradient offset-independent adiabaticity pulses. **2019**, 50, 1926-1936	5
1663	Oncological safety of intrafascial nerve-sparing radical prostatectomy compared with conventional process: a pooled review and meta-regression analysis based on available studies. **2019**, 19, 41	4
1662	Comparison of diagnostic value of multi-slice spiral CT and MRI for different pathological stages of prostate cancer. **2019**, 17, 5505-5510	3
1661	Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. **2019**, 9, 2595-2605	59
1660	Radiotherapy for prostate cancer: DISCERN quality assessment of patient-oriented websites in 2018. **2019**, 19, 42	8
1659	Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data. **2019**, 19, 26	4
1658	Risk of metastatic disease on gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. **2019**, 124, 401-407	49
1657	Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncological and functional outcomes. **2019**, 124, 746-757	8
1656	No Added Value of F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy. **2019**, 60, 1713-1716	8
1655	Validated Prospective Assessment of Quality of Life After Robot-Assisted Laparoscopic Prostatectomy: Beyond Continence and Erections. **2019**, 13, 1557988319854555	3
1654	Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105. *European Urology*, **2019**, 76, e63-e64	10.2
1653	Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway. **2019**, 61, 59-69	13
1652	, , and : Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer. **2019**, 20,	9
1651	The First In Vivo Needle-Based Optical Coherence Tomography in Human Prostate: A Safety and Feasibility Study. **2019**, 51, 390	5
1650	The Patient Journey in Prostate Cancer: Key Points for Nurses. **2019**, 195-213	
1649	Transperineal Magnetic Resonance Imaging-Targeted Biopsy May Perform Better Than Transrectal Route in the Detection of Clinically Significant Prostate Cancer: Systematic Review and Meta-analysis. **2019**, 17, e860-e870	19
1648	Clinically significant prostate cancer detection on MRI: A radiomic shape features study. **2019**, 116, 144-149	47

1647	Can We Improve the Preoperative Prediction of Prostate Cancer Recurrence With Multiparametric MRI?. **2019**, 17, e745-e750		5
1646	A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients. **2019**, 124, 609		17
1645	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. *European Urology*, **2019**, 76, 142-150	10.2	51
1644	CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. **2019**, 120, 1120-1128		9
1643	How does Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?. **2019**, 26, 804-811		12
1642	Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer. **2019**, 17, 1699-1709		13
1641	Oligometastases in prostate cancer: Ablative treatment. **2019**, 10, 38-51		19
1640	Infections after transrectal ultrasonic guided prostate biopsies - a retrospective study. **2019**, 53, 97-101		3
1639	Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer. **2019**, 37, 813.e11-813.e19		1
1638	Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer. **2019**, 79, 1007-1017		18
1637	[Active surveillance in prostate cancer]. **2019**, 58, 511-517		1
1636	Magnetic resonance imaging-transrectal ultrasound image fusion guidance of prostate biopsies: current status, challenges and future perspectives. **2019**, 53, 89-96		5
1635	A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy. **2019**, 9,		2
1634	Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis. **2019**, 20,		44
1633	Effectiveness of fosfomycin tromethamine prophylaxis in preventing infection following transrectal ultrasound-guided prostate needle biopsy: Results from a large Canadian cohort. **2019**, 17, 112-116		5
1632	MRI-Based Radiomics Signature for the Preoperative Prediction of Extracapsular Extension of Prostate Cancer. **2019**, 50, 1914-1925		25
1631	Radiation Dosimetry and Biodistribution of F-PSMA-11 for PET Imaging of Prostate Cancer. **2019**, 60, 1736-1742		20
1630	Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United States. **2019**, 130, 72-78		4

1629	Improving direct immunoassay response by layer-by-layer films of gold nanoparticles - Antibody conjugate towards label-free detection. **2019**, 102, 315-323	20
1628	Impact of Magnetic Resonance Imaging on Prostate Cancer Staging and European Association of Urology Risk Classification. **2019**, 130, 113-119	7
1627	[Contrast-agent free imaging of the prostate : Ready for clinical practice?]. **2019**, 59, 503-509	1
1626	A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies. **2019**, 22, 609-616	13
1625	Prostate cancer dose-response, fractionation sensitivity and repopulation parameters evaluation from 25 international radiotherapy outcome data sets. **2019**, 92, 20180823	4
1624	Clinical Significance of Multiparametric Magnetic Resonance Imaging as a Preoperative Predictor of Oncologic Outcome in Very Low-Risk Prostate Cancer. **2019**, 8,	2
1623	[Influence of modern diagnostic methods on the treatment of nonmetastatic castration-resistant prostate cancer]. **2019**, 58, 529-534	
1622	Kurative Therapie bei organbegrenztem Prostatakarzinom. **2019**, 21, 33-35	
1621	â€Active surveillanceâ€des lokal begrenzten Prostatakarzinoms. **2019**, 21, 29-32	
1620	Image guidance in robot-assisted radical prostatectomy: how far do we stand?. **2019**, 29, 10-13	4
1619	Clinical interpretation of prostate-specific antigen values: Type of applied cut-off value exceeds methods bias as the major source of variation. **2019**, 56, 259-265	1
1618	Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis. **2019**, 58, 916-925	7
1617	A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. **2019**, 17, e472-e481	3
1616	External validation of a nomogram for the prediction of 10-year life expectancy in candidates for radical prostatectomy. **2019**, 37, 2649-2655	3
1615	Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer. **2019**, 63, 318-323	3
1614	Contribution of Radiology to Staging of Prostate Cancer. **2019**, 49, 294-301	9
1613	[Active surveillance of prostate cancer : An update]. **2019**, 58, 329-340	
1612	Molecular Imaging and Theranostics-A Multidisciplinary Approach. **2019**, 49, 247-254	13

1611	Prostate-specific antigen screening for prostate cancer in males older than 75 years. **2019**, 152, 237-240		
1610	Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition. **2019**, 37, 297.e19-297.e31		21
1609	What is the most effective local anesthesia for transrectal ultrasonography-guided biopsy of the prostate? A systematic review and network meta-analysis of 47 randomized clinical trials. **2019**, 9, 4901		8
1608	Ex vivo fluorescence confocal microscopy: the first application for real-time pathological examination of prostatic tissue. **2019**, 124, 469-476		43
1607	Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis. **2019**, 20,		5
1606	Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer. **2019**, 24, 957-965		3
1605	Development of symptomatic lymphoceles after radical prostatectomy and pelvic lymph node dissection is independent of surgical approach: a single-center analysis. **2019**, 51, 633-640		14
1604	Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?. **2019**, 75, 20-26		15
1603	Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model. **2019**, 16, e1002758		27
1602	An overview on the methodological and reporting quality of dose-response meta-analysis on cancer prevention. **2019**, 145, 1201-1211		4
1601	Intermediäres Risikoprofil beim Prostatakarzinom. **2019**, 25, 322-329		1
1600	A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer. **2019**, 41, 412-425		4
1599	The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). *European Urology*, **2019**, 76, 461-466	10.2	6
1598	Essential Updates in Grading, Morphotyping, Reporting, and Staging of Prostate Carcinoma for General Surgical Pathologists. **2019**, 143, 550-564		13
1597	[Current controversies in the treatment of localized prostate cancer]. **2019**, 58, 524-528		0
1596	A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China. **2019**, 15, 144-150		4
1595	Aberrant , , and Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer. **2019**, 20,		19
1594	Head-to-head comparison between multiparametric MRI, the partin tables, memorial sloan kettering cancer center nomogram, and CAPRA score in predicting extraprostatic cancer in patients undergoing radical prostatectomy. **2019**, 50, 1604-1613		14

1593	Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up. *European Urology*, **2019**, 76, 130-131	10.2	
1592	End-to-side Somatic-to-autonomic Nerve Grafting to Restore Erectile Function and Improve Quality of Life After Radical Prostatectomy. *European Urology*, **2019**, 76, 189-196	10.2	7
1591	Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. **2019**, 104, 614-621		11
1590	Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement. **2019**, 44, 2545-2556		18
1589	Mini Review on the Use of Clinical Cancer Registers for Prostate Cancer: The National Prostate Cancer Register (NPCR) of Sweden. **2019**, 6, 51		12
1588	Multimodal treatments for advanced prostate cancer. **2019**, 10, 255-256		
1587	Morphologic changes after bladder neck intussusception in laparoscopic radical prostatectomy contribute to early postoperative continence. **2019**, 51, 1157-1165		1
1586	Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre. **2019**, 63, 495-499		10
1585	Active surveillance for non-muscle invasive bladder cancer. **2019**, 8, 54-60		5
1584	The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer. **2019**, 130, 1-12		28
1583	Is Extraprostatic Extension of Cancer Predictable? A Review of Predictive Tools and an External Validation Based on a Large and a Single Center Cohort of Prostate Cancer Patients. **2019**, 129, 8-20		14
1582	Biparametric vs multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatment-naïve patients: a diagnostic test accuracy systematic review and meta-analysis. **2019**, 124, 209-220		49
1581	Resonancia magnˆ tica funcional de la prstata. **2019**, 51, 1-11		
1580	Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?. **2019**, 40, 86-91		38
1579	Preoperative magnetic resonance imaging in predicting early continence recovery after robotic radical prostatectomy. **2019**, 43, 137-142		1
1578	Effectiveness of Bi-Parametric MR/US Fusion Biopsy for Detecting Clinically Significant Prostate Cancer in Prostate Biopsy Naïve Men. **2019**, 60, 346-351		7
1577	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. *European Urology*, **2019**, 76, 179-186	10.2	10
1576	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. *European Urology*, **2019**, 76, 443-449	10.2	8

1575	miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKC□and ZEB1 inhibition. **2019**, 38, 51	41
1574	Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). **2019**, 44, 1883-1893	46
1573	Misinformation on the Internet regarding Ablative Therapies for Prostate Cancer. **2019**, 133, 182-186	5
1572	Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment. **2019**, 37, 2657-2662	2
1571	Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers. **2019**, 15, 108-120	13
1570	Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. **2019**, 17, 31	70
1569	Hydro-Jet Dissection of the Cavernous Nerves Preserves Erection Function in a Radical Prostatectomy Animal Model. **2019**, 7, 104-110	
1568	Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. **2019**, 20, 14	12
1567	Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance. **2019**, 124, 730-737	10
1566	Evolution, controversies and the future of prostate cancer grading. **2019**, 69, 55-66	2
1565	F-Fluoromethylcholine-positron emission tomography/computed tomography for diagnosing bone and lymph node metastases in patients with intermediate- or high-risk prostate cancer. **2019**, 7, 119-123	3
1564	Data Visualization in Clinical Practice. **2019**, 289-304	
1563	Prostate Cancer Biomarkers. **2019**, 869-881	2
1562	Using biparametric MRI radiomics signature to differentiate between benign and malignant prostate lesions. **2019**, 114, 38-44	24
1561	Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years. *European Urology*, **2019**, 75, 1035-1036	102
1560	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. **2019**, 29, 111-125	2
1559	Prostate tumor neuroendocrine differentiation via EMT: The road less traveled. **2019**, 6, 82-90	17
1558	Impact of the baseline study with penile doppler ultrasound in patients with prostate cancer before radical prostatectomy. **2019**, 43, 84-90	

1557	Diagnosis of prostate cancer. **2019**, 6, 129-136	34
1556	Downgrading of Grade Group After Radical Prostatectomy: Comparison of Multiparametric Magnetic Resonance Imaging Guided Fusion Biopsy and Standard 12-Core Biopsy. **2019**, 127, 80-85	8
1555	Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA . **2019**, 9, e031032	3
1554	Partial versus complete prostatectomy specimen sampling: prospective non-inferiority study for pT3a tumours and surgical margin involvement. **2019**, 9, e024524	1
1553	The clinical utility of transperineal template-guided saturation prostate biopsy for risk stratification after transrectal ultrasound-guided biopsy. **2019**, 60, 454-462	5
1552	Pathological Characteristics of Prostate Cancer in Men Aged 2019, 34, e78	4
1551	Detection of individual prostate cancer via multiparametric magnetic resonance imaging in own material - initial experience. **2019**, 11, 541-546	0
1550	The role of gadolinium in magnetic resonance imaging for early prostate cancer diagnosis: A diagnostic accuracy study. **2019**, 14, e0227031	9
1549	Adjuvant radiotherapy in prostate cancer patients with positive margins or extracapsular extension. **2019**, 7, S291	
1548	Quantification of PSMA expression in prostate cancer by pharmacokinetic modeling of targeted ultrasound nanobubbles. **2019**,	0
1547	Machine Learning for Multiparametric Ultrasound Classification of Prostate Cancer using B-mode, Shear-Wave Elastography, and Contrast-Enhanced Ultrasound Radiomics. **2019**,	1
1546	Estudio de concordancia entre los resultados de la puntuación de Gleason de biopsias de próstata y los de la prostatectomía radical en pacientes con cáncer de próstata localizado. **2019**, 67, 209-214	
1545	Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. **2019**, 4, CD012663	109
1544	Multiparametric Ultrasound for the Targeting of Prostate Cancer using ARFI, SWEI, B-mode, and QUS. **2019**,	
1543	Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis. **2019**, 2, e1918145	10
1542	Interventional therapy in malignant conditions of the prostate. **2019**, 59, 28-39	2
1541	Individual Comparison of Cholesterol Metabolism in Normal and Tumour Areas in Radical Prostatectomy Specimens from Patients with Prostate Cancer: Results of the CHOMECAP Study. **2019**, 2, 198-206	2
1540	Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. **2019**, 2, 189-195	4

1539	Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men. **2019**, 2, 311-319	42
1538	A Single Educational Seminar Increases Confidence and Decreases Dropout from Active Surveillance by 5 Years After Diagnosis of Prostate Cancer. **2019**, 2, 464-470	4
1537	Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer. **2019**, 2, 329-332	33
1536	Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. **2019**, 2, 456-463	8
1535	Development and internal validation of a novel model and markers to identify the candidates for lymph node metastasis in patients with prostate cancer. **2019**, 98, e16534	6
1534	Magnetic resonance imaging-guided targeted biopsy in risk classification among patients on active surveillance: A diagnostic meta-analysis. **2019**, 98, e16122	1
1533	TGF-□and microRNA Interplay in Genitourinary Cancers. **2019**, 8,	9
1532	[When to introduce hormone therapy after total prostatectomy with positive lymph nodes? Study of the factors influencing the time of introduction of hormone therapy]. **2019**, 29, 981-988	
1531	Fifteen-year analysis of prostate biopsies in Western Australia including recent impact of multiparametric magnetic resonance imaging. **2019**, 89, 1605-1609	1
1530	[Importance of magnetic resonance imaging/ultrasound-guided fusion biopsy for the detection and monitoring of prostate cancer]. **2019**, 58, 1499-1510	0
1529	Hypofractionation for clinically localized prostate cancer. **2019**, 9, CD011462	14
1528	Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database. **2019**, 9, 17985	11
1527	Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel. **2019**, 11, 175	21
1526	Performance and inter-observer variability of prostate MRI (PI-RADS version 2) outside high-volume centres. **2019**, 53, 304-311	13
1525	Tumors of the Male Reproductive System. **2019**, 626-644	
1524	Consensus Procedures in Oncological Imaging: The Case of Prostate Cancer. **2019**, 11,	2
1523	Robot-assisted and laparoscopic vs open radical prostatectomy in clinically localized prostate cancer: perioperative, functional, and oncological outcomes: A Systematic review and meta-analysis. **2019**, 98, e15770	37
1522	Management of biochemical recurrence after radical prostatectomy for prostate cancer: A case report. **2019**, 98, e16351	

1521	Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. **2019**, 40, 940-946	21
1520	Risk stratification and avoiding overtreatment in localized prostate cancer. **2019**, 29, 612-619	7
1519	lncRNA DGCR5 Up-Regulates TGF-□1, Increases Cancer Cell Stemness and Predicts Survival of Prostate Cancer Patients. **2019**, 11, 10657-10663	6
1518	The Role of Radical Prostatectomy and Lymph Node Dissection in Clinically Node Positive Patients. **2019**, 9, 1395	5
1517	Discovering novel P38□inhibitors for the treatment of prostate cancer through virtual screening methods. **2019**, 11, 3125-3137	2
1516	Incorporating mpMRI biopsy data into established pre-RP nomograms: potential impact of an increasingly common clinical scenario. **2019**, 11, 1756287219882809	0
1515	Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer. **2019**, 19, 90	17
1514	Development and validation of a preoperative nomogram for predicting positive surgical margins after laparoscopic radical prostatectomy. **2019**, 132, 928-934	5
1513	Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer. **2019**, 98, e16705	16
1512	Bone Health in Men with Prostate Cancer: Review Article. **2019**, 17, 527-537	10
1511	Impact of the 2014 International Society of Urological Pathology Grading System on Concept of High-Risk Prostate Cancer: Comparison of Long-Term Oncological Outcomes in Patients Undergoing Radical Prostatectomy. **2019**, 9, 1272	5
1510	Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer. **2019**, 98, e16193	6
1509	Factors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient health: Cohort study protocol. **2019**, 98, e17451	8
1508	A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach. **2019**, 54, 437-447	17
1507	Active surveillance for intermediate-risk prostate cancer: yes, but for whom?. **2019**, 29, 605-611	1
1506	PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance. **2019**, 30, e0773	5
1505	The comparison of transurethral versus suprapubic catheter after robot-assisted radical prostatectomy: a systematic review and meta-analysis. **2019**, 8, 476-488	2
1504	Improved specificity with Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. **2019**, 46, 20-30	40

1503	Antimicrobial Lubricant Did Not Reduce Infection Rate in Transrectal Biopsy Patients in a Large Randomized Trial Due to Low Complication Rates. **2019**, 5, 992-997		2
1502	Interreader agreement of PI-RADS v. 2 in assessing prostate cancer with multiparametric MRI: A study using whole-mount histology as the standard of reference. **2019**, 49, 546-555		35
1501	Nationwide treatment patterns and survival of older patients with prostate cancer. **2019**, 10, 252-258		14
1500	Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. **2019**, 37, 138-144		24
1499	An updated approach to incremental nerve sparing for robot-assisted radical prostatectomy. **2019**, 124, 103-108		10
1498	Multidimensional analysis of clinicopathological characteristics of false-negative clinically significant prostate cancers on multiparametric MRI of the prostate in Japanese men. **2019**, 37, 154-164		6
1497	History of Urinary Retention Is a Risk Factor for Infection after Prostate Biopsy: A Nationwide, Population-Based Cohort Study. **2019**, 20, 202-207		2
1496	Use of fosfomycin as targeted antibiotic prophylaxis before prostate biopsy: A prospective randomized study. **2019**, 26, 391-397		6
1495	The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth than Either Drug Alone. **2019**, 33, 99-108		5
1494	Oncological long-term outcome of whole gland HIFU and open radical prostatectomy: a comparative analysis. **2019**, 37, 2073-2080		3
1493	Initial evaluation of PET/CT with F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients. **2019**, 110, 742-750		9
1492	Grading of prostate cancer: a work in progress. **2019**, 74, 146-160		25
1491	Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?. **2019**, 17, 88-96		15
1490	Mobile phone apps for the prediction of prostate cancer: External validation of the Coral and Rotterdam apps. **2019**, 45, 471-476		10
1489	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. *European Urology*, **2019**, 75, 817-825	10.2	11
1488	Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a´randomized controlled trial. **2019**, 195, 393-401		22
1487	Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men â75´years with localized prostate cancer. **2019**, 195, 374-382		7
1486	Is time from diagnosis to radical prostatectomy associated with oncological outcomes?. **2019**, 37, 1571-1580		10

1485	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. *European Urology*, **2019**, 75, 570-578	10.2	293
1484	Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective study. **2019**, 49, 87-91		1
1483	Qualitative study of patients with metastatic prostate cancer to adherence of hormone therapy. **2019**, 38, 8-12		6
1482	Urotensin II receptor expression in prostate cancer patients: A new possible marker. **2019**, 79, 288-294		3
1481	Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice. **2019**, 73, 1-6		3
1480	Circulating Tumor Cells as Surrogate Biomarker for Overall Survival in Metastatic Prostate Cancer. **2019**, 565-572		
1479	Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors. **2019**, 22, 337-343		2
1478	Prospective, Multisite, International Comparison of F-Fluoromethylcholine PET/CT, Multiparametric MRI, and Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. **2019**, 60, 794-800		37
1477	Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?. **2019**, 37, 63-70		3
1476	Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta-analysis. **2019**, 51, e13198		3
1475	Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. **2019**, 124, 218-233		31
1474	Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection. **2019**, 40, 246-253		17
1473	Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer. **2019**, 19, 4		6
1472	Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. **2019**, 145, 632-638		3
1471	A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy. **2019**, 37, 2109-2117		27
1470	Effects of metabolic syndrome on the prevalence of prostate cancer: historical cohort study using the national health insurance service database. **2019**, 145, 775-780		6
1469	The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy. **2019**, 37, 298.e1-298.e9		20
1468	Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach?. **2019**, 37, 277-287		35

1467	Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. **2019**, 79, 583-591		16
1466	Detection of Extraprostatic Extension of Cancer on Biparametric MRI Combining Texture Analysis and Machine Learning: Preliminary Results. **2019**, 26, 1338-1344		40
1465	Preoperative magnetic resonance imaging in predicting early continence recovery after robotic radical prostatectomy. **2019**, 43, 137-142		5
1464	Downregulation of lnRNA-NEF is involved in the postoperative cancer distant recurrence in prostate carcinoma patients. **2019**, 120, 9601-9607		1
1463	Impact of the baseline study with penile doppler ultrasound in patients with prostate cancer before radical prostatectomy. **2019**, 43, 84-90		0
1462	Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies - An alternative template for prostate fusion biopsy. **2019**, 110, 7-13		10
1461	The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?. **2019**, 53, 21-25		3
1460	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. **2019**, 16, 159-171		34
1459	Definitive external-beam radiotherapy versus radical prostatectomy in clinically localized high-risk prostate cancer: a retrospective study. **2019**, 19, 3		4
1458	Using the Multidimensional Prognostic Index to Predict Clinical Outcomes of Hospitalized Older Persons: A Prospective, Multicenter, International Study. **2019**, 74, 1643-1649		29
1457	Migration in last decade to high-risk prostate cancer after radical prostatectomy. **2019**, 29, 29-35		2
1456	Perceptions of Barriers Towards Active Surveillance for Low-Risk Prostate Cancer: Results From a National Survey of Radiation Oncologists and Urologists. **2019**, 26, 660-668		7
1455	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. *European Urology*, **2019**, 75, 506-514	10.2	91
1454	Does mechanical morcellation of large glands compromise incidental prostate cancer detection on specimen analysis? A pathological comparison with open simple prostatectomy. **2019**, 37, 1315-1320		3
1453	The Role of Transrectal Ultrasound for Finding Focal Lesions in Prostate Cancer Detection Compared to Systematic Sextant Biopsy. **2019**, 26, 1023-1029		
1452	Constructing and Pilot Testing a Novel Prostate Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Phantom. **2019**, 124, 33-37		3
1451	Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up. **2019**, 33, e22693		6
1450	Impact of sodium F-fluoride PET/CT, F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study. **2019**, 37, 1587-1595		5

1449	Re: Robot-assisted Laparoscopic Prostatectomy Versus Open Radical Retropubic Prostatectomy: 24-month Outcomes from a Randomised Controlled Study. *European Urology*, **2019**, 75, 200	10.2	1
1448	Development and Validation of a Self-Administered Multidimensional Prognostic Index to Predict Negative Health Outcomes in Community-Dwelling Persons. **2019**, 22, 299-305		13
1447	Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. **2019**, 58, 110-118		3
1446	R^ cidive biologique apr prostatectomie totale dans le cancer de la prostate´: quel bilan et quel traitement en 2019 ?. **2019**, 29, F13-F17		
1445	Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate. **2019**, 29, 1820-1830		16
1444	Impact of Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. **2019**, 60, 963-970		25
1443	68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. **2019**, 79, 454-461		8
1442	Combination of Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis. **2019**, 60, 944-949		39
1441	Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. **2019**, 46, 889-900		35
1440	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. *European Urology*, **2019**, 75, 176-183	10.2	60
1439	Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. **2019**, 17, 72-78.e4		5
1438	State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. **2019**, 26, 18-30		12
1437	Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer. **2019**, 123, 411-420		13
1436	Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. **2019**, 10, 36-44		15
1435	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. *European Urology*, **2019**, 75, 44-60	10.2	29
1434	External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. *European Urology*, **2019**, 75, 319-328	10.2	22
1433	Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. **2019**, 5, 171-178		30
1432	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. **2019**, 5, 381-388		9

1431	Is Retzius-sparing robot-assisted radical prostatectomy associated with better functional and oncological outcomes? Literature review and meta-analysis. **2019**, 6, 174-182	11
1430	Evidence-based approach to active surveillance of prostate cancer. **2020**, 38, 555-562	5
1429	Atlas of Ex Vivo Prostate Tissue and Cancer Images Using Confocal Laser Endomicroscopy: A Project for Intraoperative Positive Surgical Margin Detection During Radical Prostatectomy. **2020**, 6, 941-958	5
1428	Declining use of radical prostatectomy and pelvic lymphadenectomy despite more robotics: National population data over 15 years. **2020**, 16, e118-e124	6
1427	Improved detection and reduced biopsies: the effect of a multiparametric magnetic resonance imaging-based triage prostate cancer pathway in a public teaching hospital. **2020**, 38, 371-379	14
1426	Role of androgen receptor splice variants, their clinical relevance and treatment options. **2020**, 38, 647-656	6
1425	Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey. **2020**, 6, 273-279	4
1424	Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance. **2020**, 38, 663-671	7
1423	Role of the DNA damage response in prostate cancer formation, progression and treatment. **2020**, 23, 24-37	13
1422	Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. **2020**, 38, 939-948	15
1421	Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma. **2020**, 38, 993-1000	2
1420	Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy. **2020**, 38, 957-964	7
1419	Performance of [Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. **2020**, 23, 1-10	18
1418	Appetite-regulating hormones-leptin, adiponectin and ghrelin-and the development of prostate cancer: a systematic review and exploratory meta-analysis. **2020**, 23, 11-23	8
1417	The new ISUP 2014/WHO 2016 prostate cancer grade group system: first r˄ sum˄ 5´years after introduction and systemic review of the literature. **2020**, 38, 657-662	6
1416	Quality of life among patients after cystoprostatectomy as the treatment for locally advanced prostate cancer with bladder invasion. **2020**, 23, 847-853	2
1415	The impact of histopathological analysis of anterior peri-prostatic fat in radical prostatectomy patients. **2020**, 13, 19-24	1
1414	Decision models for distinguishing between clinically insignificant and significant tumors in prostate cancer biopsies: an application of Bayes' Theorem to reduce costs and improve outcomes. **2020**, 23, 102-116	1

1413	Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. **2020**, 38, 565-591		6
1412	Complication Rate After Antibiotic Prophylaxis with Fosfomycin Versus Fluorochinolones or β-lactam Antibiotics in Patients Undergoing Prostate Biopsy: A Propensity Score-adjusted Analysis. **2020**, 6, 370-375		1
1411	External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. **2020**, 52, 59-66		3
1410	Ga-PSMA I&T PET/CT for primary staging of prostate cancer. **2020**, 47, 168-177		28
1409	Consulting "Dr. Google" for Prostate Cancer Treatment Options: A Contemporary Worldwide Trend Analysis. **2020**, 3, 481-488		17
1408	Head-to-Head Comparison of Ga-PSMA-11 with F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. **2020**, 61, 527-532		64
1407	Significance of examined lymph-node count in accurate staging and long-term survival in patients undergoing radical prostatectomy: a population-based study. **2020**, 52, 271-278		1
1406	Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer. **2020**, 61, 540-545		17
1405	Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors. **2020**, 38, 1.e17-1.e23		4
1404	Effects of Retzius sparing on robot-assisted laparoscopic prostatectomy: a systematic review with meta-analysis. **2020**, 34, 4020-4029		10
1403	Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials. **2020**, 22, 1033-1039		10
1402	[F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer. **2020**, 47, 185-191		9
1401	Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study. **2020**, 38, 1735-1740		4
1400	Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients. **2020**, 22, 30-39		3
1399	Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices. **2020**, 3, 21-31		27
1398	Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men. **2020**, 80, 51-56		2
1397	Prediction of survival outcomes following postoperative radiotherapy after radical prostatectomy for prostate cancer. **2020**, 59, 157-163		1
1396	Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study. *European Urology*, **2020**, 77, 180-188	10.2	38

1395	Automated multiparametric localization of prostate cancer based on B-mode, shear-wave elastography, and contrast-enhanced ultrasound radiomics. **2020**, 30, 806-815		28
1394	Can we predict who will need lymphocele drainage following robot assisted laparoscopic prostatectomy (RALP)?. **2020**, 14, 439-445		7
1393	Preoperative PI-RADS Version 2 scores helps improve accuracy of clinical nomograms for predicting pelvic lymph node metastasis at radical prostatectomy. **2020**, 23, 116-126		7
1392	Does YouTube include high-quality resources for training on laparoscopic and robotic radical prostatectomy?. **2020**, 38, 1195-1199		10
1391	Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer. **2020**, 146, 577-588		13
1390	Visualization of peri-prostatic neurovascular fibers before and after radical prostatectomy by means of diffusion tensor imaging (DTI) with clinical correlations: preliminary report. **2020**, 14, 357-363		1
1389	Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up. **2020**, 23, 94-101		2
1388	Circulating mRNA signature as a marker for high-risk prostate cancer. **2020**, 41, 139-145		4
1387	Multiparametric MRI for prostate cancer diagnosis: current status and future directions. **2020**, 17, 41-61		82
1386	Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. **2020**, 47, 147-159		18
1385	Is Engrailed-2 (EN2) a truly promising biomarker in prostate cancer detection?. **2020**, 25, 34-39		2
1384	Development and external validation of a nomogram to predict lymph node invasion after robot assisted radical prostatectomy. **2020**, 38, 37.e11-37.e20		2
1383	Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?. **2020**, 75, 157.e1-157.e7		8
1382	Clinical characteristics and outcomes of robot-assisted laparoscopic radical prostatectomy in HIV-positive patients: a nationwide population-based analysis. **2020**, 52, 481-487		1
1381	Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy. **2020**, 19, 24-32		0
1380	Clinical and pathologic characteristics of familial prostate cancer in Asian population. **2020**, 80, 57-64		2
1379	Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. *European Urology*, **2020**, 77, 365-372	10.2	56
1378	Biomarkers for prostate cancer: prostate-specific antigen and beyond. **2020**, 58, 326-339		41

1377	Active surveillance in intermediate-risk prostate cancer. **2020**, 125, 346-354		23
1376	Impact of time from diagnosis to treatment on erectile function outcomes after radical prostatectomy. **2020**, 8, 337-341		0
1375	Impact of timing on salvage radiation therapy adverse events following radical prostatectomy: A secondary analysis of the RTOG 9601 cohort. **2020**, 38, 38.e17-38.e22		3
1374	Open radical cystectomy is a reliable surgery with acceptable complication rates in elderly male patients: a retrospective, tertiary hospital-based study. **2020**, 23, 210-215		3
1373	Observer Agreement and Accuracy of F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer. **2020**, 61, 344-349		8
1372	Investigating the equivalent performance of biparametric compared to multiparametric MRI in detection of clinically significant prostate cancer. **2020**, 45, 547-555		6
1371	[Grading of prostate cancer. For a more precise prognosis]. **2020**, 53, 19-26		
1370	Rapid and Label-Free Isolation of Tumour Cells from the Urine of Patients with Localised Prostate Cancer Using Inertial Microfluidics. **2019**, 12,		32
1369	Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high-risk prostate cancer: Histopathological and molecular analyses. **2020**, 80, 345-351		3
1368	Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer. **2020**, 38, 2513-2521		11
1367	Linear extent of positive surgical margin impacts biochemical recurrence after robot-assisted radical prostatectomy in a high-volume center. **2020**, 14, 663-675		6
1366	Artificial intelligence in multiparametric prostate cancer imaging with focus on deep-learning methods. **2020**, 189, 105316		23
1365	Optimal threshold of the prostate health index in predicting aggressive prostate cancer using predefined cost-benefit ratios and prevalence. **2020**, 52, 893-901		1
1364	Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. *European Urology*, **2020**, 77, 501-507	10.2	34
1363	Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy. **2020**, 44, 191-197		9
1362	Utility of Ga prostate-specific membrane antigen positron-emission tomography for pre-operative staging of high-risk prostate cancer in a prospective cohort. **2020**, 64, 78-86		1
1361	Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers. **2019**, 15, 1		13
1360	Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. **2020**, 27, 1929-1936		2

1359	Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?. **2020**, 3, 216-223		19
1358	Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis. **2020**, 137, 102-107		1
1357	Hospital readmissions after limited vs. extended lymph node dissection during open and robot-assisted radical prostatectomy. **2020**, 38, 5.e1-5.e8		1
1356	Re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol 2019;76:732-9. *European Urology*, **2020**, 77, e60-e61	10.2	0
1355	Noninvasive Detection and Localization of Genitourinary Cancers Using Urinary Sediment DNA Methylomes and Copy Number Profiles. *European Urology*, **2020**, 77, 288-290	10.2	6
1354	Hormone-related diseases and prostate cancer: An English national record linkage study. **2020**, 147, 803-810		11
1353	Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian Multicenter Study. **2020**, 18, 185-191		6
1352	Impact of Tumor Regional Involvement on Active Surveillance Outcomes: Validation of the Cumulative Cancer Location Metric in a US Population. **2020**, 6, 235-241		3
1351	Rectal Swabs for Detecting Multidrug Resistant Bacteria Prior to Transrectal Prostate Fusion Biopsy: A Prospective Evaluation of Risk Factor Screening and Microbiologic Findings. **2020**, 136, 127-132		1
1350	Pelvic lymph node dissection at robot-assisted radical prostatectomy: Assessing utilization and nodal metastases within a statewide quality improvement consortium. **2020**, 38, 198-203		2
1349	Histogram analysis from stretched exponential model on diffusion-weighted imaging: evaluation of clinically significant prostate cancer. **2020**, 93, 20190757		4
1348	Salvage Radical Prostatectomy After Robot-assisted Laparoscopic Prostatectomy: Case Series. **2020**, 18, e202-e207		2
1347	Early Online Attention Can Predict Citation Counts for Urological Publications: The #UroSoMe_Score. **2020**, 6, 458-462		7
1346	Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. **2020**, 38, 2501-2511		5
1345	Histologically Confirmed Diagnostic Efficacy of F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer. **2020**, 61, 710-715		22
1344	Histotripsy: The Next Generation of High-Intensity Focused Ultrasound for Focal Prostate Cancer Therapy. **2020**, 39, 1057-1067		6
1343	[Precision of prostate magnetic resonance imaging for the detection of clinically significant prostate cancer]. **2020**, 59, 72-77		1
1342	Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery. **2020**, 38, 2493-2500		8

1341	The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups. **2020**, 80, 225-234		4
1340	The evolution and resurgence of perineal prostatectomy in the robotic surgical era. **2020**, 38, 821-828		19
1339	A review of prostate cancer treatment impact on the CNS and cognitive function. **2020**, 23, 207-219		23
1338	Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401). *European Urology*, **2020**, 77, 689-698	10.2	10
1337	Surgical Strategies for Lymphocele Prevention in Minimally Invasive Radical Prostatectomy and Lymph Node Dissection: A Systematic Review. **2020**, 34, 113-120		9
1336	The Risk of Cardiovascular Disease in Prostate Cancer Patients Receiving Androgen Deprivation Therapies. **2020**, 31, 432-440		10
1335	Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies. **2020**, 104, 205-213		2
1334	Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis. **2020**, 214, 597-604		7
1333	Multiparametric MRI-Based Radiomics for Prostate Cancer Screening With PSA in 4-10 ng/mL to Reduce Unnecessary Biopsies. **2020**, 51, 1890-1899		22
1332	Extracellular vesicles in urological malignancies: an update. **2020**, 17, 11-27		41
1331	Diagnostic Role of Magnetic Resonance Imaging-Targeted Biopsy for Prostate Cancer in Biopsy-Naïve Men: A Meta-Analysis. **2020**, 104, 187-198		4
1330	Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia. **2020**, 23, 309-315		12
1329	Impact of Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer. **2020**, 47, 652-664		20
1328	Intraoperative Frozen Section for Margin Evaluation During Radical Prostatectomy: A Systematic Review. **2020**, 6, 664-673		12
1327	Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. **2020**, 3, 474-480		5
1326	Application of Dried Human Amnion Graft to Improve Post-Prostatectomy Incontinence and Potency: A Randomized Exploration Study Protocol. **2020**, 37, 592-602		4
1325	Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer. **2020**, 196, 109-116		8
1324	Application of [Ga]PSMA PET/CT in Diagnosis and Management of Prostate Cancer Patients. **2020**, 22, 1062-1069		6

1323	Does time interval between prostate biopsy and surgery affect outcomes of radical prostatectomy? A systematic review and meta-analysis. **2020**, 52, 619-631		1
1322	MRI-targeted biopsy for detecting prostate cancer: have the guidelines changed our practices and our prostate cancer detection rate?. **2020**, 52, 611-618		8
1321	Very high levels of PSA in patients with cardiogenic shock: Report of four clinical cases. **2020**, 76, 42-44		0
1320	Should all prostate needle biopsy Gleason score 4 + 4 = 8 prostate cancers be high risk? Implications for shared decision-making and patient counselling. **2020**, 38, 78.e1-78.e6		4
1319	NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer. **2020**, 501, 241-251		13
1318	Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets. **2020**, 133, 104014		6
1317	Prostate cancer screening in Portugal: prevalence and perception of potential benefits and adverse effects. **2020**, 29, 248-251		2
1316	The ongoing dilemma in pelvic lymph node dissection during radical prostatectomy: who should decide and in which patients?. **2020**, 14, 549-558		1
1315	The Horse is at the Stable Door: Management of N1M0 Prostate Cancer. **2020**, 32, 199-208		1
1314	Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies. **2020**, 137, 126-132		3
1313	Preoperative Predictors of Biochemical Recurrence-Free Survival in High-Risk Prostate Cancer Following Radical Prostatectomy. **2020**, 10, 1761		3
1312	Computer Extracted Features from Initial H&E Tissue Biopsies Predict Disease Progression for Prostate Cancer Patients on Active Surveillance. **2020**, 12,		7
1311	Dual-Time Point [Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer. **2020**, 12,		6
1310	Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study. **2021**, 4, 784-791		10
1309	Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96. *European Urology*, **2020**, 78, e196-e197	10.2	2
1308	Delay to radical prostatectomy: Who, why and does it matter?. **2020**, 205141582094593		2
1307	Use of increasing the number of biopsy cores in proportion to prostate size on prostate cancer diagnosis. **2020**, 205141582094937		
1306	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. **2020**, 21, 1331-1340		80

1305	Development and External Validation of a Novel Nomogram to Predict Side-specific Extraprostatic Extension in Patients with Prostate Cancer Undergoing Radical Prostatectomy. **2020**,	6
1304	[Stereotaxic radiotherapy of primary extracranial tumors]. **2020**, 24, 513-522	1
1303	Performance of Multiparametric MRI of the Prostate in Biopsy Naïve Men: A Meta-analysis of Prospective Studies. **2020**, 146, 189-195	4
1302	Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database. **2020**, 69, 101833	3
1301	FRAX: re-adjust or re-think. **2020**, 15, 150	7
1300	Changing the Prostate Cancer Detection Paradigm: Clinical Application of European Association of Urology Guideline-recommended Magnetic Resonance Imaging-based Risk Stratification in Men with Suspected Prostate Cancer. **2021**, 7, 1011-1018	2
1299	Secondary malignancies after radiation therapy in prostate cancer survivors: a propensity-score matched competing-risk analysis.. **2020**, 9, 2847-2854	
1298	The role of multiparametric resonance and biopsy in prostate cancer detection: comparison with definitive histological report after laparoscopic/robotic radical prostatectomy. **2020**, 45, 4178-4184	10
1297	Prostate cancer local staging using biparametric MRI: assessment and comparison with multiparametric MRI. **2020**, 132, 109350	10
1296	Imaging Tissue Physiology In Vivo by Use of Metal Ion-Responsive MRI Contrast Agents. **2020**, 13,	4
1295	Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study. **2021**, 39, 2515-2523	3
1294	Annexin A1 promotes the nuclear localization of the epidermal growth factor receptor in castration-resistant prostate cancer. **2020**, 127, 105838	6
1293	Detection of urinary prostate specific antigen by a lateral flow biosensor predicting repeat prostate biopsy outcome. **2020**, 325, 128812	6
1292	Intercenter reproducibility of software-based fusion biopsies for grade group prediction when targeting suspicious MRI lesions. **2020**, 38, 734.e11-734.e17	1
1291	Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study. **2020**, 38, 735.e17-735.e25	3
1290	Extended pelvic lymph-node dissection is independently associated with improved overall survival in patients with prostate cancer at high-risk of lymph-node invasion. **2020**, 125, 756-758	5
1289	Impact of indocyanine green-guided extended pelvic lymph node dissection during robot-assisted radical prostatectomy. **2020**, 27, 845-850	1
1288	Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow. **2020**, 15, 168	10

1287	Multiparametric magnetic resonance imaging and multiparametric magnetic resonance imaging-guided biopsy in the diagnostic pathway of prostate cancer. **2020**, 60, 63-69	0
1286	The value of a first MRI and targeted biopsies after several years of active surveillance for low-risk prostate cancer - results from the SAMS trial. **2020**, 54, 318-322	1
1285	Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. **2020**, 12,	7
1284	A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients. **2020**, 18, 489-499.e6	2
1283	Estimation of secondary cancer risk after radiotherapy in high-risk prostate cancer patients with pelvic irradiation. **2020**, 21, 82-89	5
1282	A Prospective Comparison of F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer	13
1281	PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment. **2020**, 18, 213	0
1280	An evaluation of the timing of surgical complications following radical prostatectomy: Data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). **2020**, 18, 136-141	1
1279	Clinicopathological features, treatment and outcome of Omani patients with localised prostate cancer. **2020**, 18, 219-225	1
1278	Use of bisphosphonates and other bone supportive agents in the management of prostate cancer-A UK perspective. **2020**, 74, e13611	
1277	Whether extended pelvic lymph node dissection should be performed in prostate cancer: The present evidence from a systematic review and meta-analysis. **2020**, 9, 23-30	2
1276	Primary lymph-node staging with Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens. **2021**, 39, 494.e1-494.e6	5
1275	Trends in prostatectomy utilization: Increasing upfront prostatectomy and postprostatectomy radiotherapy for high-risk prostate cancer. **2020**, 9, 8754-8764	2
1274	Cost-Effectiveness Analysis of Prostate Health Index in Decision Making for Initial Prostate Biopsy. **2020**, 10, 565382	3
1273	Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis. **2020**, 10, 607576	1
1272	A Novel Apoptosis-Related Gene Signature Predicts Biochemical Recurrence of Localized Prostate Cancer After Radical Prostatectomy. **2020**, 11, 586376	3
1271	Isotropic Expansion of the Intraprostatic Gross Tumor Volume of Primary Prostate Cancer Patients Defined in MRI-A Correlation Study With Whole Mount Histopathological Information as Reference. **2020**, 10, 596756	3
1270	Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. **2020**, 12, CD013020	8

1269	A novel "three-port" trocar placement technique for laparoscopic radical prostatectomy. **2020**, 18, 279		1
1268	MRI Characteristics Accurately Predict Biochemical Recurrence after Radical Prostatectomy. **2020**, 9,		2
1267	Biomarkers in the setting of benign prostatic hyperplasia-induced lower urinary tract symptoms: what an interventional radiologist needs to know. **2020**, 93, 20200484		
1266	Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer. **2020**, 25, 2130-2137		1
1265	Comparing the Diagnostic Performance of Multiparametric Prostate MRI Versus 68Ga-PSMA PET-CT in the Evaluation Lymph Node Involvement and Extraprostatic Extension. **2020**,		5
1264	Metastasis-directed Therapy (SBRT) Guided by PET-CT F-CHOLINE Versus PET-CT Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness. **2021**, 19, 230-236		25
1263	mpMRI-targeted biopsy versus systematic biopsy for clinically significant prostate cancer diagnosis: a systematic review and metaanalysis. **2020**, 30, 711-719		4
1262	Turbo Spin-Echo Diffusion-Weighted Imaging in Prostate Magnetic Resonance Imaging of Men With Pelvic Hardware. **2020**, 44, 519-526		2
1261	Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study. **2020**, 104, 684-691		3
1260	Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic. **2021**, 39, 1789-1796		10
1259	Rethinking prostate cancer screening: could MRI be an alternative screening test?. **2020**, 17, 526-539		5
1258	Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013. **2020**, 10, 1125		0
1257	Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. *European Urology*, **2020**, 78, 489-491	10.2	2
1256	Tumour-capsule interface measured on 18F-DCFPyL PSMA positron emission tomography/CT imaging comparable to multi-parametric MRI in predicting extra-prostatic extension of prostate cancer at initial staging. **2020**, 64, 829-838		2
1255	Diagnostic accuracy of multiparametric magnetic resonance imaging combined with clinical parameters in the detection of clinically significant prostate cancer: A novel diagnostic model. **2020**, 27, 866-873		2
1254	Risk of invasive prostate cancer and prostate cancer death in relatives of patients with prostatic borderline or in situ neoplasia: A nationwide cohort study. **2020**, 126, 4371-4378		1
1253	Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. **2020**, 73, 630-635		4
1252	Diagnostic performance of imaging techniques for detecting of local recurrence after prostate brachytherapy. **2020**, 24, 323-331		1

1251	PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management. **2020**, 36, 151044	
1250	Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population-based cohort study. **2020**, 59, 904-910	1
1249	Prediction models for prostate cancer to be used in the primary care setting: a systematic review. **2020**, 10, e034661	9
1248	Predictors of ISUP score upgrade in patients with low-risk prostate cancer. **2021**, 107, 254-260	1
1247	Superior survival benefits of Radical Prostatectomy than External Beam Radiotherapy in aging 75 and older men with high-risk or very high-risk Prostate Cancer: a population-matched study. **2020**, 11, 5371-5378	2
1246	Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer. **2021**, 39, 1797-1804	5
1245	Development of a novel nomogram incorporating platelet-to-lymphocyte ratio for the prediction of lymph node involvement in prostate carcinoma. **2020**, 38, 930.e1-930.e6	2
1244	Diagnostic Performance of [F]Fluorocholine and [Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study. **2020**, 9,	5
1243	Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?. **2020**, 20, 58	3
1242	Evaluation of MicroRNAs as Non-Invasive Diagnostic Markers in Urinary Cells from Patients with Suspected Prostate Cancer. **2020**, 10,	6
1241	Application of Radiomics for the Prediction of Radiation-Induced Toxicity in the IMRT Era: Current State-of-the-Art. **2020**, 10, 1708	10
1240	The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer. **2020**, 10,	1
1239	Cytotoxic and anti-angiogenic effects of zoledronic acid in DU-145 and PC-3 prostate cancer cell lines. **2020**, 47, 7675-7683	3
1238	B7-1 and GM-CSF enhance the anti-tumor immune effect of DC-tumor fusion vaccine in the treatment of prostate cancer. **2020**, 37, 107	2
1237	Comparison between laparoscopic and open prostatectomy: Postoperative urinary continence analysis. **2020**, 44, 535-541	0
1236	Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience. **2020**, 38, 315-322	7
1235	Elastography Targeted Prostate Biopsy in Patients under Active Surveillance. **2020**, 104, 948-953	0
1234	Comparison of risk-calculator and MRI and consecutive pathways as upfront stratification for prostate biopsy. **2021**, 39, 2453-2461	2

1233	Real life data of MRI-targeted biopsy - experience from a single nonacademic centre using cognitive fusion and 1.5 tesla scanning. **2020**, 54, 387-392	1
1232	Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. **2020**, 5, 383-400	1
1231	Comparison between laparoscopic and open prostatectomy: Postoperative urinary continence analysis. **2020**, 44, 535-541	
1230	[Prostate cancer screening in France: Results from the EDIFICE surveys]. **2020**, 30, 332-338	1
1229	Robotic prostatectomy after abandoned open radical prostatectomy-Technical aspects and outcomes.. **2020**, 1, 174-179	
1228	Histopathological re-evaluations of biopsies in prostate cancer: a nationwide observational study. **2020**, 54, 463-469	1
1227	Potential biomarkers and risk assessment models to enhance the tumor-node-metastasis (TNM) staging classification of urologic cancers. **2020**, 20, 921-932	1
1226	Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer. **2020**, 9,	2
1225	Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT. **2020**, 34, 932-941	2
1224	Presentaci□n cl□nico-patol□gica del adenocarcinoma prost□tico en un Hospital de tercer nivel en Colombia. **2020**, 29, 115-122	
1223	Risk factors for infection complications after transrectal ultrasound-guided transperineal prostate biopsy. **2021**, 39, 2463-2467	9
1222	Representativeness of personality and involvement preferences in a web-based survey on healthcare decision-making. **2020**, 20, 851	2
1221	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-na□e Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. **2020**,	4
1220	Prostate specific antigen test uptake: a cross sectional study on elderly men in Western Iran. **2020**, 20, 298	0
1219	Multiparametric MRI of Prostate Cancer: Recent Advances. **2020**, 8, 1	2
1218	Carbon Nanospheres Exert Antitumor Effects Associated with Downregulation of 4E-BP1 Expression on Prostate Cancer. **2020**, 15, 5545-5559	4
1217	Comparing effectiveness of radical prostatectomy versus external beam radiotherapy in patients with locally advanced prostate cancer: A population-based analysis. **2020**, 99, e21642	1
1216	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. **2020**, 6, e203187	14

1215	Impact of radiation dose on recurrence in high-risk prostate cancer patients. **2020**, 80, 1322-1327	1
1214	The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study. **2020**, 25, 2107-2114	4
1213	Efficacy of 3T Multiparametric MR Imaging followed by 3T in-Bore MR-Guided Biopsy for Detection of Clinically Significant Prostate Cancer Based on PIRADSv2.1 Score. **2020**, 31, 1619-1626	1
1212	Advances in the diagnostic options for prostate cancer. **2020**, 132, 52-62	
1211	A novel multi-stimuli-responsive nanomedicine based on FeO@Au nanoparticles against cancer. **2020**, 46, 1832-1843	8
1210	Patient reported outcome measures concerning urinary incontinence after robot assisted radical prostatectomy: development and validation of an online prediction model using clinical parameters, lower urinary tract symptoms and surgical experience. **2021**, 15, 593-602	4
1209	The comparison of the survival outcome between robotic-assisted radical prostatectomy and radiation therapy for localized prostate cancer in men over 70´years: Korean Nationwide Observational Study. **2021**, 15, 585-592	0
1208	Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study. **2020**, 43, 628-635	4
1207	Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios. **2020**, 9, 7742-7750	6
1206	Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study. **2020**, 9, 6646-6657	4
1205	Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level â□0.5 ng/mL. **2020**, 41, 906-915	8
1204	Comparison of PI-RADS version 2.1 and PI-RADS version 2 regarding interreader variability and diagnostic accuracy for transition zone prostate cancer. **2020**, 45, 4133-4141	8
1203	Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center. **2020**, 54, 382-386	2
1202	[Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy]. **2020**, 51, 562-571	0
1201	Prediction of Radioresistant Prostate Cancer Based on Differentially Expressed Proteins. **2021**, 105, 316-327	1
1200	Single-night stay for open radical prostatectomy. **2021**, 15, E130-E134	1
1199	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. **2020**, 25,	2
1198	MR-Guided Radiotherapy for Prostate Cancer. **2020**, 10, 616291	21

1197	Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results. **2020**, 22, 79-87	5
1196	Evaluation of transrectal ultrasound-based dosimetry for brachytherapy of prostate cancer: a single-center experience. **2020**, 12, 327-334	
1195	Polypeptide-Based Molecular Platform and Its Docetaxel/Sulfo-Cy5-Containing Conjugate for Targeted Delivery to Prostate Specific Membrane Antigen. **2020**, 25,	5
1194	Impact of "Time-From-Biopsy-to-Prostatectomy" on Adverse Oncological Results in Patients With Intermediate and High-Risk Prostate Cancer. **2020**, 7, 561853	4
1193	PSMA-basierte Theranostik beim Prostatakarzinom. **2020**, 15, 498-507	
1192	Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group. **2020**, 24, 892-897	1
1191	Active surveillance in prostate cancer is possible for Afro-Caribbean population: Comparison of oncological outcomes with a Caucasian cohort. **2020**, 30, 532-540	0
1190	Multiparametric MRI: Local Staging of Prostate Cancer. **2020**, 8, 1	1
1189	Multiparametric Ultrasound for Targeting Prostate Cancer: Combining ARFI, SWEI, QUS and B-Mode. **2020**, 46, 3426-3439	4
1188	Asymptomatic Uncountable Urinary Bladder Stones Removal: Play the Winner. **2020**, 3, 122-125	
1187	Dose-volume Histogram-based Predictors for Hematuria and Rectal Hemorrhage in Patients Receiving Radiotherapy After Radical Prostatectomy. **2020**, 34, 1289-1295	0
1186	Harnessing the potential of multimodal radiotherapy in prostate cancer. **2020**, 17, 321-338	7
1185	Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. **2020**, 45, 349-355	2
1184	Acute kidney injury and its impact on renal prognosis after robot-assisted laparoscopic radical prostatectomy. **2020**, 16, 1-7	1
1183	Impact of Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain. **2020**, 25, 405-411	1
1182	Management of Active Surveillance-Eligible Prostate Cancer during Pretransplantation Workup of Patients with Kidney Failure: A Simulation Study. **2020**, 15, 822-829	4
1181	Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers. **2020**, 2020, 8730608	10
1180	Serum Levels of Matrix Metalloproteinase-1 in Brazilian Patients with Benign Prostatic Hyperplasia or Prostate Cancer. **2020**, 2020, 6012102	0

1179	Predictive model using prostate MRI findings can predict candidates for nerve sparing radical prostatectomy among low-intermediate risk prostate cancer patients. **2020**, 9, 437-444	1
1178	Systematic review and meta-analysis of trials evaluating the role of adjuvant radiation after radical prostatectomy for prostate cancer: Implications for early salvage. **2020**, 14, 330-336	3
1177	Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening. **2020**, 80, 824-830	6
1176	[PSMA-based theranostics for prostate cancer : From imaging to treatment]. **2020**, 59, 617-625	2
1175	TEP/TDM 18F-choline dans les r˙ cidives biologiques des cancers de la prostate traites par radioth˙ rapie externe ou curieth˙ rapie´: impact du PSA et de sa cin˙ tique. **2020**, 44, 53-64	
1174	Personalized strategies in population screening for prostate cancer. **2020**, 147, 2977-2987	6
1173	Prostate cancer screening research can benefit from network medicine: an emerging awareness. **2020**, 6, 13	11
1172	Comparison of Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer. **2020**, 9, 382-390	9
1171	Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life. **2020**, 32, e177-e187	2
1170	Risk of dementia in prostate cancer survivors: A nationwide cohort study in Korea. **2020**, 44, 100578	5
1169	Increased expression of microRNA-93 correlates with progression and prognosis of prostate cancer. **2020**, 99, e18432	3
1168	Unmet expectations in prostate cancer patients and their association with decision regret. **2020**, 14, 731-738	11
1167	"In-Bore" MRI-Guided Prostate Biopsy for Prostate Cancer Diagnosis: Results from 140 Consecutive Patients. **2020**, 14, 22-31	7
1166	Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. **2020**, 40, 1-12	8
1165	External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study. **2020**, 38, 847.e9-847.e16	5
1164	Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies. **2020**, 13, 100801	3
1163	Development and validation of an explainable artificial intelligence-based decision-supporting tool for prostate biopsy. **2020**, 126, 694-703	8
1162	Association between Basal Total Testosterone Levels and Prostate Cancer D'Amico Risk Classes. **2020**, 104, 716-723	1

1161	Comparing the effect of positioning on cerebral autoregulation during radical prostatectomy: a prospective observational study. **2021**, 35, 891-901	3
1160	The role of taxane-based chemotherapy in the treatment of prostate cancer. **2020**, 30, 527-533	3
1159	Hepatic Vascular Malformation Mimics PSMA-Positive Prostate Cancer Metastasis. **2020**, 45, e283-e284	1
1158	Analysis of Learning Curve in Robot-Assisted Radical Prostatectomy Performed by a Surgeon. **2020**, 2020, 9191830	2
1157	MicroRNA-939 Directly Targets to Inhibit the Aggressiveness of Prostate Cancer via Deactivation of the WNT/□-Catenin Pathway. **2020**, 13, 4257-4270	8
1156	Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review. **2020**, 12,	4
1155	18F-choline PET/computed tomography and clinical parameters in the detection of significant prostate cancer in patients with increased prostate-specific antigen levels and previous negative biopsies. **2020**, 41, 674-681	
1154	Enhanced recovery after surgery (ERAS) pathway optimizes outcomes and costs for minimally invasive radical prostatectomy. **2020**, 48, 300060520920072	5
1153	Comparative Effectiveness of Radiotherapy versus Focal Laser Ablation in Patients with Low and Intermediate Risk Localized Prostate Cancer. **2020**, 10, 9112	2
1152	Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. **2020**, 9, 5643-5654	2
1151	Predictors of prostate-specific antigen testing in men aged â□5´years: A cross-sectional study based on patient-reported outcomes. **2020**, 27, 711-718	2
1150	Oncological control following partial gland ablation for intermediate-risk prostate cancer. **2020**, 38, 671-677	3
1149	Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single-centre open-label uncontrolled trial. **2020**, 52, e13705	2
1148	Radiomics Based on Multiparametric Magnetic Resonance Imaging to Predict Extraprostatic Extension of Prostate Cancer. **2020**, 10, 940	11
1147	A systematic review and meta-analysis of magnetic resonance imaging and ultrasound guided fusion biopsy of prostate for cancer detection-Comparing transrectal with transperineal approaches. **2020**, 38, 650-660	7
1146	Early salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: Its impact and optimal candidate. **2020**, 16, 273-279	0
1145	Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer. **2020**, 10, 814	4
1144	SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair. **2020**, 12,	6

1143	Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country. **2020**, 1	1
1142	Radiomics Based on MRI as a Biomarker to Guide Therapy by Predicting Upgrading of Prostate Cancer From Biopsy to Radical Prostatectomy. **2020**, 52, 1239-1248	14
1141	Evaluation of serum fatty acid binding protein-4 (FABP-4) as a novel biomarker to predict biopsy outcomes in prostate biopsy naïve patients. **2020**, 52, 1483-1490	4
1140	rs1138272 Polymorphism Affects Prostate Cancer Risk. **2020**, 56,	5
1139	Lâ□dˋ nocarcinome prostatique, premier cancer chez lâ□omme □ˋ en France. **2020**, 59, 29-33	
1138	Quality of life in active surveillance for early prostate cancer. **2020**, 27, 296-306	4
1137	Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: A meta-analysis. **2020**, 99, e19153	0
1136	A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings. **2020**, 126, 104-113	8
1135	DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types. **2020**, 9,	46
1134	Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer. **2020**, 9, 3278-3286	2
1133	Non-metastatic prostate cancer: rationale for conservative treatment and impact on disease-related morbidity and mortality in the elderly. **2020**, 54, 105-109	2
1132	Perioperative therapies for urological cancers. **2020**, 50, 357-367	1
1131	Radiomics prediction model for the improved diagnosis of clinically significant prostate cancer on biparametric MRI. **2020**, 10, 368-379	21
1130	Comparison of Ga-PSMA-11 PET/CT with C-acetate PET/CT in re-staging of prostate cancer relapse. **2020**, 10, 4993	6
1129	Interobserver variability, detection rate, and lesion patterns of Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. **2020**, 47, 2339-2347	14
1128	Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia. **2020**, 8, 1076-1085	2
1127	Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial. **2020**, 13, 367-376	0
1126	Magnetic resonance radiomics for prediction of extraprostatic extension in non-favorable intermediate- and high-risk prostate cancer patients. **2020**, 61, 1570-1579	14

1125	Biomarkers for Early Cancer Diagnosis: Prospects for Success through the Lens of Tumor Genetics. **2020**, 42, e1900122		3
1124	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. *European Urology*, **2020**, 77, 614-627	10.2	52
1123	Health-related quality of life after open and robot-assisted radical prostatectomy in low- and intermediate-risk prostate cancer patients: a propensity score-matched analysis. **2020**, 38, 3075-3083		4
1122	Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer. **2020**, 50, 963-969		1
1121	Clinically significant prostate cancer detection and segmentation in low-risk patients using a convolutional neural network on multi-parametric MRI. **2020**, 30, 6582-6592		24
1120	FASN Protein Overexpression Indicates Poor Biochemical Recurrence-Free Survival in Prostate Cancer. **2020**, 2020, 3904947		7
1119	The Role of Exenterative Surgery in Advanced Urological Neoplasms. **2020**, 14, 57-65		1
1118	Obesity strongly predicts clinically undetected multiple lymph node metastases in intermediate- and high-risk prostate cancer patients who underwent robot assisted radical prostatectomy and extended lymph node dissection. **2020**, 52, 2097-2105		9
1117	Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer. **2020**, 10, 888		16
1116	The Role of MRI-TRUS Fusion Biopsy in the Diagnosis of Clinical Significant Prostate Cancer (CsPca). **2020**,		
1115	Androgen deprivation therapy improves the in vitro capacity of high-density lipoprotein (HDL) to receive cholesterol and other lipids in patients with prostate carcinoma. **2020**, 19, 133		1
1114	Can the combination of biparametric magnetic resonance imaging and PSA-related indicators predict the prostate biopsy outcome?. **2020**, 52, e13734		1
1113	ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer. *European Urology*, **2020**, 78, 452-459	10.2	4
1112	Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment. **2020**, 105,		15
1111	Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. **2020**, 10, 10704		2
1110	The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study. **2020**, 17, 1366-1374		3
1109	PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer. **2020**, 80, 1118-1127		2
1108	Single-institution Cost Comparison: Single-port Versus Multiport Robotic Prostatectomy. **2021**, 7, 532-536		8

1107	Prospective Study of the Clinical Impact of Epithelial and Mesenchymal Circulating Tumor Cells in Localized Prostate Cancer. **2020**, 12, 4549-4560		2
1106	Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. Lancet 2020;395:1208-16: PSMA Positron Emission Tomography: One Tracer Fixes Them All!. *European*	10.2	1
1105	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. **2020**, 123, 1089-1100		30
1104	Basal total testosterone serum levels predict biopsy and pathological ISUP grade group in a large cohort of Caucasian prostate cancer patients who underwent radical prostatectomy. **2020**, 12, 1756287220929481		2
1103	Intraductal carcinoma of the prostate in an Irish prostate cancer patient cohort-an aggressive pathology and a strong familial link. **2020**, 8, 107-111		
1102	Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of Prostate Cancer. **2020**, 15, 4289-4309		7
1101	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. **2020**, 8,		21
1100	Prostate imaging: Contribution of PET PSMA and MRI. **2020**, 24, 423-428		3
1099	Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis. **2020**, 130, 109131		8
1098	A comparison of side-effects and quality-of-life in patients operated on for prostate cancer with and without salvage radiation therapy. **2020**, 54, 393-400		2
1097	Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation. **2020**, 20, 81		2
1096	miR-196a-mediated downregulation of p27 protein promotes prostate cancer proliferation and relates to biochemical recurrence after radical prostatectomy. **2020**, 80, 1024-1037		6
1095	Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Non-organ-confined Pathology and Biochemical Recurrence After Radical Prostatectomy. **2021**, 7, 1316-1323		3
1094	New Advances in Magnetic Resonance Techniques in Abdomen and Pelvis. **2020**, 28, 433-445		2
1093	[Predictive factors of active surveillance interruption for prostate cancer after 5years of follow-up]. **2020**, 30, 463-471		
1092	European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology. **2020**, 8, 970-987		98
1091	Salvage Radiotherapy for Prostate Cancer. **2020**, 32, 156-162		8
1090	Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. **2020**, 23, 220-231		16

1089	Hacia un cribado personalizado del cáncer de próstata. **2020**, 1,		0
1088	Exerts Tumor-Suppressive Functions in Prostate Cancer via Suppression. **2020**, 9,		4
1087	Contrast-enhanced ultrasound with dispersion analysis for the localization of prostate cancer: correlation with radical prostatectomy specimens. **2020**, 38, 2811-2818		3
1086	Prostate Cancer Nodal Staging: Using Deep Learning to Predict Ga-PSMA-Positivity from CT Imaging Alone. **2020**, 10, 3398		19
1085	[Multicenter comparison of complications after robot-assisted and open simple prostatectomy]. **2020**, 59, 565-572		4
1084	Active surveillance for prostate cancer: an update. **2020**, 11, 8-11		
1083	Magnetic Resonance Imaging of Prostate Adenocarcinoma: Detection and Staging. **2020**, 29, 17-30		0
1082	Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al's Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019; 76:871. *European Urology*, **2020**, 77, e128-e129	10.2	4
1081	A Systematic Review and Meta-Analysis of Pelvic Drain Insertion After Robot-Assisted Radical Prostatectomy. **2020**, 34, 401-408		4
1080	Salvage Treatment for Biochemical Failure After Radical Prostatectomy: Do We Now Have the Answers?. *European Urology*, **2020**, 77, 699-700	10.2	1
1079	Postanesthesia care unit delirium following robot-assisted vs open retropubic radical prostatectomy: A prospective observational study. **2020**, 16, e2094		3
1078	The accuracy of prostate lesion localization in cognitive fusion. **2020**, 74, 223-229		4
1077	Infectious complications of prostate biopsy: winning battles but not war. **2020**, 38, 2743-2753		11
1076	Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results. **2020**, 38, 3101-3111		
1075	Comparison of Cognitive Function After Robot-Assisted Prostatectomy and Open Retropubic Radical Prostatectomy: A Prospective Observational Single-Center Study. **2020**, 139, 110-117		5
1074	Prostatic-specific antigen density behavior according to multiparametric magnetic resonance imaging result. **2020**, 38, 410-417		7
1073	External validation of the Martini nomogram for prediction of side-specific extraprostatic extension of prostate cancer in patients undergoing robot-assisted radical prostatectomy. **2020**, 38, 372-378		5
1072	Targeted Biopsy With Reduced Number of Cores: Optimal Sampling Scheme in Patients Undergoing Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Prostate Biopsy. **2020**, 46, 1197-1207		4

1071	All change in the prostate cancer diagnostic pathway. **2020**, 17, 372-381		20
1070	Urologists' referral and radiation oncologists' treatment patterns regarding high-risk prostate cancer patients receiving radiotherapy within 6 months after radical prostatectomy: A prospective cohort analysis. **2020**, 64, 134-143		1
1069	Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy. **2020**, 38, 3085-3090		10
1068	Combination of Multiparametric Magnetic Resonance Imaging With Elastic-fusion Biopsy Has a High Sensitivity in Detecting Clinically Significant Prostate Cancer in Daily Practice. **2020**, 18, e501-e509		4
1067	Novel patient-derived 3D culture models to guide clinical decision-making in prostate cancer. **2020**, 10, 7-15		3
1066	Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients' disease management and adequacy of impact. **2020**, 10, 2104		14
1065	Observer uncertainties of soft tissue-based patient positioning in IGRT. **2020**, 21, 73-81		4
1064	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. **2020**, 148, 102861		10
1063	Impact of advanced radiotherapy techniques and dose intensification on toxicity of salvage radiotherapy after radical prostatectomy. **2020**, 10, 114		4
1062	Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. **2020**, 125, 827-835		2
1061	The role of cystoprostatectomy in management of locally advanced prostate cancer: a systematic review. **2020**, 18, 14		1
1060	The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. *European Urology*, **2020**, 78, 335-344	10.2	13
1059	[Percutaneous MR-guided prostate cancer cryoablation: Predictive factors and oncologic outcomes]. **2020**, 30, 12-18		2
1058	PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. **2020**, 20, 10		30
1057	The long-term outcomes of Gleason grade groups 2 and 3 prostate cancer managed by active surveillance: Results from a large, population-based cohort. **2020**, 14, 174-181		5
1056	Assessing Extraprostatic Extension with Multiparametric MRI of the Prostate: Mehralivand Extraprostatic Extension Grade or Extraprostatic Extension Likert Scale?. **2020**, 2, e190071		5
1055	Morbidity, perioperative outcomes and complications of robot-assisted radical prostatectomy in kidney transplant patients: A French multicentre study. **2020**, 38, 599.e15-599.e21		2
1054	Improvement of the intermediate risk prostate cancer sub-classification by integrating MRI and fusion biopsy features. **2020**, 38, 386-392		3

1053	The impact of extended pelvic lymph node dissection on the risk of hospital readmission within 180´days after robot assisted radical prostatectomy. **2020**, 38, 2799-2809	3
1052	Predictive Factors of the Risk of Long-Term Hospital Readmission after Primary Prostate Surgery at a Single Tertiary Referral Center: Preliminary Report. **2020**, 104, 465-475	2
1051	Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats. **2020**, 50, 967-979	7
1050	Opportunistic prostate cancer screening: A population-based analysis. **2020**, 38, 393-400	3
1049	A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. **2020**, 12,	2
1048	Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading Prediction. **2020**, 9,	14
1047	AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC. **2020**, 104, 253-262	2
1046	Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study. **2019**, 12,	5
1045	Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system. **2020**, 38, 2469-2476	10
1044	A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study. **2020**, 31, 1251-1259	2
1043	[Reports of prostate needle biopsies-what pathologists provide and urologists want]. **2020**, 59, 461-468	0
1042	Indications and outcome in surgically treated asymptomatic meningiomas: a single-center case-control study. **2020**, 162, 2155-2163	12
1041	Sight and switch off: Nerve density visualization for interventions targeting nerves in prostate cancer. **2020**, 6, eaax6040	14
1040	Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy. **2020**, 20, 97	7
1039	Early Mortality of Prostatectomy vs. Radiotherapy as a Primary Treatment for Prostate Cancer: A Population-Based Study From the United States and East Germany. **2019**, 9, 1451	
1038	Intraindividual comparison between Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients. **2020**, 47, 2796-2803	13
1037	Does deep sedation with analgesia have positive effects on anxiety, pain and compliance in patients before and after prostate biopsy?. **2020**, 74, e13517	1
1036	Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles. **2020**, 28, 102213	24

1035	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. **2020**, 20, 362		13
1034	Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer. **2020**, 25, 1398-1404		5
1033	Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer. **2020**, 20, 361		7
1032	A Novel Perineal Nerve Block Approach for Transperineal Prostate Biopsy: An Anatomical Analysis-based Randomized Single-blind Controlled Trial. **2020**, 146, 25-31		5
1031	Knockdown of lncRNA TUG1 Enhances Radiosensitivity of Prostate Cancer via the TUG1/miR-139-5p/SMC1A Axis. **2020**, 13, 2319-2331		21
1030	Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer. **2020**, 125, 827-837		4
1029	Ergebnisse des prospektiven Nationalen Schweizer Registers. **2020**, 24, 22-27		
1028	Imaging assessment of local recurrence of prostate cancer after radical prostatectomy. **2020**, 45, 4073-4083		2
1027	Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis. **2020**, 18, e517-e522		4
1026	The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial. *European Urology*, **2020**, 78, 184-192	10.2	20
1025	Prognostic value of seminal vesicle invasion on preoperative multi-parametric magnetic resonance imaging in pathological stage T3b prostate cancer. **2020**, 10, 5693		1
1024	Tumour location determined by preoperative MRI is an independent predictor for positive surgical margin status after Retzius-sparing robot-assisted radical prostatectomy. **2020**, 126, 152-158		7
1023	Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?. **2020**, 126, 124-132		15
1022	Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population-based study in Sweden. **2020**, 126, 142-151		3
1021	Work status and work ability after radical prostatectomy or active surveillance for prostate cancer. **2020**, 54, 194-200		1
1020	Harnessing the patient voice in prostate cancer research: Systematic review on the use of patient-reported outcomes in randomized controlled trials to support clinical decision-making. **2020**, 9, 4039-4058		5
1019	Prospective Evaluation of Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis. **2021**, 7, 764-771		12
1018	External validation of the "optimal PSA follow-up schedule after radical prostatectomy" in a new cohort. **2020**, 25, 1393-1397		3

1017	Standardized and Simplified Robot-assisted Superextended Pelvic Lymph Node Dissection for Prostate Cancer: The Monoblock Technique. *European Urology*, **2020**, 78, 424-431	10.2	5
1016	Validation of automated magnetic resonance image segmentation for radiation therapy planning in prostate cancer. **2020**, 13, 14-20		7
1015	Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. **2020**, 147, 92-98		39
1014	Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. **2020**, 99, e19760		18
1013	Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer. **2020**, 20, 324		1
1012	Comparing Prostate Imaging-Reporting and Data System Version 2 (PI-RADSv2) Category 1 and 2 Groups: Clinical Implication of Negative Multiparametric Magnetic Resonance Imaging. **2020**, 2020, 2819701		
1011	Men's view on participation in decisions about prostate-specific antigen (PSA) screening: patient and public involvement in development of a survey. **2020**, 20, 65		6
1010	External Validation of an MRI-Derived Radiomics Model to Predict Biochemical Recurrence after Surgery for High-Risk Prostate Cancer. **2020**, 12,		23
1009	Can we improve the detection rate of prostate cancer using standard 12-core TRUS-guided prostate biopsy? Focused on the location of prostate biopsy. **2020**, 9, 3758-3764		1
1008	Trends in risk-group distribution and Pentafecta outcomes in patients treated with nerve-sparing, robot-assisted radical prostatectomy: a 10-year low-intermediate volume single-center experience. **2021**, 39, 389-397		3
1007	Advanced ultrasound in the diagnosis of prostate cancer. **2021**, 39, 661-676		14
1006	Early experience with Watson for Oncology: a clinical decision-support system for prostate cancer treatment recommendations. **2021**, 39, 407-413		7
1005	Telomere-based risk models for the early diagnosis of clinically significant prostate cancer. **2021**, 24, 88-95		
1004	PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy. **2021**, 4, 73-83		16
1003	Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. **2021**, 127, 340-348		4
1002	Superior early and long-term continence following early micturition on day 2 after robot-assisted radical prostatectomy: a randomized prospective trial. **2021**, 39, 771-777		1
1001	Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies. **2021**, 39, 1153-1159		0
1000	National trends in the management of patients with positive surgical margins at radical prostatectomy. **2021**, 39, 1141-1151		

999	Pelvic lymph node distribution and metastases of prostate and bladder cancer: a systematic literature review and template proposal. **2021**, 39, 751-759		2
998	Influence of previous laparo-endoscopic inguinal hernia repair on performing radical prostatectomy: a nationwide survey among urological surgeons. **2021**, 35, 2583-2591		2
997	Histological comparison between predictive value of preoperative 3-T multiparametric MRI and Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. **2021**, 127, 71-79		12
996	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. **2021**, 127, 96-107		3
995	Accuracy of MRI-guided Versus Systematic Prostate Biopsy in Patients Under Active Surveillance: A Systematic Review and Meta-analysis. **2021**, 19, 3-11.e1		0
994	The impact of atrial fibrillation on outcomes in patients undergoing radical prostatectomy. **2021**, 39, 1509-1519		1
993	Prognostic performance of magnetic resonance imaging-guided biopsy in defining prostate cancer anterior lesions. **2021**, 39, 1473-1479		2
992	Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts. **2021**, 39, 1421-1429		1
991	Oncological outcomes of patients with ductal adenocarcinoma of the prostate receiving radical prostatectomy or radiotherapy. **2021**, 8, 227-234		1
990	External evaluation of the Briganti nomogram to predict lymph node metastases in intermediate-risk prostate cancer patients. **2021**, 39, 1489-1497		1
989	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. **2021**, 145, 461-493		41
988	Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series. **2021**, 23, 364-371		4
987	Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy. **2021**, 8, 170-175		5
986	Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center. **2021**, 7, 95-101		20
985	Evaluation of the clinical use of PET/CT with Ga-PSMA for the assessment of biochemical recurrence of low or intermediate-risk prostate cancer. **2021**, 39, 73.e9-73.e18		1
984	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *European Urology*, **2021**, 79, 243-262	10.2	382
983	The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer. **2021**, 31, 2747-2753		4
982	Early Effects of High-intensity Focused Ultrasound (HIFU) Treatment for Prostate Cancer on Fecal Continence and Anorectal Physiology. **2021**, 148, 211-216		

981	Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States. **2021**, 127, 249-256	3
980	Pelvic lymph-node staging with F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial. **2021**, 48, 509-520	17
979	The role of Gallium-prostate-specific membrane antigen positron emission tomography on staging of high-risk localized prostate cancer: for all high-risk patients or would it be better to select them?. **2021**, 9, 54-59	
978	F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy. **2021**, 48, 521-531	6
977	Different clinical presentations of xanthogranulomatous prostatitis: A case series and review of the literature. **2021**, 14, 293-299	
976	Machine learning-based analysis of [F]DCFPyL PET radiomics for risk stratification in primary prostate cancer. **2021**, 48, 340-349	34
975	Early outcomes of robot-assisted radical prostatectomy following completion of a structured training curriculum: a single surgeon cohort study. **2021**, 14, 246-254	
974	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. **2021**, 109, 174-185	31
973	MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort. **2021**, 24, 406-413	2
972	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. **2021**, 24, 423-430	11
971	The significance of the visible tumor on preoperative magnetic resonance imaging in localized prostate cancer. **2021**, 9, 6-11	2
970	Can the Use of Serial Multiparametric Magnetic Resonance Imaging During Active Surveillance of Prostate Cancer Avoid the Need for Prostate Biopsies?-A Systematic Diagnostic Test Accuracy Review. **2021**, 4, 426-436	6
969	KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. **2021**, 24, 362-369	6
968	HALP score and albumin levels in men with prostate cancer and benign prostate hyperplasia. **2021**, 75, e13766	2
967	Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity. **2021**, 105, 362-369	1
966	Definitive radiotherapy for prostate cancer in Norway 2006-2015: Temporal trends, performance and survival. **2021**, 155, 33-41	2
965	Optimized MRI Assessment for Clinically Significant Prostate Cancer: A STARD-Compliant Two-Center Study. **2021**, 53, 1210-1219	2
964	Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer. **2021**, 81, 102-108	1

963	Salvage low-dose-rate brachytherapy for local recurrences after prostatectomy and adjuvant or salvage external beam irradiation: Feasibility study on five patients and literature review. **2021**, 20, 19-28		3
962	Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). **2021**, 127, 188-192		0
961	Optimal Ga-PSMA and F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. **2021**, 48, 1211-1218		11
960	Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications. **2021**, 39, 296.e1-296.e9		0
959	Holmium Laser Enucleation of Prostate Within 6 Weeks of Transrectal Ultrasound Guided Prostate Biopsy is Safe and Effective. **2021**, 148, 88-92		1
958	Screening strategy for de novo donor-specific HLA antibodies beyond the first year after kidney transplantation: Personalized or "one size fits all"?. **2021**, 35, e14170		0
957	Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. *European Urology*, **2021**, 79, 595-604	10.2	27
956	Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test. **2021**, 24, 457-464		
955	Risk of Stroke in Cancer Survivors: A Meta-analysis of Population-Based Cohort Studies. **2021**, 96, e513-e526		19
954	Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?. **2021**, 31, 3754-3764		4
953	Patient-derived tumour models for personalized therapeutics in urological cancers. **2021**, 18, 33-45		5
952	Safety and Efficacy of Ultra-hypofractionation in Node-positive Prostate Cancer. **2021**, 33, 172-180		2
951	Minimal channel GreenLight photovaporization before permanent implant prostate brachytherapy for patients with obstructive symptoms: Technically feasible and safe. **2021**, 20, 50-57		
950	Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolisation, a Pilot Study. **2021**, 32, 247-255		4
949	Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. *European Urology*, **2021**, 79, 419-426	10.2	8
948	Current and emerging therapies for localized high-risk prostate cancer. **2021**, 21, 267-282		2
947	Prevalence of post-prostatectomy erectile dysfunction and a review of the recommended therapeutic modalities. **2021**, 33, 401-409		9
946	Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in GaPSMA-11 PET images of patients with primary prostate cancer. **2021**, 48, 1987-1997		12

945	Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer. **2021**, 197, 89-96	10
944	Perioperative and Functional Outcomes of Robot-Assisted Radical Prostatectomy in Octogenarian Men. **2021**, 35, 1025-1029	0
943	The Nexus of Endocrine Signaling and Cancer: How Steroid Hormones Influence Genomic Stability. **2021**, 162,	8
942	The Role of Magnetic Resonance Imaging in (Future) Cancer Staging: Note the Nodes. **2021**, 56, 42-49	5
941	Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer. **2021**, 81, 157-169	2
940	Photodynamic therapy for prostate cancer - A narrative review. **2021**, 33, 102158	9
939	Effect of puboprostatic ligament preservation during robotic-assisted laparoscopic radical prostatectomy on early continence: Randomized controlled trial. **2021**, 8, 260-268	
938	Efficacy of a decision support intervention for reducing decisional conflict in patients with elevated serum prostate-specific antigen: A randomized controlled trial. **2021**, 50, 101865	2
937	Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [Ga]Ga-PSMA-11 PET/MRI. **2021**, 48, 1795-1805	18
936	Lymphatic embolization for the management of symptomatic pelvic lymphocele after radical prostatectomy with lymph node dissection: Report of two cases. **2021**, 4, 5-9	0
935	Optimizing MRI-targeted prostate biopsy: the diagnostic benefit of additional targeted biopsy cores. **2021**, 39, 193.e1-193.e6	3
934	Diagnosis of prostate cancer in one day: The benefits of cytology in tumour detection. **2021**, 32, 211-216	
933	The role of immune PSA complex (iXip) in the prediction of prostate cancer. **2021**, 26, 26-30	2
932	Fosfomycin-trometamol (FT) or fluoroquinolone (FQ) as single-dose prophylaxis for transrectal ultrasound-guided prostate biopsy (TRUS-PB): A prospective cohort study. **2021**, 102, 269-274	2
931	Multiparametric Magnetic Resonance Imaging Should Be Preferred Over Digital Rectal Examination for Prostate Cancer Local Staging and Disease Risk Classification. **2021**, 147, 205-212	2
930	Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis. **2021**, 24, 15-23	2
929	Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion. **2021**, 127, 318-325	12
928	A 5-Item Frailty Index for Predicting Morbidity and Mortality After Radical Prostatectomy: An Analysis of the American College of Surgeons National Surgical Quality Improvement Program Database. **2021**, 35, 483-489	4

927	Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). **2021**, 147, 235-242	3
926	Over-diagnosed prostate cancer in solid organ recipients: lessons from the last 3 decades. **2021**, 53, 241-248	0
925	PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients. **2021**, 126, 460-465	6
924	Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. **2021**, 7, 309-316	25
923	Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. **2021**, 4, 42-48	15
922	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. **2021**, 4, 66-72	9
921	Contemporary Trends in Magnetic Resonance Imaging at the Time of Prostate Biopsy: Results from a Large Private Insurance Database. **2021**, 7, 86-94	16
920	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. **2021**, 4, 301-304	1
919	Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. **2021**, 7, 301-308	3
918	How to implement the requirements of a quality assurance system for prostate cancer. **2021**, 39, 41-47	0
917	Evaluation of Risk Factors for Adverse Functional Outcomes after Radical Prostatectomy in Patients with Previous Transurethral Surgery of the Prostate. **2021**, 105, 408-413	
916	Grade group 2 (10% â□GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate. **2021**, 26, 764-769	0
915	Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. **2021**, 13,	1
914	Metastatic prostate adenocarcinoma and high-grade appendiceal mucinous neoplasm mimicking acute appendicitis in a post-radiation therapy patient. **2021**, 9, 2050313X20988421	
913	Discrepancy between Multiparametric Magnetic Resonance Imaging and Ga Prostate-Specific Membrane Antigen Positron Emission Tomography: A Simultaneous Acquired Positron Emission Tomography-Magnetic Resonance Imaging Case. **2021**, 36, 50-52	
912	A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age. **2021**, 23, 36-40	0
911	The clinical impact of strict criteria for active surveillance of prostate cancer in Korean population: Results from a prospective cohort. **2021**, 62, 430-437	1
910	Benefits and harms of the new prostate cancer grade grouping on the prediction of long-term oncological outcomes in patients after radical prostatectomy. **2021**, 28, 390-395	1

909	Online adaptive planning for prostate stereotactic body radiotherapy using a 1.5 Tesla magnetic resonance imaging-guided linear accelerator. **2021**, 17, 20-24	5
908	Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies. **2021**, 11, 8027-8042	5
907	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Postsurgical Setting. **2021**, 37-48	
906	IL-4 Counteracts the Cytotoxic Effects of Peripheral Blood Mononuclear Cells on Hormone-sensitive Prostate Cancer Cells. **2021**, 35, 1973-1977	1
905	Long Noncoding RNAs as Innovative Urinary Diagnostic Biomarkers. **2021**, 2292, 73-94	2
904	Risk stratification tools in prostate cancer, where do we stand?. **2021**, 10, 12-18	3
903	Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer. **2021**, 81, 223-230	2
902	Contemporary role of multiparametric magnetic resonance imaging in the management of prostate cancer. **2021**, 23, 1	
901	A Novel Set of Immune-associated Gene Signature predicts Biochemical Recurrence in Localized Prostate Cancer Patients after Radical Prostatectomy. **2021**, 12, 3715-3725	5
900	Pelvic floor muscle exercise with biofeedback helps regain urinary continence after robot-assisted radical prostatectomy. **2021**, 38, 39-46	1
899	Active Surveillance for Incidental (cT1a/b) Prostate Cancer: Long-Term Outcomes of the Prospective Noninterventional HAROW Study. **2021**, 105, 428-435	2
898	A Machine Learning-Driven Approach to Predict the Outcome of Prostate Biopsy: Identifying Cancer, Clinically Significant Disease, and Unfavorable Pathological Features on Prostate Biopsy. **2021**, 591-600	
897	N-acetylcysteine maintains penile length and erectile function in bilateral cavernous nerve crush rat model by reducing penile fibrosis. **2021**, 23, 215-221	
896	The predictive factor for pathological downgrading after prostatectomy in patients with biopsy Gleason score 4+3 or 4+4 prostate cancer. **2021**, 14, 56	1
895	Dynamic Changes of Generic Quality of Life after Different Treatments for Localized Prostate Cancer. **2021**, 10,	2
894	Genome-wide Expression Analysis Identifies the Association between SEC14L2 and Castration-resistant Prostate Cancer Survival. **2021**, 12, 2173-2180	1
893	The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0. **2021**, 11, 3	8
892	Examination of Necessity for Pelvic Drain Placement After Robot-assisted Radical Prostatectomy. **2021**, 35, 2895-2899	0

891	On the use of the "": application in cost estimation. **2021**, 10, 22-23	
890	Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml. **2021**, 23, 415-420	0
889	Magnetic Resonance Imaging/Ultrasound Fusion-guided Transperineal Versus Magnetic Resonance Imaging/Ultrasound Fusion-guided Transrectal Prostate Biopsy-A Systematic Review. **2021**,	4
888	A comparison of the survival outcomes of robotic-assisted radical prostatectomy and radiation therapy in patients over 75 years old with non-metastatic prostate cancer: A Korean multicenter study. **2021**, 62, 535-544	0
887	Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review. **2021**, 17, 91-102	1
886	Whole-body magnetic resonance imaging: technique, guidelines and key applications. **2021**, 15, 1164	5
885	High BMI, Aggressive Tumours and Long Console Time Are Independent Predictive Factors for Symptomatic Lymphocele Formation after Robot-Assisted Radical Prostatectomy and Pelvic Lymph Node Dissection. **2021**, 105, 453-459	0
884	Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach. **2021**, 22, 1087-1099	2
883	MicroRNAs and Natural Compounds Mediated Regulation of TGF Signaling in Prostate Cancer. **2020** , 11, 613464	2
882	Genetics, molecular biomarkers, and artificial intelligence to improve diagnostic and prognostic efficacy. **2021**, 167-176	
881	Testosterone Replacement Therapy in Men with Untreated or Treated Prostate Cancer: Do We Have Enough Evidences?. **2021**, 39, 705-723	6
880	Is there still a role for digital rectal examination in the prostate cancer diagnostic pathway in the COVID-19 and post COVID-19 era?. **2021**, 24, 92-94	3
879	Urologische oncologie. **2021**, 457-480	
878	Current surgical procedures for benign prostatic hyperplasia and impression of new surgical modalities. **2021**, 13, 95-100	
877	Predictors of complications occurring after open and robot-assisted prostate cancer surgery: a retrospective evaluation of 1062 consecutive patients treated in a tertiary referral high volume center. **2021**, 1	0
876	A review on the role of tissue-based molecular biomarkers for active surveillance. **2021**, 1	0
875	The role of surgery in high risk and advanced prostate cancer: A narrative review. **2021**, 47, S56-S64	
874	Magnetic Resonance Imaging Detection of Glucose-Stimulated Zinc Secretion in the Enlarged Dog Prostate as a Potential Method for Differentiating Prostate Cancer From Benign Prostatic Hyperplasia. **2021**, 56, 450-457	1

873	Diagnostic performance of Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study. **2021**, 48, 3315-3324	11
872	Comparison of initial and second opinion reads of multiparametric magnetic resonance imaging of the prostate for transperineal template-guided biopsies with MRI-Ultrasound fusion. **2021**, 39, 781.e1-781.e7	2
871	PSA and obesity among men with localized prostate cancer: results of the ANDROCAN study. **2021**, 39, 2945-2951	0
870	High-Risk Prostate Cancer: A Very Challenging Disease in the Field of Uro-Oncology. **2021**, 11,	
869	Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: A multicentric, prospective study of the Society of Urological Surgery Andrology group. **2021**, 75, e14095	2
868	Transperineal prostate biopsy: The modern gold standard to prostate cancer diagnosis. **2021**, 47, S19-S26	5
867	Prostate cancer detection with magnetic resonance imaging (MRI)/ cognitive fusion biopsy: Comparing standard and targeted prostate biopsy with final prostatectomy histology. **2021**, 15, E483-E487	1
866	Health-related quality of life and self-reported cognitive function in patients with delayed neurocognitive recovery after radical prostatectomy: a prospective follow-up study. **2021**, 19, 64	2
865	Anorectal application of 5% lidocaine cream reduces pain prior to periprostatic nerve block during transrectal ultrasound guided prostate biopsy: Randomized, prospective controlled study. **2021**, 55, 149-154	1
864	Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population. **2021**, 28, 578-583	0
863	The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects. **2021**, 24, 43-51	
862	Radiomics and Prostate MRI: Current Role and Future Applications. **2021**, 7,	13
861	Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients. **2021**, 42, 503-509	2
860	Value of C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases. **2020**, 10, 600380	3
859	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. **2021**, 81, 286-294	0
858	Predictive model containing PI-RADS v2 score for postoperative seminal vesicle invasion among prostate cancer patients. **2021**, 10, 584-593	
857	Ablative options for prostate cancer management. **2021**, 47, S49-S55	1
856	Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older Patients. **2021**, 38, 111-123	2

855	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. **2021**, 11, e040531	1
854	Prostate cancer. **2021**, 7, 9	72
853	Comparison of functional and oncological outcomes of innovative "three-port" and traditional "four-port" laparoscopic radical prostatectomy in patients with prostate cancer. **2021**, 21, 21	0
852	Morbidity and All-Cause Mortality Following Radical Prostatectomy Compared with Observation for Localized Prostate Cancer in Chinese Men: A Non-Randomized Retrospective Study. **2021**, 27, e928596	
851	Deep Learning Regression for Prostate Cancer Detection and Grading in Bi-Parametric MRI. **2021**, 68, 374-383	29
850	Identification and validation of a six immune-related gene signature for prediction of biochemical recurrence in localized prostate cancer following radical prostatectomy. **2021**, 10, 1018-1029	4
849	Role of Fusion Imaging in Image-Guided Thermal Ablations. **2021**, 11,	5
848	Evaluation of MR elastography for prediction of lymph node metastasis in prostate cancer. **2021**, 46, 3387-3400	4
847	The absolute tumor-capsule contact length in the diagnosis of extraprostatic extension of prostate cancer. **2021**, 46, 4014-4024	0
846	Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. **2021**, 39, 787-796	75
845	Effect of domain knowledge encoding in CNN model architecture-a prostate cancer study using mpMRI images. **2021**, 9, e11006	0
844	Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy. **2021**, 28, 566-572	3
843	Pathologic upgrading in favorable intermediate risk active surveillance patients: Clinical heterogeneity and implications for active surveillance decision. **2021**, 39, 782.e7-782.e14	0
842	Prostate cancer metastasis to the testis: an unexpected presentation of a solitary recurrence. **2021**, 14,	
841	Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI. **2021**, 11, 6048	3
840	The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer. **2021**, 11, 1286	6
839	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. **2021**, 15, E545-E552	0
838	Tumor detection of F-PSMA-1007 in the prostate gland in patients with prostate cancer using prostatectomy specimens as reference method. **2021**,	0

837	Fear of Recurrence in Prostate Cancer Patients: A Cross-sectional Study After Radical Prostatectomy or Active Surveillance. **2021**, 25, 44-51	2
836	Mesorectal Lymph Node Metastases as Index Lesion in Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer. **2021**, 8, 637134	
835	Prospective comparison of F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. **2021**, 48, 2951-2959	7
834	Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: A population-based analysis. **2021**, 65, 649-654	0
833	How I Treat Metastatic Hormone-Sensitive Prostate Cancer?. **2021**, 42, 100-107	
832	Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy. **2021**,	2
831	Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. **2021**, 10,	13
830	Tissue linked glycosylation as potential prognostic biomarker for biochemical recurrence-free survival. **2021**, 26, 275-285	0
829	High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial. **2021**, 11, e044055	
828	Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis. **2021**, 39, 782.e1-782.e5	5
827	F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. **2021**, 15, 301-307	1
826	Herb-target virtual screening and network pharmacology for prediction of molecular mechanism of Danggui Beimu Kushen Wan for prostate cancer. **2021**, 11, 6656	7
825	Prostate specific membrane antigen positron emission tomography/computed tomography and staging high risk prostate cancer: a non-systematic review of high clinical impact literature. **2021**, 73, 32-41	2
824	Use of intraoperative fluorescence to enhance robot-assisted radical prostatectomy. **2021**, 17, 1083-1095	1
823	The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging. **2021**, 28, 1294-1301	2
822	Hormone therapy use and the risk of acute kidney injury in patients with prostate cancer: a population-based cohort study. **2021**, 24, 1055-1062	1
821	Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes. **2021**, 1	2
820	Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study. **2021**, 24, 852-859	3

819	Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study. **2021**, 24, 917-924	6
818	Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment. **2021**, 26, 537-548	2
817	The role of magnetic resonance imaging-guided biopsy for diagnosis of prostate cancer; comparison between FUSION and "IN-BORE" approaches. **2021**, 73, 90-97	0
816	Impact of Chronic Prostatitis on the PI-RADS Score 3: Proposal for the Addition of a Novel Binary Suffix. **2021**, 11,	1
815	Restaging the Biochemical Recurrence of Prostate Cancer with [Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management. **2021**, 13,	2
814	Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database. **2021**, 3, e158-e165	6
813	Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer. **2021**, 8, 608369	1
812	A Nomogram Based on a Multiparametric Ultrasound Radiomics Model for Discrimination Between Malignant and Benign Prostate Lesions. **2021**, 11, 610785	6
811	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. **2021**, 39, 781.e17-781.e24	2
810	Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis. **2021**, 11, 649171	3
809	Feasibility study for fluorescence confocal microscopy (FCM) on diagnostic prostate biopsies. **2021**, 11, 1322-1332	2
808	. **2021**,	
807	External Validation of the Long Short-Term Memory Artificial Neural Network-Based SCaP Survival Calculator for Prediction of Prostate Cancer Survival. **2021**, 53, 558-566	0
806	Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries. **2021**, 7, 538-544	0
805	Comparison of Perioperative, Oncological, and Functional Outcomes of Three-Dimensional Versus Robot-Assisted Laparoscopic Radical Prostatectomy: A Preliminary Study. **2021**,	0
804	The Value of Low Prostate Imaging-Reporting and Data System (PI-RADS) Scores in Preventing Unnecessary Prostate Biopsies. **2021**, 57,	
803	[Active surveillance-much safety, little recruitment : Is it possible to extend the indication for "intermediate-risk" prostate cancer?]. **2021**, 60, 1304-1312	
802	Impact of Grade Groups on Prostate Cancer-Specific and Other-Cause Mortality: Competing Risk Analysis from a Large Single Institution Series. **2021**, 13,	3

801	Feasibility and Oncologic Outcome of Salvage Surgery in Isolated Seminal Vesicle Remnants after Radical Prostatectomy. **2021**, 1-7	2
800	De Novo Radiomics Approach Using Image Augmentation and Features From T1 Mapping to Predict Gleason Scores in Prostate Cancer. **2021**, 56, 661-668	2
799	The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy. **2021**, 81, 463-468	2
798	The Primacy of High B-Value 3T-DWI Radiomics in the Prediction of Clinically Significant Prostate Cancer. **2021**, 11,	5
797	Radiomic and Genomic Machine Learning Method Performance for Prostate Cancer Diagnosis: Systematic Literature Review. **2021**, 23, e22394	7
796	Atypical small acinar proliferation and its significance in pathological reports in modern urological times.. **2022**, 9, 12-17	
795	Reconstruction of the ligamentous apparatus of the lower pelvis in robot-assisted radical prostatectomy as a stage of the learning curve. **2021**, 22, 76-84	
794	The prostate cancer therapy enzalutamide compared with abiraterone acetate/prednisone impacts motivation for exploration, spatial learning and alters dopaminergic transmission in aged castrated mice.	
793	Comparative Survival Outcomes of High-risk Prostate Cancer Treated with Radical Prostatectomy or Definitive Radiotherapy Regimens. **2021**, 26, 55-63	2
792	Short Time Delay Between Previous Prostate Biopsy for Prostate Cancer Assessment and Holmium Laser Enucleation of the Prostate Correlates with Worse Perioperative Outcomes. **2021**,	1
791	Transvesical Versus Posterior Approach to Retzius-Sparing Robot-Assisted Radical Prostatectomy: A Retrospective Comparison With a 12-Month Follow-Up. **2021**, 11, 641887	5
790	Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. **2021**, 39, 785.e1-785.e10	1
789	The Establishment of New Thresholds for PLND-Validated Clinical Nomograms to Predict Non-Regional Lymph Node Metastases: Using Ga-PSMA PET/CT as References. **2021**, 11, 658669	1
788	Radiotherapy in nodal oligorecurrent prostate cancer. **2021**, 197, 575-580	4
787	External Validation of the Extraprostatic Extension Grade on MRI and Its Incremental Value to Clinical Models for Assessing Extraprostatic Cancer. **2021**, 11, 655093	3
786	Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach. **2021**, 22,	5
785	Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. **2021**, 39, 1234-1242	44
784	Polymorphisms in Genes Encoding Glutathione Transferase Pi and Glutathione Transferase Omega Influence Prostate Cancer Risk and Prognosis. **2021**, 8, 620690	0

783	Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?. **2021**, 39, 235.e1-235.e4	2
782	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. **2021**, 4, 150-169	9
781	Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML). **2021**, 11,	2
780	The Influence of Anti-Diabetic Drugs on Prostate Cancer. **2021**, 13,	4
779	A Genomic-Clinicopathologic Nomogram for the Prediction of Lymph Node Invasion in Prostate Cancer. **2021**, 2021, 5554708	0
778	Comparative effectiveness of robotic and open radical prostatectomy. **2021**, 10, 2158-2170	0
777	The Significance of Prostate Specific Antigen Persistence in Prostate Cancer Risk Groups on Long-Term Oncological Outcomes. **2021**, 13,	1
776	Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database. **2021**, 21, 573	0
775	Cancer TreatmentâInduced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review. **2021**, 42, 240-246	1
774	Pelvic Plexus Block Versus Periprostatic Nerve Block for Ultrasound-Guided Prostate Biopsy: A Meta-Analysis. **2021**, 11, 655906	1
773	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. **2021**, 131,	5
772	Salvage Versus Primary Robot-assisted Radical Prostatectomy: A Propensity-matched Comparative Effectiveness Study from a High-volume Tertiary Centre. **2021**, 27, 43-52	4
771	Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review (Preprint).	
770	Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer. **2021**, 13,	2
769	Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal System. **2021**, 46, 562-568	1
768	Tomoelastography Based on Multifrequency MR Elastography for Prostate Cancer Detection: Comparison with Multiparametric MRI. **2021**, 299, 362-370	6
767	Radical Prostatectomy: Sequelae in the Course of Time. **2021**, 8, 684088	1
766	The effect of risk factors on surgical and oncological results in high-risk prostate cancer: A multicentre study of the urooncology society, Turkey. **2021**, 75, e14281	

765	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. **2021**, 24, 1120-1128	2
764	Oncological and functional outcome after partial prostate HIFU ablation with Focal-One: a prospective single-center study. **2021**, 24, 1189-1197	2
763	A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer. **2021**, 16, 82	
762	The one hundred most cited publications in prostate brachytherapy. **2021**, 20, 611-623	1
761	Assessment of changes in penile sensation by electrophysiological study after radical prostatectomy: A pilot study. **2021**, 15, 111-114	1
760	Predictive value of standard serum markers for bone metastases in prostate cancer. **2021**, 27,	1
759	The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy. **2021**, 39, 297.e9-297.e16	1
758	The Epidemiology of Prostate Cancer. 1-16	3
757	Evaluation of the Ginsburg Scheme: Where Is Significant Prostate Cancer Missed?. **2021**, 13,	0
756	Einsatz von PSMA-PET/CT beim Prostatakarzinom. **2021**, 3, 147-160	
755	Target-Specific Magnetic Resonance Imaging of Human Prostate Adenocarcinoma Using NaDyF-NaGdF Core-Shell Nanoparticles. **2021**, 13, 24345-24355	2
754	Optimizing External Beam Radiotherapy as per the Risk Group of Localized Prostate Cancer: A Nationwide Multi-Institutional Study (KROG 18-15). **2021**, 13,	0
753	Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions. **2021**, 10,	2
752	Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial. **2021**, 10, 3240-3248	3
751	Does the type of cryoprobe affect oncological and functional outcomes in men with clinically localized prostate cancer treated with primary whole gland prostate cryoablation?. **2021**, 15, 79-84	0
750	A thigh urinary fistula following radical prostatectomy and external beam radiation therapy for prostate cancer: a case report. **2021**, 36, 101558	
749	68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer. **2021**, 1-7	1
748	The role of pre-biopsy mpMRI in lymph node staging for prostate cancer. **2021**, 3915603211016805	

747	Primary Gleason grade and Gleason grade group at positive surgical margins: a systematic review and meta-analysis. **2021**, 127 Suppl 1, 13-22	3
746	Artificial Intelligence Based Algorithms for Prostate Cancer Classification and Detection on Magnetic Resonance Imaging: A Narrative Review. **2021**, 11,	11
745	Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort. **2021**, 4, e2112214	0
744	Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study. **2021**, 18, e1003616	2
743	Reassessment of Prostate Biopsy Specimens for Patients Referred for Robot-assisted Radical Prostatectomy Rarely Influences Surgical Planning. **2021**, 28, 36-42	1
742	Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade. **2021**, 13,	4
741	Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines?. **2021**, 10,	0
740	Integration of functional imaging in brachytherapy. **2021**,	0
739	External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer. **2021**, 26, 1736-1744	1
738	[Diagnostic markers in urology]. **2021**, 60, 1323-1330	
737	Einsatz von PSMA-PET/CT beim Prostatakarzinom. **2021**, 14, E25-E38	
736	Salvage Robotic-assisted Laparoscopic Radical Prostatectomy Following Focal High-Intensity Focused Ultrasound for ISUP 2/3 Cancer. **2021**, 156, 147-153	1
735	Occupational exposure to polycyclic aromatic hydrocarbons and risk of prostate cancer. **2021**, 20, 71	2
734	Challenge of prostate MRI segmentation on T2-weighted images: inter-observer variability and impact of prostate morphology. **2021**, 12, 71	6
733	REX-1 Represses RASSF1a and Activates the MEK/ERK Pathway to Promote Tumorigenesis in Prostate Cancer. **2021**, 19, 1666-1675	0
732	Vigilancia activa del cáncer de próstata. **2021**, 53, 1-8	
731	History of urological malignancies before kidney transplantation, oncological outcome on the long term. **2021**, 45, 623-623	
730	Changes in prostate cancer screening practice by blood PSA testing between 2011 and 2017, a French population-based study. **2021**, 37, 1435-1441	2

729	Evaluation of image-based prognostic parameters of post-prostatectomy urinary incontinence: A literature review. **2021**, 28, 890-897	3
728	Integration of clinicopathologic identification and deep transferrable image feature representation improves predictions of lymph node metastasis in prostate cancer. **2021**, 68, 103395	2
727	External validation of two MRI-based risk calculators in prostate cancer diagnosis. **2021**, 39, 4109-4116	0
726	Structural model for formation of packages of clinical and diagnostic tests to organize personalized medical care for patients with malignant tumors of the prostate gland. **2021**, 27, 45-55	
725	Role of ZEB family members in proliferation, metastasis and chemoresistance of prostate cancer cells: Revealing signaling networks. **2021**,	2
724	Managing Discordant Findings Between Multiparametric Magnetic Resonance Imaging and Transrectal Magnetic Resonance Imaging-directed Prostate Biopsy-The Key Role of Magnetic Resonance Imaging-directed Transperineal Biopsy. **2021**,	1
723	Evaluation of Quantitative Ga-68 PSMA PET/CT Repeatability of Recurrent Prostate Cancer Lesions Using Both OSEM and Bayesian Penalized Likelihood Reconstruction Algorithms. **2021**, 11,	1
722	PET/CT Imaging of Prostate Cancer. Modern Versions of Radiopharmaceuticals. **2021**, 4, 23-36	
721	Mismatched Imaging Findings of Prostate Cancer Diagnosis: 68´Ga-PSMA PET/CT vs mpMRI. **2021**, 55, 199-202	1
720	Role of salvage lymph node dissection in patients previously treated for prostate cancer: systematic review. **2021**, 47, 484-494	2
719	Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer. **2021**, 10, 2728-2736	1
718	Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions. **2021**,	0
717	Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer. **2021**, 11,	0
716	Narrative review of management strategies and outcomes in node-positive prostate cancer. **2021**, 10, 3176-3187	1
715	Can Prostate-Specific Antigen Density Be an Index to Distinguish Patients Who Can Omit Repeat Prostate Biopsy in Patients with Negative Magnetic Resonance Imaging?. **2021**, 13, 5467-5475	2
714	A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging. **2021**, 39, 431.e15-431.e22	1
713	Prostate Cancer Ultrasound: Is Still a Valid Tool?. **2021**, 9, 1	1
712	Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. **2021**, 160, 115-119	3

711	An integrated nomogram combining deep learning, Prostate Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for identification of clinically significant prostate cancer on biparametric MRI: a retrospective multicentre study. **2021**, 3, e445-e454	4
710	Perineal recurrence of prostate cancer along a brachytherapy needle track: A case report. **2021**, 25, 476-479	1
709	Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance. **2022**, 32, 680-689	5
708	The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice. **2021**, 13,	1
707	Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study. **2021**, 13,	
706	Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: results of a multicenter trial with 30 days' follow-up. **2021**,	3
705	Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. **2021**, 11,	3
704	Patient dosimetry of Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand. **2021**, 35, 1193-1202	0
703	[Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update]. **2021**, 60, 1450-1457	0
702	Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies. **2021**, 1-7	0
701	The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry. **2021**, 29, 68-76	4
700	Prostate-specific Antigen Testing in Men with Disabilities: A Cross-sectional Analysis of the Health Information National Trends Survey. **2021**,	0
699	Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate-FACT-P (Version 4) in Prostate Cancer Patients. **2021**, 1	
698	Total thiol can contribute to differentiating prostate cancer from BPH: Prostate Thiol Index as a new player. **2021**, 53, e14190	
697	An overview of the latest in state-of-the-art murine models for prostate cancer. **2021**, 16, 1349-1364	0
696	Incidence, predictive factors and survival outcomes of incidental prostate cancer in patients who underwent radical cystectomy for bladder cancer. **2021**, 73, 349-356	2
695	Low endogenous testosterone levels are associated with the extend of lymphnodal invasion at radical prostatectomy and extended pelvic lymph node dissection. **2021**, 53, 2027-2039	2
694	68Ga-PSMA PET/CT and mpMRI for primary lymph node staging of intermediate to high-risk prostate cancer: a systematic review and meta-analysis of diagnostic test accuracy. **2021**, 9, 523-537	0

693	Does greater patient involvement in healthcare decision-making affect malpractice complaints? A large case vignette survey. **2021**, 16, e0254052	0
692	Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer. **2021**, 11, 715020	0
691	Prospective Longitudinal Health-related Quality of Life Analysis of the Finnish Arm of the PRIAS Active Surveillance Cohort: 11 Years of Follow-up. **2021**,	0
690	Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy. **2021**, 81, 983-991	1
689	Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance. **2021**, 73, 357-366	3
688	[PI-RADS´2.1 and structured reporting of magnetic resonance imaging of the prostate]. **2021**, 61, 802-809	1
687	Comparison of G8 and ISAR Screening Results in Geriatric Urology. **2021**, 8,	0
686	Comparison of treatment results for patients with high-risk prostate cancer according to the EAU and NCCN criteria. **2021**, 17, 54-61	0
685	Prostate Cancer Detection Using 3-D Shear Wave Elasticity Imaging. **2021**, 47, 1670-1680	2
684	Comparing the risk of cardiovascular disease following GnRH agonist and GnRH antagonist therapy for patient with prostate cancer: a systematic review and meta-analysis. **2021**, 73, 276-282	0
683	The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy. **2021**, 81, 1064-1070	0
682	[MRI-guided minimally invasive treatment of prostate cancer]. **2021**, 61, 829-838	1
681	Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer. **2021**, 29, 40-46	1
680	A Comprehensive Study of Data Augmentation Strategies for Prostate Cancer Detection in Diffusion-Weighted MRI Using Convolutional Neural Networks. **2021**, 34, 862-876	7
679	Hemodynamic, renal and hormonal effects of lung protective ventilation during robot-assisted radical prostatectomy, analysis of secondary outcomes from a randomized controlled trial. **2021**, 21, 200	1
678	Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. **2021**,	1
677	Use of TDI during MRI/US fusion-guided biopsy for suspected prostate cancer. **2021**, 78, 259-269	2
676	Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. **2021**, 4, 532-539	13

675	The role of magnetic resonance imaging in active surveillance of prostate cancer. **2021**, 54, 246-253	
674	Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens. **2021**,	0
673	Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative Prognostic Indicator in Prostate Cancer-A Multi-Institutional Study. **2021**, 13,	4
672	Robot-assisted radical prostatectomy in indian men of age 75 years and above: a propensity score-matched analysis. **2021**, 1	2
671	Multiple direction needle-path planning and inverse dose optimization for robotic low-dose rate brachytherapy. **2021**,	
670	Metformin exerts anti-AR-negative prostate cancer activity via AMPK/autophagy signaling pathway. **2021**, 21, 404	4
669	Prostate Cancer Predisposition. **2021**, 48, 283-296	6
668	Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy. **2021**, 10, 6492-6502	1
667	Elective nodal radiotherapy in prostate cancer. **2021**, 22, e348-e357	6
666	PSMA Theranostics: A "Must Have" in Every Prostate Cancer Center. Illustration of Two Clinical Cases and Review of the Literature. **2021**, 19, e235-e247	0
665	A Review on the Current Treatment Paradigm in High-Risk Prostate Cancer. **2021**, 13,	4
664	Biphasic GA 68-labeled prostate specific membrane antigen-11 positron emission tomography/computed tomography scans in the differential diagnosis and risk stratification of initial primary prostate cancer. **2021**, 11, 3619-3628	0
663	Prostate interventions in patients with mild haemophilia: Safe and feasible. **2021**, 27, e659-e666	1
662	Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer. **2021**, 30, 25-33	2
661	Making Radiomics More Reproducible across Scanner and Imaging Protocol Variations: A Review of Harmonization Methods. **2021**, 11,	17
660	Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy-A Multicenter Study. **2021**, 11, 705964	0
659	Prostate Cancer in Older Adults: Risk of Clinically Meaningful Disease, the Role of Screening and Special Considerations. **2021**, 23, 130	2
658	Incremental modification of robotic prostatectomy technique can lead to aggregated marginal gains to significantly improve functional outcomes without compromising oncological control. **2021**, 1	1

657	Alterations in protein expression and site-specific N-glycosylation of prostate cancer tissues. **2021**, 11, 15886	2
656	Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy. **2021**, 1	
655	A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. **2021**, 11, e046588	1
654	Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens. **2021**, 11, 17447	1
653	Computational and Bioinformatics Methods for MicroRNA Gene Prediction. **2022**, 2257, 349-373	2
652	Are outpatient transperineal prostate biopsies without antibiotic prophylaxis equivalent to standard transrectal biopsies for patient safety and cancer detection rates?A retrospective cohort study in 222 patients. **2021**, 15, 28	0
651	Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry. **2021**, 18, 707-724	4
650	MRI-Based Nomogram of Prostate Maximum Sectional Area and Its Zone Area for Prediction of Prostate Cancer. **2021**, 11, 708730	0
649	Analysis of risk factors for Gleason score upgrading after radical prostatectomy in a Chinese cohort. **2021**, 10, 7772-7780	1
648	Minimally Invasive Lymphocele Drainage Using the Da Vinci Single-Port Platform: Step-By-Step Technique of a Prostate Cancer Referral Center. **2021**, 35, 1357-1364	4
647	Textured-Based Deep Learning in Prostate Cancer Classification with 3T Multiparametric MRI: Comparison with PI-RADS-Based Classification. **2021**, 11,	6
646	Imaging features of the evolving patterns of metastatic prostate cancer. **2021**,	1
645	The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade. **2021**,	0
644	Incidental prostate cancer after transurethral resection of the prostate: analysis of incidence and risk factors in 458 patients. **2021**, 73, 471-480	3
643	Impact of delay from transperineal biopsy to radical prostatectomy upon objective measures of cancer control.. **2022**, 9, 170-176	
642	The Reproducibility of Deep Learning-Based Segmentation of the Prostate Gland and Zones on T2-Weighted MR Images. **2021**, 11,	1
641	Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. **2021**, 162, 98-104	0
640	Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy. **2021**, 81, 1278-1286	1

639	Reconstruction of the Denonvillier's fascia and posterior ligament of the external urethral sphincter: Assessment of its effect on urinary continence after laparoscopic radical prostatectomy. **2021**, 93, 274-279	
638	Geriatric Assessments Can Predict Functional Outcome and Mortality after Urological Tumor Surgery. **2021**, 1-10	1
637	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. **2021**, 20, 1114-1129	2
636	Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL: pathological outcome analysis of a population-level database. **2021**,	1
635	[Urethro-vesical anastomosis reconstruction using extra-peritoneal robot-assisted laparoscopy for anastomotic stenosis after radical prostatectomy]. **2021**, 31, 591-597	
634	[Management of testosterone in advanced hormone-sensitive prostate cancer: still up to date?]. **2021**,	0
633	Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis. **2021**,	1
632	Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative Ga-PSMA-11 PET/CT. **2021**, 11, 745530	
631	Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review. **2021**, 7, e30430	0
630	Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. **2021**, 155, 144-151	1
629	Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer. **2021**, 155, 192-198	2
628	Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review. **2021**, 11, 681448	2
627	Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer. **2021**, 206, 595-603	3
626	Interreader agreement in evaluation of 68Ga-PSMA PET/CT at the time of initial staging: comparison of the three evaluation criteria in the pretreatment risk groups. **2022**, 43, 86-91	0
625	Prostate Cancer awareness in the Lebanese population: a cross sectional national survey. **2021**, 21, 1744	0
624	VIDEOUROLOGY ABSTRACTS. **2021**, 35, 1427-1430	
623	Incremental Impact of [´Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI. **2021**, 1	2
622	Comparative results of nerve-sparing robotic-assisted prostatectomy. **2021**, 22, 44-48	

621	Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain. **2021**, 19, 223		
620	Evaluation of factors associated with the detection of incidental prostate cancer after open prostatectomy for benign prostatic hyperplasia. **2021**, e14261		0
619	Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression. **2021**, 20210842		0
618	Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis. **2021**, 20210509		2
617	An evaluation of factors affecting pain during transrectal ultrasonographic prostate biopsy: a real-life scenario in a retrospective cohort study. **2021**, 9, e12144		
616	Focal Brachytherapy for Localized Prostate Cancer: Midterm Outcomes. **2021**, 11, e477-e485		3
615	Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. **2021**, 22, 1240-1249		11
614	Endogenous testosterone density predicts unfavorable disease at final pathology in intermediate risk prostate cancer. **2021**, 53, 2517-2526		0
613	An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?. *European Urology*, **2021**, 81, 5-5	10.2	7
612	Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study. **2021**, 21, 131		2
611	Systematic biopsy should not be omitted in the era of combined magnetic resonance imaging/ultrasound fusion-guided biopsies of the prostate. **2021**, 53, 2251-2259		0
610	Extraperitoneal Single-Port Robot-Assisted Radical Prostatectomy. **2021**, 35, S100-S105		0
609	DemirtasâEIrciyes Modification of Laparoscopic Transperitoneal Radical Prostatectomy. **2021**, 35,		
608	Impact of prostate-specific antigen screening on tumor size in patients with prostate cancer in a super-aging district in Kyoto, Japan. **2021**, 26, 2303-2309		
607	Rotterdam mobile phone app including MRI data for the prediction of prostate cancer: A multicenter external validation. **2021**, 47, 2640-2645		0
606	Performance of Indocyanine Green Fluorescence for Detecting Lymph Node Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. **2021**, 19, 466.e1-466.e9		1
605	MiR-223-3p targets FOXO3a to inhibit radiosensitivity in prostate cancer by activating glycolysis. **2021**, 282, 119798		4
604	[Place of molecular imaging in the management of prostate cancer]. **2021**, 25, 663-666		

603	Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center. *European Urology*, **2021**, 80, 489-496	10.2	3
602	Impact of Lymphovascular Invasion on Overall Survival in Patients With Prostate Cancer Following Radical Prostatectomy: Stage-per-Stage Analysis. **2021**, 19, e319-e325		0
601	The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. **2021**, 284, 119132		4
600	Pro-angiogenic effect of PC-3 exosomes in endothelial cells in vitro. **2021**, 87, 110126		1
599	PSMA-targeted low-molecular double conjugates for diagnostics and therapy. **2021**, 225, 113752		2
598	Patterns of care for prostate cancer radiotherapy-results from a´survey among German-speaking radiation oncologists. **2021**, 197, 962-970		2
597	The Role of Multiparametric Magnetic Resonance in Volumetric Modulated Arc Radiation Therapy Planning for Prostate Cancer Recurrence After Radical Prostatectomy: A Pilot Study. **2020**, 10, 603994		1
596	[Artificial intelligence in the diagnosis of prostate cancer]. **2021**, 83, 38-45		
595	Clinical utility of current biomarkers for prostate cancer detection. **2021**, 62, 1-13		6
594	Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment. **2021**, 2021, 6230826		4
593	Starch-Capped AgNPs' as Potential Cytotoxic Agents against Prostate Cancer Cells. **2021**, 11,		4
592	The clinical value of indocyanine green fluorescence navigation system for laparoscopic partial nephrectomy in the case of complex renal clear cell carcinoma (R.E.N.A.L score â). **2021**, 12, 1764-1769		0
591	Contemporary application of artificial intelligence in prostate cancer: an i-TRUE study. **2021**, 13, 1756287220986640		6
590	Why Is a b-value Range of 1500-2000 s/mm Optimal for Evaluating Prostatic Index Lesions on Synthetic Diffusion-Weighted Imaging?. **2021**, 22, 922-930		2
589	Establishment and prospective validation of an SUV cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by Ga-PSMA PET/CT: a real-world study. **2021**, 11, 8396-8411		4
588	A comparison of perioperative outcomes between extraperitoneal robotic single-port and multiport radical prostatectomy with the da Vinci Si Surgical System. **2021**, 23, 640-647		2
587	Utility of T-weighted MRI texture analysis in assessment of peripheral zone prostate cancer aggressiveness: a single-arm, multicenter study. **2021**, 11, 2085		6
586	Surgical Delay and Pathological Outcomes for Clinically Localized High-Risk Prostate Cancer. **2020**, 3, e2028320		5

585	Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. **2020**, 3, e2031349	14
584	Whole-body magnetic resonance imaging for prostate cancer assessment: Current status and future directions. **2020**,	6
583	Management of Localized and Locally Advanced Prostate Cancer. **2020**, 579-590	0
582	Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound. **2020**, 45, 3882-3895	4
581	Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?. **2019**, 169, 3-11	12
580	Endogenous testosterone mirrors prostate cancer aggressiveness: correlation between basal testosterone serum levels and prostate cancer European Urology Association clinical risk classes in a large cohort of Caucasian patients. **2020**, 52, 1261-1269	8
579	PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer. **2021**, 23, 172-178	8
578	In Search for risk predictors at the microscopic scenario of a negative biopsy. A systematic review. **2019**, 43, 337-347	3
577	The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. **2019**, 201, 322-331	81
576	Einsatz von PSMA-PET/CT beim Prostatakarzinom. **2020**, 43, 289-302	0
575	Therapeutic Ultrasound and Prostate Cancer. **2017**, 34, 187-200	10
574	Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress. **2020**, 19, 541-550	2
573	Postoperative change in Gleason score of prostate cancer in fusion targeted biopsy: a matched pair analysis. **2021**, 55, 27-32	3
572	Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. **2020**, 204, 496-502	9
571	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. **2020**, 204, 701-706	9
570	[F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer. **2020**, 204, 734-740	11
569	Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer. **2021**, 42, 476-481	1
568	Ki67 in Gleason Pattern 3 as a Marker of the Presence of Higher-Grade Prostate Cancer. **2021**, 29, 112-117	6

567	18F-Fluciclovine PET/CT in Therapeutic Decision Making for Prostate Cancer: A Large Single-Center Practice-Based Analysis. **2021**, 46, 187-194	4
566	Real Time Ultrasound Molecular Imaging of Prostate Cancer with PSMA-targeted Nanobubbles.	4
565	Interrupted versus continuous suturing for vesicourethral anastomosis during radical prostatectomy: protocol for a systematic review and meta-analysis. **2017**, 7, e019823	2
564	Frequent clonal relations between metastases and non-index prostate cancer lesions. **2019**, 4,	12
563	Antibiotic prophylaxis for transrectal ultrasound-guided prostatic biopsies: a comparison of two regimens. **2020**, 26,	2
562	[Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?. **2019**, 9, 84	7
561	Added value of Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous Tc bone scintigraphy. **2020**, 10, 31	10
560	Voxel-based comparison of [Ga]Ga-RM2-PET/CT and [Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer. **2020**, 10, 62	8
559	Results from extended lymphadenectomies with [In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer. **2020**, 10, 17	11
558	Optimization of [F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer. **2020**, 7, 31	6
557	Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. **2020**, 4, 16	4
556	Phospholipase C (PLC)Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line. **2019**, 25, 4438-4449	4
555	Eriocalyxin B Induces Apoptosis and Autophagy Involving Akt/Mammalian Target of Rapamycin (mTOR) Pathway in Prostate Cancer Cells. **2019**, 25, 8534-8543	5
554	Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma. **2017**, 12, e0171495	3
553	Computer aided detection in prostate cancer diagnostics: A promising alternative to biopsy? A retrospective study from 104 lesions with histological ground truth. **2017**, 12, e0185995	13
552	Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO). **2017**, 12, e0187794	12
551	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. **2020**, 15, e0239414	3
550	Transrectal or transvaginal ultrasoundguided biopsy for pelvic masses: external validation and usefulness in oncologic patients. **2019**, 38, 149-155	2

549	Prognostic value of microRNA-20b expression level in patients with prostate cancer. **2020**, 35, 827-831	1
548	Towards personalized prostate cancer screening. **2020**, 1,	1
547	Untangling the association between prostate-specific antigen and diabetes: a systematic review and meta-analysis. **2020**, 59, 11-26	1
546	Adipose Tissue-Derived Stem Cell Therapy for Cavernous Nerve Injury-Induced Erectile Dysfunction in the Rat Model: A Systematic Review and Meta-Analysis Using Methodological Quality Assessment. **2019**, 12, 206-217	7
545	Qualidade de vida relacionada ˆsa ̃de e fatores psicossociais ap ́os prostatectomia radical. **2019**, 32, 169-177	1
544	Can natural killer cell activity help screen patients requiring a biopsy for the diagnosis of prostate cancer?. **2020**, 46, 244-252	4
543	Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. **2018**, 7, 55	5
542	Texture Analysis of F-18 Fluciclovine PET/CT to Predict Biochemically Recurrent Prostate Cancer: Initial Results. **2020**, 6, 301-307	4
541	Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway. **2020**, 12, 9948-9958	5
540	Salvage lymph node dissection after Ga-PSMA or F-FEC PET/CT for nodal recurrence in prostate cancer patients. **2017**, 8, 84180-84192	31
539	Comparisons of health-related quality of life among surgery and radiotherapy for localized prostate cancer: a systematic review and meta-analysis. **2017**, 8, 99057-99065	9
538	Tissue ACE phenotyping in prostate cancer. **2019**, 10, 6349-6361	5
537	Biparametric (bp) and multiparametric (mp) magnetic resonance imaging (MRI) approach to prostate cancer disease: a narrative review of current debate on dynamic contrast enhancement. **2020**, 9, 2235-2247	3
536	What is an acceptable false negative rate in the detection of prostate cancer?. **2018**, 7, 54-60	10
535	Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. **2019**, 31, 511-520	3
534	Lead-time bias in esophageal cancer screening in high-risk areas in China. **2020**, 32, 467-475	1
533	Long Non-Coding RNA GAS5 Suppresses Tumor Progression and Enhances the Radiosensitivity of Prostate Cancer Through the miR-320a/RAB21 Axis. **2020**, 12, 8833-8845	4
532	Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer. **2019**, 15, 589-594	2

531	Factors Related to Prostate-Specific Antigen-Based Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years. **2018**, 4, e10352	1
530	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. **2018**, 7, e11256	7
529	Sociodemographic Representativeness in a Nationwide Web-Based Survey of the View of Men on Involvement in Health Care Decision-Making: Cross-Sectional Questionnaire Study. **2020**, 22, e19517	3
528	Confocal Laser Endomicroscopy and Optical Coherence Tomography for the Diagnosis of Prostate Cancer: A Needle-Based, In Vivo Feasibility Study Protocol (IDEAL Phase 2A). **2018**, 7, e132	5
527	Long- versus short-term androgen deprivation therapy with high-dose radiotherapy for biochemical failure after radical prostatectomy: a randomized controlled trial. **2020**, 16, 2035-2044	2
526	Serum Testosterone Level Can Be Predictive Factor for Upstaging in Clinically Localized Prostate Cancer. **2020**, 18, 116-123	1
525	Laparoscopic radical prostatectomy in 2018: 20 years of worldwide experiences, experimentations, researches and refinements. **2019**, 74, 37-53	5
524	Prostate cancer surgery: a voyage through time. **2019**, 74, 26-27	0
523	Cigarette smoking is not associated with prostate cancer diagnosis and aggressiveness: a cross sectional Italian study. **2018**, 70, 598-605	8
522	Radiological Wheeler staging system: a retrospective cohort analysis to improve the local staging of prostate cancer with multiparametric MRI. **2019**, 71, 264-272	6
521	Extended pelvic lymphadenectomy for prostate cancer: should the Cloquet's nodes dissection be considered only an option?. **2019**, 71, 136-145	17
520	Body Mass Index and prostatic-specific antigen are predictors of prostate cancer metastases in patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection. **2019**, 71, 516-523	8
519	Extended pelvic lymph node dissection during radical prostatectomy: comparison between initial robotic experience of a high-volume open surgeon and his contemporary open series. **2019**, 71, 597-604	2
518	Reliability of the different versions of Partin tables in predicting extraprostatic extension of prostate cancer: a systematic review and meta-analysis. **2019**, 71, 457-478	3
517	Can preoperative multiparametric MRI avoid unnecessary prostate biopsies before holmium laser enucleation of the prostate? Preliminary results of a multicentric cohort of patients. **2019**, 71, 524-530	5
516	Open approach, extended pelvic lymph node dissection, and seminal vesicle invasion are independent predictors of hospital readmission after prostate cancer surgery: a large retrospective study. **2020**, 72, 72-81	5
515	Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study). **2020**, 72, 595-604	6
514	Is there any additional value to 68Ga-PSMA PET/CT in patients with suspicion of prostate cancer despite negative MRI and systematic biopsy?. **2020**, 72, 511-513	3

513	PSMA uptake on [68Ga]-PSMA-11-PET/CT positively corrects with prostate cancer aggressiveness. **2019**,	3
512	Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer. **2021**, 62, 214-220	25
511	Dietary Nutrient Patterns and Prostate Cancer Risk: A Case-Control Study from Iran. **2019**, 20, 1415-1420	2
510	Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study. **2020**, 21, 505-509	10
509	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. **2020**, 24, 1-176	9
508	PSA and PSA Kinetics Thresholds for the Presence of Ga-PSMA-11 PET/CT-Detectable Lesions in Patients With Biochemical Recurrent Prostate Cancer. **2020**, 12,	6
507	Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors. **2020**, 12,	24
506	Impact of Androgen Deprivation Therapy Associated to Conformal Radiotherapy in the Treatment of D'Amico Intermediate-/High-Risk Prostate Cancer in Older Patients. **2020**, 13,	3
505	Actualizacio n de las indicaciones del uso de la radioterapia de intensidad modulada en el Instituto Nacional de Cancerologi a. Protocolo cli nico informado en la evidencia. **2019**, 23, 45-55	0
504	Progress in Imaging Diagnosis and Image-guided Puncture Biopsy of Prostate Cancer. **2019**, 3, 175	1
503	Increased expression of is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells. **2020**, 19, 755-761	5
502	Assessment of biochemical recurrence of prostate cancer (Review). **2019**, 55, 1194-1212	8
501	High expression of citron kinase predicts poor prognosis of prostate cancer. **2020**, 19, 1815-1823	4
500	Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients. **2018**, 20, 56-61	4
499	Radical prostatectomy in patients aged 75 years or older: review of the literature. **2017**,	7
498	High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection. **2020**, 22, 323-329	21
497	Clinical and oncologic findings of extraprostatic extension on needle biopsy in metastatic prostate cancer. **2020**, 22, 427-431	2
496	Magnetic resonance image-guided focused ultrasound robotic system with four computer-controlled axes with endorectal access designed for prostate cancer focal therapy. **2020**, 6, 32	2

495	Erectile dysfunction in prostate cancer patients treated with intensity-modulated radiation therapy. **2020**, 57, 70-75	2
494	Neoadjuvant Therapy in High-Risk Prostate Cancer. **2020**, 36, 251-261	1
493	STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs. **2018**, 34, 180-184	5
492	Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml. **2019**, 35, 202-207	6
491	Survey of prostate biopsy practices among urologists in Nigeria. **2020**, 27, 377-383	0
490	Transrectal ultrasound-guided prostate rebiopsy: How many core sampling should be applied to which patient?. **2018**, 10, 15-19	1
489	Is cystoscopy follow-up protocol safe for low-risk bladder cancer without muscle invasion?. **2020**, 12, 25-30	2
488	Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform. **2019**, 60, 235-243	10
487	A structured framework for optimizing high-intensity focused ultrasound ablative treatment in localized prostate cancer. **2019**, 60, 312-318	3
486	Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer. **2017**, 34, 388-396	4
485	Comparison of Single and Prolonged Fluoroquinolone Prophylaxis and Risk Factors for Infectious Complications After Transrectal Prostate Biopsy. **2018**, 35, 373-377	5
484	Multimodality Image Fusion with PSMA PET/CT and High-Intensity Focused Ultrasound Focal Therapy for Primary Diagnosis and Management of Prostate Cancer: A Planned Research Initiative. **2017**, 8,	2
483	Prognostic influence of 5 alpha reductase inhibitors in patients with localized prostate cancer under active surveillance. **2018**, 44, 132-137	3
482	The factors predicting upgrading of prostate cancer by using International Society for Urological Pathology (ISUP) 2014 Gleason grading system. **2019**, 45, S36-S41	0
481	Robotic radical prostatectomy in 93 cases: Outcomes of the first ERUS robotic urology curriculum trained surgeon in Turkey. **2019**, 45, 183-188	2
480	Comparison of surgical, oncological, and functional outcomes of robot-assisted and laparoscopic radical prostatectomy in patients with prostate cancer. **2019**, 45, 410-417	8
479	External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer. **2020**, 73, 19-25	4
478	Improving the Diagnosis of Clinically Significant Prostate Cancer with Magnetic Resonance Imaging. **2018**, 102,	6

477	Cancer detection rates and inter-examiner variability of MRI/TRUS fusion targeted biopsy and systematic transrectal biopsy. **2020**, 164, 314-319	4
476	Incidence, Management, and Clinical Outcomes of Prostate Cancer in Kidney Transplant Recipients. **2019**, 17, 298-303	8
475	Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer. **2019**, 17, 506-513	12
474	Prostate Cancer: Locoregional Disease. **2021**, 791-803	
473	Transperineal MRI-US Fusion-Guided Target Biopsy of the Prostate after Abdominoperineal Resection: A Case Report. **2021**, 105, 57	
472	Guidelines for radiotherapy of prostate cancer (2020 edition). **2021**, 5, 160-182	0
471	Diagnostic accuracy and clinical implications of robotic assisted MRI-US fusion guided target saturation biopsy of the prostate. **2021**, 11, 20250	2
470	The Auto-Regressive Model and Spectrum Information Entropy Judgment Method for High Intensity Focused Ultrasound Echo Signal. **2021**, 11, 9558	0
469	Imaging of Prostate Cancer. **2021**,	1
468	Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. **2021**, 1	1
467	Long-term consequences of bilateral cavernous crush injury in normal and diabetic rats: a functional study. **2021**,	0
466	Psychological distress among patients awaiting histopathologic results after prostate biopsy: An unaddressed concern. **2021**, 3915603211049889	0
465	The lymphocyte/monocyte ratio and red blood cell transfusion during radical retropubic prostatectomy. **2021**, 1	0
464	Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study. **2021**, 27, 194	0
463	Head-to-head comparison of Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial. **2021**,	3
462	Comparison of PET/CT and MRI in the Diagnosis of Bone Metastasis in Prostate Cancer Patients: A Network Analysis of Diagnostic Studies. **2021**, 11, 736654	0
461	Magnetic resonance elastography of the prostate in patients with lower urinary tract symptoms: feasibility of the modified driver at high multi-frequencies. **2021**, 1	
460	Diagnosis, Clinical Workup, and TNM Classification. **2017**, 143-159	

459	Geriatric Oncology in Tropical and Developing Countries. **2017**, 1-20	
458	Bone Target Therapy in Urologic Malignancies. **2017**, 1-16	
457	What should be done to minimize pain without any sexual function deterioration in transrectal prostate biopsy?. **2017**, 70, 372-377	
456	Robotic Surgery in Prostate Cancer. **2017**, 205-229	
455	Robot-assisted radical prostatectomy, the experience after performed the first 50 procedures. **2017**, 18, 129-132	2
454	Radical Prostatectomy in Locally Advanced Prostate Cancer. **2018**, 411-420	
453	Can We Screen and Still Reduce Overdiagnosis?. **2018**, 9-20	
452	Modern urology perspectives on prostate cancer biomarkers. **2018**, 71, 420-426	7
451	Expression of platelet-derived growth factor alpha and beta genes PDGFRA and PDGFRB associated with biochemical recurrence of prostate cancer after radical prostatectomy. **2018**, 13, 45-50	1
450	ADT in Combination with Radiation Therapy for Clinically Localized Prostate Cancer. **2018**, 99-112	
449	Outcomes of robotic-assisted radical prostatectomy for patients in two extreme age-groups (65 years). **2018**, 91, 92-97	1
448	Preliminary results of using a voice-controlled robotic camera driver during 3D laparoscopic radical prostatectomy. **2018**, 71, 394-398	
447	ADT as Salvage Therapy After Definitive Treatment for Clinically Localized Prostate Cancer. **2018**, 113-119	
446	Partial Nephrectomy as Treatment of an Atypical Metastasis from Prostate Cancerâ Case Report and Review of Literature. **2018**, 08, 8-16	
445	Management of Side Effects of Therapy. **2018**, 303-304	
444	Re-salvage MRI-guided Focal High-dose-rate Brachytherapy for Locally Recurrent Prostate Cancer. **2018**, 10, e2429	1
443	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial (Preprint).	
442	POSTOPERATIVE COMPLICATIONS OF MINIMALLY INVASIVE THERAPIES FOR PROSTATE CANCER. **2018**, 14, 43-50	

441 Advances in nonsurgical treatment of locally advanced and high-risk prostate cancer. **2018**, 12, 214-216

440 Cancer Screening Guidelines: A Rapid Review. **2018**, 4, 95-97

439 Cancer in the Very Elderly and Management. **2019**, 177-188

438 Uroonkologie beim älteren Patienten. **2019**, 1-10

437 Indications, surgical technique, and long-term results of nerve sparing. **2019**, 74, 54-62 0

436 Prävention im Alter durch Risikovermeidung, Früherkennung und frühe Behandlung. **2019**, 73-106

435 Extrafascial robot-assisted laparoscopic radical prostatectomy in locally advanced prostate cancer. **2019**, 74, 78-87 1

434 Types of Cancer. **2019**, 53-150 0

433 Salvage lymph node dissection in patients with oligometastatic recurrence of prostate cancer confirmed by PET-CT. **2019**, 14, 79-86 1

432 Robot-assisted extended lymphadenectomy in prostate cancer. **2019**, 74, 88-96 0

431 An Evaluation of Response to Therapy in Patients Undergoing Radiotherapy or Surgery in the Treatment of Prostate Cancer. **2019**, 34, 263-270

430 Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer. **2019**, 18, 143-148 3

429 Progress in the Diagnosis and Treatment of Prostate Cancer Specific Membrane Antigen for Prostate Cancer. **2019**, 09, 697-702

428 Robot-assisted laparoscopic radical prostatectomy. **2019**, 6, 67-76

427 Impact of functional imaging in prostate cancer: a clinical point of view. **2019**, 63, 1-6

426 The Treatments for Low-Risk Prostate Cancer. **2019**, 17, 7-21

425 Treatment of Patients With High Risk Prostate Cancer. **2019**, 17, 34-47

424 Combined modality radiotherapy for high-risk prostate cancer. Analysis of treatment-Related complications. **2019**, 18, 15-21

423	Current clinical utility of prostate cancer markers. **2019**, 13, 78-82	
422	Benefits and risks of testosterone therapy in older men. **2019**, 71, 217-229	1
421	Early removal of urethral catheter after endoscopic extraperitoneal radical prostatectomy. **2019**, 15, 53-63	1
420	Salvage lymph node dissection in patients with prostate cancer treated with radical prostatectomy or radiotherapy and positive choline positron emission tomography (PET/CT) scan. **2019**, 43, 331-335	1
419	Therapeutic options in patients with biochemical recurrence after radical prostatectomy. **2019**, 18, 5021-5025	3
418	Reply: Off-Target Report on F-Sodium Fluoride PET/CT for Detection of Skeletal Metastases in Prostate Cancer. **2019**, 60, 1836	
417	Neoadjuvant androgen deprivation therapy through intense inhibition of the androgen target: "" or ""?. **2019**, 7, S230	1
416	Current view on nerve-sparing radical prostatectomy. **2019**, 15, 17-27	
415	Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study (Preprint).	
414	D' finition du workflow clinique et du protocole TEP/IRM PSMA pour lâ valuation du cancer de la prostate´: exp' rience initiale et r' sultats. **2019**, 203, 662-669	
413	Robot-Assisted Radical Prostatectomy. **2020**, 63-91	
412	Post-Treatment MR Imaging of Prostate. **2020**, 155-170	
411	What the Urologist Wants to Know from Prostate MRI. **2020**, 13-35	
410	T Staging and Target Volume Definition by Imaging in GU Tumors. **2020**, 221-254	
409	A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy. **2020**, 80, 376-387	2
408	Development and Validation of a Preoperative Nomogram for Predicting Survival of Patients with Locally Advanced Prostate Cancer after Radical Prostatectomy.	
407	Peritoneal Flap in Robot-Assisted Radical Prostatectomy. **2020**, 117, 243-250	6
406	Evolution of prostate cancer diagnosis: retrospective analysis of magnetic resonance imaging/ultrasound fusion guided biopsies protocol in routine practice and patients management. **2020**, 9, 629-636	1

405	El paciente superviviente al cáncer en la consulta de atención primaria. **2020**, 27, 1-42	
404	Oncological results of radical prostatectomy depending on the data of multiparametric magnetic resonance imaging and patient selection for nerve-sparing technique. **2020**, 16, 74-81	
403	New Androgen Receptor Axis-Targeted Agents in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer: From Bench to Clinical Trials. **2020**, 18, 99-108	
402	MODERN OPPORTUNITIES OF PET/CT IN THE DIAGNOSIS OF PROSTATE CANCER. **2021**, 20, 115-122	
401	Systematic review comparing Anterior vs Retzius-sparing robotic assisted radical prostatectomy: can the approach really make a difference?. **2021**,	1
400	Significant Inter- and Intralaboratory Variation in Gleason Grading of Prostate Cancer: A Nationwide Study of 35,258 Patients in The Netherlands. **2021**, 13,	1
399	Immune Microenvironment and Response in Prostate Cancer Using Large Population Cohorts. **2021**, 12, 686809	7
398	Minimally invasive magnetic resonance image-guided prostate interventions. **2021**, 20210698	1
397	Radiomics for Identification and Prediction in Metastatic Prostate Cancer: A Review of Studies. **2021**, 11, 771787	5
396	Menâ view on participation in decisions about Prostate-Specific Antigen (PSA) screening: Patient and public involvement in development of a survey.	
395	Early salvage versus adjuvant therapy for treatment of prostate cancer following prostatectomy. **2021**, 26, e8	
394	Clinicopathological correlation of pre-biopsy quantitative PSMA uptake in patients with persistently raised serum PSA: initial experience in 74 patients with simultaneous 68-Ga PSMA PET/MRI. 205141582095640	
393	Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial). **2021**, 60, 539-543	
392	Should We Reconsider the Necessity of a Refinement of Prostate Cancer Risk Classification and Radiotherapy Treatment Strategy? Experiences from a Retrospective Analysis of Data from a Single Institution. **2020**, 10,	
391	Penile reinnervation as a new technique for treating erectile dysfunction in patients after radical prostatectomy. **2020**, 8, 135-144	
390	Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study. **2020**, 22, e16322	1
389	The evolving role of immune cells in prostate cancer. **2022**, 525, 9-21	5
388	Molecular Imaging in Photon Radiotherapy. **2020**, 216, 845-863	0

387	Health-related quality of life and rates of toxicity after high-dose-rate brachytherapy in combination with external beam radiation therapy for high-risk prostate cancer. **2020**, 61, 250-259	1
386	The Value of Incorporating Multiparametric MRI for Active Surveillance in Patients with Prostate Cancer. **2020**, 79-87	
385	Safety and Efficacy of Using Tranexamic Acid at the Beginning of Robotic-Assisted Radical Prostatectomy in a Double-Blind Prospective Randomized Pilot Study. **2020**, 63, 176-182	0
384	Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy. **2020**, 61, 652-659	
383	Perineal recurrence of prostate ductal adenocarcinoma after transperineal brachytherapy: a case report and literature review. **2020**, 12, 612-617	
382	Urologic Imaging. **2020**, 201-256	
381	Robots in Cancer Surgery: A Boon or Bane. **2020**, 11, 803-823	
380	Geriatric Oncology in Tropical and Developing Countries. **2020**, 939-958	
379	Usefulness of Bi-Parametric Magnetic Resonance Imaging with b=1,800 s/mm Diffusion-Weighted Imaging for Diagnosing Clinically Significant Prostate Cancer. **2020**, 38, 370-376	0
378	Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment. **2020**, 22, 454-458	1
377	Cusp Catastrophe Regression Analysis of Testosterone in Bifurcating the Age-Related Changes in PSA, a Biomarker for Prostate Cancer. **2020**, 363-381	
376	Preoperative and Intraoperative Lymphatic Mapping for Radioguided Sentinel Node Biopsy in Cancers of the Male Reproductive System. **2020**, 331-356	2
375	Malignant Tissue Optical Properties. **2020**, 3-106	0
374	Prostatakarzinom: Onkologische Kennzeichen. **2020**, 1-18	
373	Targeted prostate biopsy using a cognitive fusion of multiparametric magnetic resonance imaging and transrectal ultrasound in patients with previously negative systematic biopsies and non-suspicious digital rectal exam. **2020**, 61, 49-54	2
372	Factors predicting pathological upgrading after prostatectomy in patients with Gleason grade group 1 prostate cancer based on opinion-matched biopsy specimens. **2020**, 12, 384-389	2
371	Contemporary Distribution of High-Grade Prostate Cancer in the Circumstances of Opportunistic Testing. **2020**, 21, 299-305	
370	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.	1

369	High DND1 Level Indicates a Poor Prognostic Factor in Prostate Cancer. **2021**, 2021, 9948241	1
368	Head-to-Head Comparison of Ga-PSMA-11 PET/CT and Multiparametric MRI for Pelvic Lymph Node Staging Prior to Radical Prostatectomy in Patients With Intermediate to High-Risk Prostate Cancer: A Meta-Analysis. **2021**, 11, 737989	1
367	Selection of patients for nerve sparing surgery in robot-assisted radical prostatectomy.. **2022**, 3, 6-18	2
366	Urinary Volatiles and Chemical Characterisation for the Non-Invasive Detection of Prostate and Bladder Cancers. **2021**, 11,	4
365	History of urological malignancies before kidney transplantation, oncological outcome on the long term. **2021**, 45, 623-634	
364	The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs intraprostatic tracer injection for sentinel node detection. **2021**, 1	2
363	Diagnostic value of PCA3, TMPRSS2:ERG and prostatic specific antigen derivatives in the detection of prostate cancer. **2020**, 16, 65-73	1
362	Risk factors and methods for prevention of lymphogenic complications in oncourological operations in pelvic area (systematic review). **2020**, 16, 144-151	
361	Uropathology macroscopy: a pragmatic approach. **2020**, 26, 312-319	
360	Radiomic and Genomic Machine Learning Method Performance for Prostate Cancer Diagnosis: Systematic Literature Review (Preprint).	
359	Controversies in Prostate Cancer Diagnosis and Management. **2021**, 163-184	
358	PAE in the Treatment of Prostate Malignant Tumor. **2021**, 85-101	
357	Multimodal Treatment Plans in Prostate Cancer. **2021**, 43-53	
356	Salvage Robot-Assisted Radical Prostatectomy for Recurrent Localized Prostate Cancer after Radiation Therapy. **2021**, 37-46	
355	Non-interventional study of treatment approaches in patients with locally advanced prostate cancer who have undergone prostatectomy or radiation therapy (PREVENT). **2020**, 16, 109-116	
354	Rapidly Evolving Diffuse Omental Carcinomatosis of Prostate Cancer in 68Ga-PSMA PET/CT. **2021**, 46, e216-e217	1
353	The Clinical Applications of Serum and Urinary Biomarkers in Prostate Cancer. **2020**, 1, 30-38	
352	Radical prostatectomy in locally advanced cancer - an indispensable onset of multimodal therapy?. **2017**, 70, 20-21	1

351	How is the association between urinary prostate cancer antigen 3 (PCA3) levels and Gleason scores in patients suspicious of prostate cancer?. **2019**, 11, 283-288	1
350	Metastatic Prostate Cancer to the Renal Pelvis and Proximal Ureter: A Case Report and Review of the Literature. **2019**, 4,	1
349	Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer. **2020**, 20, 201	
348	The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer. **2020**, 29, 98-104	
347	Prostate cancer detection rate and Gleason score in relation to prostate volume as assessed by magnetic resonance imaging cognitive biopsy and standard biopsy. **2020**, 46, 449-454	1
346	Patients' experience with MRI-guided in-bore biopsy versus TRUS-guided biopsy in prostate cancer: a pilot study. **2020**, 14, 1127	
345	Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate. **2021**, 37, 72-78	
344	Development of an Indian nomogram for predicting extracapsular extension in prostate cancer. **2021**, 37, 65-71	
343	Genetic Mutations Associated With Prostate Cancer and Normal Serum PSA and DRE-Implications for Prostate Cancer Screening and Management: NYU Case of the Month, November 2020. **2020**, 22, 177-181	
342	Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. **2021**, 13, 3868-3889	2
341	Transrectal povidone-iodine efficiency in reducing infections occurring after transrectal ultrasound guided biopsy of the prostate. **2021**, 100, e27539	
340	Transrectal povidone-iodine efficiency in reducing infections occurring after transrectal ultrasound guided biopsy of the prostate. **2021**, 100, e27539	0
339	Detection and Segmentation of Pelvic Bones Metastases in MRI Images for Patients With Prostate Cancer Based on Deep Learning.. **2021**, 11, 773299	0
338	Deep learning-assisted prostate cancer detection on bi-parametric MRI: minimum training data size requirements and effect of prior knowledge. **2021**, 1	7
337	Implications of a Novel Biopsy Downloading System on Prostate Cancer Detection Rate, Surveillance and Focal Therapy - A Prospective Study. **2021**,	
336	A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease. **2021**, 13,	1
335	Effectiveness of cognitive behavioural therapy on quality of life in patients with prostate cancer after androgen deprivation therapy: a protocol for systematic review and meta-analysis. **2021**, 11, e049314	
334	Magnetometer-Guided Sentinel Lymph Node Dissection in Prostate Cancer: Rate of Lymph Node Involvement Compared with Radioisotope Marking. **2021**, 13,	0

333	Men’s perception of information and descriptions of emotional strain in the diagnostic phase of prostate cancer-a qualitative individual interview study. **2021**, 1-10	0
332	Tratamiento del cáncer de próstata localizado. **2021**, 53, 1-8	
331	Development and validation of the 3D U-Net algorithm for segmentation of pelvic lymph nodes on diffusion-weighted images. **2021**, 21, 170	0
330	Additional Value of PET Radiomic Features for the Initial Staging of Prostate Cancer: A Systematic Review from the Literature. **2021**, 13,	2
329	The utility of prostate MRI within active surveillance: description of the evidence. **2021**, 1	1
328	Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml in Western China.. **2021**,	0
327	Contrast-Enhanced Ultrasound (CEUS). **2021**, 161-177	
326	Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment.. **2021**,	0
325	Resonancia Magnˆ tica de cuerpo con difusión una alternativa diagnóstica en la evaluación y estadiaje de pacientes con cáncer de próstata.. **2020**, 8, 23-28	
324	Papel y Evolución de la Resonancia Magnˆ tica Multiparamˆ trica en la Detección del Cáncer de Próstata. **2020**, 8, 1-6	
323	Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer. **2020**, 20, 1-1	
322	The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer. **2020**, 29, 98-104	0
321	Prostate cancer detection rate and Gleason score in relation to prostate volume as assessed by magnetic resonance imaging cognitive biopsy and standard biopsy. **2020**, 46, 449-454	1
320	Patientsâ€™ experience with MRI-guided in-bore biopsy versus TRUS-guided biopsy in prostate cancer: a pilot study. **2020**, 14, 1127	
319	Nuclear medicine therapy of prostate cancer: State of the art and future perspectives. **2021**,	
318	Role of platelet mass index in the differential diagnosis of patients with elevated prostate-specific antigen levels.	
317	Machine and Deep Learning Prediction Of Prostate Cancer Aggressiveness Using Multiparametric MRI.. **2021**, 11, 802964	1
316	Diagnosis and Localization of Prostate Cancer via Automated Multiparametric MRI Equipped with Artificial Intelligence. **2022**, 2, 21-29	1

315	Risk model based on MRI fusion biopsy characteristics predicts biochemical recurrence after radical prostatectomy.. **2022**,	1
314	Predictors of disparity between targeted and in-zone systematic cores during transrectal MR/US-fusion prostate biopsy.. **2022**,	
313	Preoperative Predictors of Lymph Node Invasion and Biochemical Recurrence in High-risk Prostate Cancer.. **2022**, 2, 49-54	1
312	MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data.. **2022**,	2
311	Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: TRoMbone trial. **2021**,	2
310	Pelvic lymph node dissection in high-risk prostate cancer. **2022**, 48, 54-66	0
309	Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.. **2022**, 1	0
308	Prediction of recurrence by metabolites and expression of TOP2A and EZH2 in prostate cancer patients treated with radiotherapy.. **2022**, e4694	0
307	A data-driven ultrasound approach discriminates pathological high grade prostate cancer.. **2022**, 12, 860	1
306	HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.. **2022**, 22, 78	
305	Extent of pelvic lymph node dissection improves early oncological outcomes for patients with high-risk prostate cancer without lymph node involvement after robot-assisted radical prostatectomy.. **2022**, 27, 781	0
304	Network models of prostate cancer immune microenvironments identify ROMO1 as heterogeneity and prognostic marker.. **2022**, 12, 192	1
303	Validation of diagnostic nomograms based on CE-MS urinary biomarkers to distinguish clinically significant prostate cancer.	
302	MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patientâ physician decision tool. 205141582110659	0
301	Stromal Fibroblasts Counteract the Caveolin-1-Dependent Radiation Response of LNCaP Prostate Carcinoma Cells.. **2022**, 12, 802482	0
300	Personalized management of prostate cancer: from molecular and imaging markers to radiogenomics.. **2022**, 87, e58-e62	0
299	Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.. **2022**, 54, 541	0
298	Drift compensation on electronic nose data for non-invasive diagnosis of prostate cancer by urine analysis.. **2022**, 25, 103622	0

297	Recommendations on Weight Loss and Healthy Lifestyle in Prostate Cancer Clinical Guidelines: A Systematic Review.. **2022**, 19,		
296	Fear of cancer recurrence and PSA anxiety in patients with prostate cancer: a systematic review.. **2022**,		2
295	Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.. *European Urology* , **2022**,	10.2	2
294	Predicting the diagnosis of prostate cancer with a scoring system based on novel biomarkers.. **2022** , 22, 13		0
293	Geriatric assessment using the G8 to predict postoperative complications in patients undergoing major uro-oncologic surgery: Comparison with the Charlson Comorbidity Index.. **2022**,		0
292	Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category.. **2022**, 37, 38-44		1
291	Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database.. **2022**,		
290	Prostate cancer brachytherapy: SFRO guidelines 2021.. **2021**,		1
289	Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males.. **2022**, 22, 35		0
288	The potential of prostate gland radiomic features in identifying the Gleason score.. **2022**, 144, 105318		1
287	Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system score three lesions in African American prostate cancer patients managed with active surveillance.. **2022**, 54, 799		
286	Imaging of clinically silent rectoprostatic hematoma in MRI guided in-bore prostate biopsy.. **2022**, 12, 1840		
285	Comparison of Different Machine Learning Models in Prediction of Postirradiation Recurrence in Prostate Carcinoma Patients.. **2022**, 2022, 7943609		
284	Free-breathing 3D Stack of Stars GRE (StarVIBE) sequence for detecting pulmonary nodules in F-FDG PET/MRI.. **2022**, 9, 11		0
283	Seminal vesicle inter- and intra-fraction motion during radiotherapy for prostate cancer: a review.. **2022**,		0
282	Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer.. *European Urology*, **2021**,	10.2	7
281	A statistical, voxelised model of prostate cancer for biologically optimised radiotherapy.. **2022**, 21, 136-145		0
280	A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer.. **2022**, 12, 2335-2350		0

279	Effect of Sedation Anesthesia With Intravenous Propofol on Transrectal Ultrasound-Guided Prostate Biopsy Outcomes.. **2022**, 37, e115	
278	Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model.. **2022**,	1
277	Patient characteristics predicting prolonged length of hospital stay following robotic-assisted radical prostatectomy.. **2022**, 14, 17562872221080737	1
276	Relationship between Apparent Diffusion Coefficient Distribution and Cancer Grade in Prostate Cancer and Benign Prostatic Hyperplasia.. **2022**, 12,	0
275	Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016.. **2022**, 22, 220	
274	Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.. **2022**,	0
273	IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute. **2021**,	0
272	Construction of pelvic floor muscle rehabilitation training program for patients undergoing laparoscopic radical prostatectomy.. **2022**, 11, 392-402	0
271	Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.. **2022**,	
270	Integration of Prostate Biopsy Results with Pre-Biopsy Multiparametric Magnetic Resonance Imaging Findings Improves Local Staging of Prostate Cancer.. **2022**, 8465371211073158	2
269	Acquired and congenital spinal cord injury is associated with lower likelihood of PSA screening.. **2022**,	
268	Anaesthesia for Major Urological Surgery.. **2022**, 40, 175-197	
267	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer. **2022**,	
266	Pelvic Lymph Node Dissection at Radical Prostatectomy for Intermediate Risk Prostate Cancer: Assessing Utility and Nodal Metastases Within a Statewide Quality Improvement Consortium.. **2022** ,	
265	Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side-specific negative lymph node metastasis at radical prostatectomy.. **2022**,	
264	Concordance between Preoperative mpMRI and Pathological Stage and Its Influence on Nerve-Sparing Surgery in Patients with High-Risk Prostate Cancer.. **2022**, 29, 2385-2394	1
263	Multiple analyses suggests texture features can indicate the presence of tumor in the prostate tissue.. **2022**, 1	
262	Moderate hypofractionation for salvage radiotherapy (HYPO-SRT) in patients with biochemical recurrence after prostatectomy: a cohort study with meta-analysis.. **2022**,	0

261	Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials.. **2022**, 14, e22942	0
260	Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study. **2022**, 74,	0
259	UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.. **2022**, 16, E184-E196	1
258	Biomarkers Accurately Inform Treatment Decisions in Localised Prostate Cancer.. **2022**,	0
257	Comparison of Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer.. **2022**, 6, 5	0
256	Addition of Enzalutamide to Leuprolide and Definitive Radiotherapy is Tolerable and Effective in High-Risk Localized or Regional Non-Metastatic Prostate Cancer: Results from a Phase II Trial. **2022**, 100941	0
255	A Comparison between Patient- and Physician-Reported Late Radiation Toxicity in Long-Term Prostate Cancer Survivors.. **2022**, 14,	1
254	Laparoscopic pelvic lymph node dissection in cadaver surgical training from the combined perspectives of urologists, gastroenterologists and gynecologists improves overall knowledge and technique: initial experience of multidisciplinary cadaver surgical training at a single institution in Japan.. **2022**, 1	0
253	Favorable Impact on Postoperative Abdominal Symptoms in Robot-assisted Radical Prostatectomy Using Enhanced Recovery After Surgery Protocol.. **2022**, 2, 247-252	
252	Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to previous PI-RADS versions.. **2022**, 1	
251	Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients.. **2022**, 22, 337	0
250	The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis.. **2022**, 12,	1
249	Imaging of Oligometastatic Disease.. **2022**, 14,	0
248	Robot-assisted radical prostatectomy in the treatment of patients with clinically high-risk localized and locally advanced prostate cancer: single surgeons functional and oncologic outcomes.. **2022**, 22, 49	0
247	Value of the capsular enhancement sign on dynamic contrast-enhanced prostate multiparametric MRI for the detection of extracapsular extension.. **2022**, 150, 110275	0
246	Efficacy of Tadalafil in Penile Rehabilitation Started Before Nerve-Sparing Robot-Assisted Radical Prostatectomy: A Double-Blind Pilot Study.. **2022**, 10, 100508	1
245	Deep learning model for automatic prostate segmentation on bicentric T2w images with and without endorectal coil. **2021**, 2021, 3370-3373	0
244	Using IVIM Parameters to Differentiate Prostate Cancer and Contralateral Normal Tissue through Fusion of MRI Images with Whole-Mount Pathology Specimen Images by Control Point Registration Method.. **2021**, 11,	

243	Anaesthesia-Specifi c Oxygen Transport Assessment in Robot-Assisted Pelvic Surgery: a Clinical Trial. **2021**, 11, 307-315	
242	Current biomarkers of prostate cancer. **2021**, 8, 96-108	
241	Association of Race and Ethnicity With Prostate Cancer-Specific Mortality in Canada.. **2021**, 4, e2136364	1
240	Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial. **2021**, 11, 23503	
239	Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology. **2021**,	0
238	Application of 16 G Biopsy Needle in Transperineal Template-Guided Prostate Biopsy.. **2021**, 1-5	2
237	Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer.. **2021**,	0
236	The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.. **2021**, 23,	3
235	Personalized 5-Year Prostate Cancer Risk Prediction Model in Korea Based on Nationwide Representative Data.. **2021**, 12,	
234	Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.. **2021**, e1492	1
233	Clinical Evaluation of an Abbreviated Contrast-Enhanced Whole-Body MRI for Oncologic Follow-Up Imaging.. **2021**, 11,	1
232	Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact Survey 2018.. **2021**, 13, 9127-9137	0
231	Real-world data in elderly men from Yokosuka City 15 years after introducing prostate-specific antigen-based population screening.. **2022**, 16, 38	0
230	Development and validation of a nomogram for predicting prostate cancer in patients with PSA â 20 ng/mL at initial biopsy.. **2021**, 100, e28196	1
229	Insights of RKIP-Derived Suppression of Prostate Cancer.. **2021**, 13,	1
228	Laparoscopic Surgery for Pelvic Organ Prolapse and Urinary Incontinence. **2022**, 153-164	
227	A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data.. **2022**, 14,	1
226	Role of 68Ga and 18F PSMA PET/CT and PET/MRI in biochemical recurrence of prostate cancer: a systematic review of prospective studies.. **2022**,	1

225	Effect of Clinical Parameters on Risk of Death from Cancer after Radical Prostatectomy in Men with Localized and Locally Advanced Prostate Cancer.. **2022**, 14,	0
224	Current Imaging in Metastatic Bone Diseases: Does PET Replace Bone Scintigraphy. **2022**, 8, 92-101	
223	Can multi-parametric magnetic resonance imaging and prostate-specific antigen density accurately stratify patients prior to prostate biopsy?. 205141582210848	
222	Data_Sheet_1.docx. **2020**,	
221	Data_Sheet_1.docx. **2019**,	
220	DataSheet_1.docx. **2020**,	
219	Data_Sheet_1.docx. **2020**,	
218	Data_Sheet_1.DOC. **2020**,	
217	Data_Sheet_1.pdf. **2020**,	
216	Table_1.DOCX. **2020**,	
215	Table_2.docx. **2020**,	
214	Table_1.DOCX. **2018**,	
213	Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review.. **2022**, 26, 273	1
212	Artificial intelligence supporting cancer patients across Europe-The ASCAPE project.. **2022**, 17, e0265127	1
211	SURGICAL TREATMENT OF HIGH-RISK PROSTATIC CARCINOMA AND OLIGOMETASTATIC DISEASE.. **2019**, 58, 21-23	0
210	PSA-IgM and iXip in the diagnosis and management of prostate cancer: clinical relevance and future potential. A review.. **2022**, 92, e2021344	0
209	Targeting Local Recurrence After Surgery With MRI Imaging for Prostate Cancer in the Setting of Salvage Radiation Therapy.. **2022**, 12, 775387	3
208	Efficacy and safety of three different analgesic methods for patients undergoing transrectal ultrasound-guided prostate biopsy: a prospective, randomized controlled trial.. **2020**, 24, 166-172	

207	Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer.. **2022**, 20, eAO6599	0
206	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. **2022**, 1-55	
205	Ex Vivo High-Resolution Magic Angle Spinning (HRMAS) H NMR Spectroscopy for Early Prostate Cancer Detection.. **2022**, 14,	0
204	A comparative study of transperineal software-assisted magnetic resonance/ultrasound fusion biopsy and transrectal cognitive fusion biopsy of the prostate.. **2022**, 22, 72	3
203	Efficacy of different types of radical prostatectomy in patients with localized prostate cancer. **2022** , 18, 49-57	
202	Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma. **2022**, 13,	1
201	Developing a consensus statement for psychosocial support in active surveillance for prostate cancer.	
200	Diverse PSMA expression in primary prostate cancer: reason for negative [Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens.. **2022**, 1	0
199	Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.. **2022**, 1	1
198	Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.. **2022**, 1	0
197	Machine learning in predicting extracapsular extension (ECE) of prostate cancer with MRI: a protocol for a systematic literature review.. **2022**, 12, e052342	0
196	Accuracy of a new electronic nose for prostate cancer diagnosis in urine samples.. **2022**,	0
195	Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform. **2022**, 12, 751	
194	Type 2 Diabetes-Related Variants Influence the Risk of Developing Prostate Cancer: A Population-Based Case-Control Study and Meta-Analysis. **2022**, 14, 2376	1
193	Integration of magnetic resonance imaging into prostate cancer nomograms.. **2022**, 14, 17562872221096386	
192	Volumetric modulated arc therapy (VMAT): A review of clinical outcomes- What is the clinical evidence for the most effective implementation?.	0
191	Comparison of Systematic, Targeted and Combined Prostate Biopsy: Our Clinical Outcomes. **2022**, 21, 40-44	
190	ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. **2022**,	2

189	Urinary toxicity in patients treated with radical EBRT for prostate cancer: Analysis of predictive factors in an historical series. **2022**,	
188	Clinicopathological and oncological significance of persistent prostate-specific antigen after radical prostatectomy: A systematic review and meta-analysis. **2022**,	
187	Based on network pharmacology and molecular docking to predict the mechanism of Huangqi in the treatment of castration-resistant prostate cancer. **2022**, 17, e0263291	
186	The value of bone scans to predict survival time in patients with diagnosed prostate cancer: single-center retrospective study. **2022**, 6, 004-011	
185	Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data.	1
184	Can the prophylactic administration of tranexamic acid reduce the blood loss after robotic-assisted radical prostatectomy? Robotic Assisted Radical Prostatectomy with tranEXamic acid (RARPEX): study protocol for a randomized controlled trial. **2022**, 23,	
183	Diagnostic Accuracy of Predictive Models in Prostate Cancer: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-10	0
182	Polymorphic variants of the CASP3, CASP9, BCL-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis.	
181	Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.	0
180	Web-Based Peer Navigation for Men with Prostate Cancer and Their Family Caregivers: A Pilot Feasibility Study. **2022**, 29, 4285-4299	0
179	Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker. **2022**,	
178	Similarity of competing risks models with constant intensities in an application to clinical healthcare pathways involving prostate cancer surgery.	
177	Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification.	1
176	Knowledge, Attitudes, and Behaviors of Imams on Prostate Cancer in Kahramanmaras, Turkey.	
175	Image-guided in-Vivo Needle-Based Confocal Laser Endomicroscopy in the Prostate: Safety and Feasibility Study in 2 Patients. **2022**, 21, 153303382210931	
174	Tumor-Targeted Injectable Double-Network Hydrogel for Prevention of Breast Cancer Recurrence and Wound Infection via Synergistic Photothermal and Brachytherapy. 2200681	3
173	Comparative assessment of the learning curve of retropubic, laparoscopic, perineal, and robot-assisted radical prostatectomy. **2022**, 10, 63-71	
172	Application of Multiple Ultrasonic Techniques in the Diagnosis of Prostate Cancer. 12,	

171	Nanotechnological strategies for prostate cancer imaging and diagnosis.	1
170	A Novel Angiogenesis-Related Gene Signature to Predict Biochemical Recurrence of Patients with Prostate Cancer following Radical Therapy. **2022**, 2022, 1-13	
169	Cancer de la prostate localisˆ de haut risque et localement avancˆ ´: rˆ sultats oncologiques ˆlong terme de la prostatectomie. **2022**,	
168	American Society of Anesthesiologistsâ(ASA) Physical Status System and Risk of Major Clavien-Dindo Complications After Robot-Assisted Radical Prostatectomy at Hospital Discharge: Analysis of 1143 Consecutive Prostate Cancer Patients.	0
167	Intraindividual Comparison Between [18F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer Patients. 12,	
166	68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement. **2022**, 6,	
165	Validation of diagnostic nomograms based on CEâMS urinary biomarkers to detect clinically significant prostate cancer.	1
164	Differential co-expression network analysis with DCoNA reveals isomiR targeting aberrations in prostate cancer.	
163	Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice.	0
162	Interlaboratory Gleason grading variation affects treatment: a Dutch historic cohort study in 30 509 patients with prostate cancer. jclinpath-2021-208067	0
161	Effects of estradiol on bone in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial. **2022**, 187, 241-256	
160	Intervention Offering Self-management Support Through mHealth and Health Coaching to Patients with Prostate Cancer: An Interpretive Description of Patientsâ Experiences and Perspectives (Preprint).	
159	Risk of Dementia in Cancer Survivors: A Meta-Analysis of Population-Based Cohort Studies. **2022**, 1-14	1
158	Impact of prostate biopsy technique on outcomes of the precision prostatectomy procedure. **2022**, 4, e000122	
157	A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis.	1
156	Gross tumor volume delineation in primary prostate cancer on 18F-PSMA-1007 PET/MRI and 68Ga-PSMA-11 PET/MRI. **2022**, 22,	0
155	Changes of lower urinary tract function after robot-assisted radical prostatectomy: An urodynamic follow-up within 1 year. **2022**, 0	
154	Comparison of Machine and Deep Learning models for automatic segmentation of prostate cancers on multiparametric MRI. **2022**,	

153	Transperineal Ultrasound Before and After Prostatectomy.	
152	Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. **2022**, 12,	0
151	Evaluation of cystoprostatectomy on patients with prostate cancer extending to bladder: a retrospective study from single center. **2022**, 22,	
150	The clinical relative biological effectiveness and prostate-specific antigen kinetics of carbon-ion radiotherapy in low-risk prostate cancer.	
149	Effect of Degarelix administration on bone health in prostate cancer patients without bone metastases. The Blade study.	
148	Artificial intelligence for prostate MRI: open datasets, available applications, and grand challenges. **2022**, 6,	1
147	The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.	0
146	High Neuroticism Is Related to More Overall Functional Problems and Lower Function Scores in Men Who Had Surgery for Non-Relapsing Prostate Cancer. **2022**, 29, 5823-5832	0
145	Long-term results after robot-assisted radical prostatectomy of a simplified inguinal hernia prevention technique without artificial substance use.	
144	Biochemical relapse predictive factors in patients with lymph node metastases during radical prostatectomy. **2022**,	
143	Race and prostate cancer: genomic landscape.	0
142	Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT. **2022**, 53,	
141	Machine learning model for the prediction of prostate cancer in patients with low prostate-specific antigen levels: A multicenter retrospective analysis. 12,	0
140	Machine-Learning-Based Digital Twin System for Predicting the Progression of Prostate Cancer. **2022**, 12, 8156	0
139	Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer. **2022**, 14, 4015	1
138	18F-Fluoroethylcholine PET/CT Radiomic Analysis for Newly Diagnosed Prostate Cancer Patients: A Monocentric Study. **2022**, 23, 9120	0
137	The Effects of Multimodal Prehabilitation Interventions in Men Affected by Prostate Cancer on Physical, Clinical and Patient Reported Outcome Measures: A Systematic Review. **2022**, 151333	
136	Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy. **2022**, 12,	0

135	Retzius-sparing robotic prostatectomy is associated with higher positive surgical margin rate in anterior tumors, but not in posterior tumors, compared to conventional anterior robotic prostatectomy. **2022**,	1
134	Utility of Diffusion Weighted Imaging-Based Radiomics Nomogram to Predict Pelvic Lymph Nodes Metastasis in Prostate Cancer.	
133	Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.	
132	Detection of lymph node metastases in patients with prostate cancer: Comparing conventional and digital [18 F]-fluorocholine PET-CT using histopathology as a reference.	0
131	Long-term oncologic outcomes of robot-assisted versus open radical prostatectomy for prostate cancer with seminal vesicle invasion: a multi-institutional study with a minimum 5-year follow-up.	0
130	Consensus Document on Perioperative Antithrombotic Management: Part 2. Case Study. **2022**, 97, 204-228	
129	A preoperative MRI-based prediction model for biochemical failure after radical prostatectomy.	
128	A novel radical prostatectomy specific index (PSI) for the prediction of major cardiovascular events following surgery.	0
127	Correlation between Bladder Neck Preservation, Positive Surgical Margins, and Biochemical Recurrence in Laparoscopic and Open Radical Prostatectomy: A Prospective Cohort Study. **2022**, 12, 8304	
126	Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imagingâ€detected Prostate Imaging Reporting and Data System/Likert â… Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score. **2022**,	3
125	Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer. 12,	
124	Chemistries of bifunctional PROTAC degraders. **2022**, 51, 7066-7114	7
123	PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer. **2022**, 12, e061815	0
122	Short-term outcomes of robotic inguinal hernia repair during robotic prostatectomy â€An analysis of the Abdominal Core Health Quality Collaborative. **2022**,	0
121	The clinical consequences of routine 68Ga-PSMA-11 PET/CT in patients with newly diagnosed prostate cancer, ISUP grade 5 and no metastases based on standard imaging â€preliminary results. 1-6	0
120	Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial. **2022**, 29, 10732748211204	0
119	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. **2022**, 1-55	0
118	Comparison of amikacin with fosfomycin as an add-on to ciprofloxacin for antibiotic prophylaxis in transrectal prostate biopsy: A single-center retrospective study. 63,	0

117	Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications. **2022**, 255-275	0
116	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. **2022**, 1023-1075	0
115	Current Imaging Modalities to Assess Prostate Cancer. **2022**, 117-143	0
114	References. **2023**, 113-141	0
113	Metabolic-related gene signature model forecasts biochemical relapse in primary prostate cancer. **2022**,	1
112	A smart, practical, deep learning-based clinical decision support tool for patients in the prostate-specific antigen gray zone: model development and validation.	0
111	Single tertiary cancer center experience on the management of pT3b prostate cancer after robotic-assisted laparoscopic prostatectomy. Publish Ahead of Print,	0
110	MRI Extraprostatic Extension Grade: Accuracy and Clinical Incremental Value in the Assessment of Extraprostatic Cancer. **2022**, 2022, 1-7	0
109	Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial. **2022**, 14, 4476	0
108	The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer. **2022**, 22,	0
107	Pharmacokinetic modeling of PSMA-targeted nanobubbles for quantification of extravasation and binding in mice models of prostate cancer.	0
106	Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells. Volume 17, 4321-4337	1
105	Menâ perception of information and psychological distress in the diagnostic phase of prostate cancer: a comparative mixed methods study. **2022**, 21,	0
104	Single-port robot-assisted perineal radical prostatectomy with the da Vinci XI system: initial experience and learning curve using the cumulative sum method.	0
103	Additional value of Mini-Cog˙ in urogeriatric patients concurrently screened by G8 scores.	0
102	Recurrence rate after radical prostatectomy following primary staging of high-risk prostate cancer with 68Ga-PSMA PET/CT. 1-6	0
101	microRNA-205 in prostate cancer: Overview to clinical translation. **2022**, 188809	0
100	Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer. **2022**, 45, 68-75	0

99	Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial. **2022**, 187, 617-627	0
98	How can we best manage biochemical failure after radical prostatectomy?. **2022**, 63, 592	0
97	Dosimetric analysis of patients receiving radiotherapy with VMAT technique in localized prostate cancer and its correlation with side effects. **2022**, 0	0
96	Definitions of â□ureâ□after LDR-brachytherapy in low- and intermediate-risk prostate cancer - Phoenix or surgical?. **2022**, 101112	0
95	PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. **2022**, 12, 2594	1
94	Simplified approach to the medial internal iliac region using a uretero-hypogastric nerve fascia development procedure for extended pelvic lymph node dissection during robot-assisted radical prostatectomy for high-risk prostate cancer.	0
93	Gleason score, surgical and distant metastasis are associated with cancer-specific survival and overall survival in middle aged high-risk prostate cancer: A population-based study. 10,	0
92	Identifying patients with rapid progression from hormone-sensitive to castration-resistant prostate cancer: a retrospective study.	0
91	A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer. 13,	0
90	Prostate cancer in transgender women: considerations for screening, diagnosis and management.	0
89	A Nomogram for Predicting Prostate Cancer with Lymph Node Involvement in Robot-Assisted Radical Prostatectomy Era: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group). **2022**, 12, 2545	0
88	PET/TC-PSMA en c□cer de pr□tata: perfil de pacientes en la vida real. **2022**, 27,	0
87	Ga-68 Prostate-Specific Membrane Antigen PET/CT: Imaging and Clinical Perspective in Prostate Cancer. **2022**, 17, 595-606	0
86	Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies.	0
85	PET/TC 18F-PSMA para localizaci□ anat□mica de las recurrencias en el c□cer de pr□tata. **2022**, 25,	0
84	Long noncoding RNA as a potential diagnostic tool for prostate cancer: a systematic review and meta-analysis. 1-20	0
83	T□cnicas, indicaciones y resultados del vaciamiento ganglionar por v□ laparoscópica rob□tica en el tratamiento del c□cer de pr□tata. **2022**, 54, 1-6	0
82	The potential of miR-153 as aggressive prostate cancer biomarker. **2023**, 8, 53-59	0

81	Minimal Residual Disease (MRD) and a New Immunotherapy in Locally Advanced Prostate Cancer. **2022**,	0
80	Artificial Intelligence for Clinical Diagnosis and Treatment of Prostate Cancer. **2022**, 14, 5595	0
79	Evaluation of a radiomics nomogram derived from Fluoride-18 PSMA-1007 PET/CT for risk stratification in newly diagnosed prostate cancer. 12,	0
78	Utility of diffusion weighted imaging-based radiomics nomogram to predict pelvic lymph nodes metastasis in prostate cancer. **2022**, 22,	0
77	Combining prostate health index and multiparametric magnetic resonance imaging may better predict extraprostatic extension after radical prostatectomy. Publish Ahead of Print,	1
76	Occurrence and significance of fluoroquinolone-resistant and ESBL-producing Escherichia coli and Klebsiella pneumoniae complex of the rectal flora in Ghanaian patients undergoing prostate biopsy. **2022**, 4,	0
75	Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT). **2022**, 12, e068580	0
74	Complexities of Prostate Cancer. **2022**, 23, 14257	0
73	A Pilot Study of68Ga-PSMA11 and68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. jnumed.122.264448	0
72	Four Point Peritoneal Flap Fixation. **2022**, 257-258	0
71	The circHMGCS1-miR-205â5p-ErBB3 axis mediated the Sanggenon C-induced anti-proliferation effects on human prostate cancer. **2023**, 187, 106584	0
70	High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer. **2023**, 38, 100465	0
69	Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study.	0
68	MRI-Derived Apparent Diffusion Coefficient of Peri-Prostatic Adipose Tissue Is a Potential Determinant of Prostate Cancer Aggressiveness in Preoperative Setting: A Preliminary Report. **2022**, 19, 15996	0
67	GAS1RR, an immune-related enhancer RNA, is related to biochemical recurrence-free survival in prostate cancer. 153537022211318	0
66	PSMA PET/CT Patterns of Recurrence After Mono-Brachytherapy in Men with Low and Intermediate Prostate Cancer and Subsequent Management.	0
65	Variation in patient reported outcomes following radical prostatectomy: A bi-national registry-based study. **2022**,	0
64	Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer. **2022**, 12,	0

63	The impact of robotic-assisted transperineal biopsy of the prostate on erectile function.	0
62	Fracture risk and assessment in adults with cancer.	0
61	Radiomic-Based machine learning model for the accurate prediction of prostate cancer risk stratification.	0
60	The Effect of Music Therapy on Anxiety and Pain in Patients Undergoing Prostate Biopsy: A Systematic Review and Meta-Analysis. **2022**, 102913	0
59	Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy.	0
58	Findings from an international survey of urology trainee experience with prostate biopsy.	0
57	Robotically-controlled three-dimensional micro-ultrasound for prostate biopsy guidance.	0
56	Sustainable functional urethral reconstruction improves early urinary continence after RARP : an RCT.	0
55	Combination of multiparametric magnetic resonance imaging and transperineal template-guided mapping prostate biopsy to determine potential candidates for focal therapy. **2022**,	0
54	Evaluation of quality of life of patients with solitary renal cancer metastases in bones before and after surgical treatment in combination with targeted therapy and without it. **2022**, 18, 41-50	0
53	Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine. **2022**, 12, 3184	0
52	Safety profile of robotic-assisted transperineal MRI-US-fusion guided biopsy of the prostate. 12,	0
51	High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade.	0
50	A preoperative magnetic resonance imaging-based model to predict biochemical failure after radical prostatectomy. **2023**, 13,	0
49	Is there any effect of alpha-adrenergic blocker usage in preventing febrile urinary tract infections after prostate biopsy?. **2023**, 6, 1-6	0
48	Retzius-sparing robot-assisted radical prostatectomy in a medium size oncological center holds adequate oncological and functional outcomes.	0
47	Impact of prebiopsy MRI on prostate cancer staging: Results from the Norwegian Prostate Cancer Registry.	0
46	Influence of lymph node degeneration on metastases in prostate cancer: or why we must look for a needle in a haystack. **2023**, 23,	0

45	Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy. **2023**, 39,	0
44	Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer. 13,	1
43	Nomograms in PCa: where do we stand.	0
42	PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications. **2023**, 13, 158	1
41	Construction of DNA methylation-based nomogram for predicting biochemical-recurrence-free survival in prostate cancer. **2022**, 101, e32205	0
40	Variables Associated with False-Positive PSA Results: A Cohort Study with Real-World Data. **2023**, 15, 261	1
39	Incremental prognostic value of ADC histogram analysis in patients with high-risk prostate cancer receiving adjuvant hormonal therapy after radical prostatectomy. 13,	0
38	Does inflammation markers or treatment type moderate exercise intensity effects on changes in muscle strength in cancer survivors participating in a 6-month combined resistance- and endurance exercise program? Results from the Phys-Can trial. **2023**, 15,	0
37	Differential co-expression network analysis with DCoNA reveals isomiR targeting aberrations in prostate cancer. **2023**, 39,	0
36	Dual-energy x-ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy.	0
35	Clinicopathological implications of histological mapping in radical prostatectomy specimens. **2023**, 154334	0
34	Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy. **2023**,	0
33	Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease. **2023**, 15, 1020	0
32	Single-port robot-assisted perineal radical prostatectomy with the da Vinci XI system: initial experience and learning curve using the cumulative sum method. **2023**, 21,	0
31	Prostate cancer segmentation from MRI by a multistream fusion encoder.	0
30	The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer After Radiation Therapy at a Community Cancer Center. **2023**, 8, 101193	0
29	Item analysis of G8 screening in uro-oncologic geriatric patients.	0
28	Direct comparison between Grade Group assessed on systematic and MRI/ultrasound fusion targeted biopsies correlated to the radical prostatectomy specimens in patients with prostate cancer. **2023**, 33, 265-271	0

27	Genitourinary cancer: A perspective review. **2022**, 8, 111	0
26	Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring. **2023**, 152, 2166-2173	0
25	Outcomes following external beam radiotherapy to the prostate and pelvic lymph nodes in addition to androgen deprivation therapy in non-metastatic prostate adenocarcinoma with regional lymph node involvement: a retrospective cohort study. **2023**, 5,	0
24	Driving Factors for Digital Technology Innovation in Financial Markets in Indonesia. **2023**, 99-107	0
23	Prognostic value of genomic mutations in metastatic prostate cancer. **2023**, 9, e13827	0
22	Determination of Whether Apex or Non-Apex Prostate Cancer Is the Best Candidate for the Use of Prostate-Specific Antigen Density to Predict Pathological Grade Group Upgrading and Upstaging after Radical Prostatectomy. **2023**, 12, 1659	0
21	Radikal prostatektomi yapılan hastalarda lenf nodu invazyonunu öngören preoperatif nomogramların karşılaştırılması **2023**, 15, 16-22	0
20	Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. **2023**,	1
19	External Validation of Briganti and Memorial Sloan-Kettering Cancer Centre Nomograms for Predicting Lymph Node Invasion in the Indian Cohort of Patients with Prostate Cancer.	0
18	Changes in mortality of Polish residents in the early and late old age due to main causes of death from 2000 to 2019. 11,	0
17	A Clinically-Achievable Injectable and Sprayable in Situ Lyotropic Liquid Crystalline Platform in Treating Hormone-Sensitive and Castration-Resistant Prostate Cancer. **2023**, 17, 6045-6061	0
16	Salvage stereotactic reirradiation for intraprostatic cancer recurrence: A large retrospective study. **2023**, 83, 743-750	0
15	The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy. **2023**, 83, 695-700	0
14	Application of machine learning algorithm in prediction of lymph node metastasis in patients with intermediate and high-risk prostate cancer.	0
13	Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging. 13,	0
12	Characterization of high-grade prostate cancer at multiparametric MRI: assessment of PI-RADS version 2.1 and version 2 descriptors across 21 readers with varying experience (MULTI study). **2023** , 14,	0
11	Lacosamide alleviates bilateral cavernous nerve injury-induced erectile dysfunction in the rat model by ameliorating pathological changes in the corpus cavernosum.	0
10	Nuklearmedizin der Prostata und des äußeren Genitale. **2022**, 1-16	0

9	Histopathologically Validated Diagnostic Accuracy of PSMA-PET/CT in the Primary and Secondary Staging of Prostate Cancer and the Impact of PSMA-PET/CT on Clinical Management: A Systematic Review and Meta-analysis. **2023**,	0
8	Does previous transurethral resection of the prostate negatively influence subsequent robotic-assisted radical prostatectomy in men diagnosed with prostate cancer? A systematic review and meta-analysis.	0
7	Gender bias in shared decision-making among cancer care guidelines: A systematic review.	0
6	Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer.	0
5	Human Prostate-Specific Antigen Carries N-glycans with Ketodeoxynononic Acid. **2023**,	0
4	PI-RADS-based segmented threshold of PSMA-PET SUVmax is better than traditional fixed threshold for diagnosing clinically significant prostate cancer especially for PI-RADS 3 lesions.	0
3	Treatment of intermediate-risk prostate cancer with active surveillance in the routine careâ€long-term outcomes of a prospective noninterventional study (HAROW). Publish Ahead of Print,	0
2	Role of radiomic analysis of [18F]fluoromethylcholine PET/CT in predicting biochemical recurrence in a cohort of intermediate and high risk prostate cancer patients at initial staging.	0
1	PSMA-PET -guided dose-escalated volumetric arc therapy for newly diagnosed lymph node-positive prostate cancer: 5 Year outcomes following the FROGG and EviQ node-positive guidelines.	0